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Abstract
The functional assay of agonists acting on G protein coupled receptors 
(GPGRs) coupled to the G^a subunit usually involves the measurement of effector 
(adenylate cyclase) activity. However, the activity of adenylate cyclase can be 
modulated by proteins other than Gsa, and their levels and subtypes vary between 
cell lines. As such, measurement of agonist efficacy at the level of the G protein 
would be most ideal. This is currently not possible with traditional assays such as 
the [^^SjGTPyS binding and high affinity GTPase assays, since activated Gga has 
low rates of GTP exchange and hydrolysis (Wieland et al. 1994; Gierschik et al. 
1994).
A Fl-AG™-tagged form of the human IP prostanoid receptor (a Ggoi-coupled 
GPCR) was expressed stably in HEK293 cells and bound [^Hjiloprost with high 
affinity and stimulated cAMP production when exposed to agonist. A cDNA 
encoding the Gj-ia sequence but with the carboxyl-terminal six amino acids of G^a 
was also constructed. Co-expression of this chimeric G protein Gji/Gs6 a, but not 
Ggoc or Gjia, resulted in robust stimulation by iloprost. This significantly high levels 
of agonist-stimulated [^^S]GTPyS binding and high affinity GTPase were not 
abolished by treatment with both cholera and pertussis toxins. This correlated with 
the loss of both cholera (arginine 201 of Gga(L)) and pertussis (cysteine 351 of 
Gjia) toxin-susceptible sites in the G;i/Gs6 a protein. This clearly demonstrated the 
utility of chimeric G proteins to combine the high GTP exchange and hydrolysis 
capacity of G^a with the ability to couple to a Gga-coupled GPCR.
The stoichiometry of GPCR to Ga can have a direct impact on the 
signalling cascades of GPCRs (Kenakin 1995a; 1997). In addition, there is 
evidence that GPCR and Ga may not be localised in the same microdomain of the 
plasma membrane (Neubig 1994). Through the use of a fusion protein between 
the {3 2-adrenergic receptor and Gga, Bertin et al. (1994) demonstrated productive 
interactions between the fused partners. A fusion protein of the FLAG™-tagged
human IP prostanoid receptor with Gsa(L)(HA) was therefore generated and stably 
expressed in HEK293 cells. These cells bound [^Hjiloprost with high affinity and 
also stimulated adenylate cyclase upon addition of agonist. When compared to 
the freely interacting IP prostanoid receptor, the fusion protein FhlPR-Gga 
exhibited enhanced agonist-stimulated activities in both the [^^SJGTPyS binding 
and high affinity GTPase assays. Furthermore, cholera toxin treatment diminished 
its capacity to hydrolyse GTP but not the incorporation of [ SjGTPyS.
The fidelity of signalling in GPCR-Ga fusion proteins was established by 
studying the Ga activity of a series of FhlPR-Ga fusions. When stably expressed 
in HEK293 cells and stimulated by iloprost, the FhlPR-Gj-ia protein failed to 
elevate the low levels of high affinity GTPase and [^^S]GTPyS binding activity. 
These low levels of activity were shown to be derived from activation of 
endogenous Gga but not receptor-linked G^a. Substituting the carboxyl-terminal 
six amino acids of FhlPR-Gna with Gga resulted in the production of the FhlPR- 
Gji/GgGa fusion protein. This protein produced substantial elevation of both high 
affinity GTPase and [^^S]GTPyS binding activity upon stimulation by iloprost. In 
addition, these activities were resistant to both cholera and pertussis toxin 
treatments, as was observed for the freely interacting Gii/Gg6 a protein. This 
clearly demonstrated that fusing the GPCR and Ga did not alter their individual 
characteristics.
The assay of agonist activity at the G protein level for a Gga-coupled GPCR 
is now possible by using the chimeric Gj-i/GgGa protein or GPCR-Ga fusions. The 
GPCR-Ga fusion approach is superior to the chimeric protein as the stoichiometry 
of GPCR to Ga is fixed at 1:1 and the interacting partners are co-targeted to the 
same microdomain of the plasma membrane.
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CHAPTER 1 INTRODUCTION
1.1 G-protein coupled receptors (GPCR)
Receptors play a very important role in transducing extracellular signals into 
cells. Among the many families of receptors, G-protein coupled receptors (GPCR) 
are by far the largest (about 1000). Ligands that act on GPCRs range from 
cations, chromophores, odourous'chemicals, small biogenic amines, nucleotides, 
lipid derived messengers and chemokines to large peptide hormones. Correlating 
with the broad range of ligands is the wide distribution of GPCRs in our body, 
mediating such diverse functions as vision, smell, neurotransmission, 
cardiovascular regulation, immune and inflammatory responses, pain control, 
growth, metabolism and even reproduction. Malfunctioning of GPCRs therefore 
can give rise to a variety of diseases.
GPCRs are very well studied and their basic mode of action well 
established. Despite this wealth of knowledge, we continue to benefit from new 
experimental approaches such as structural and mutational studies, undertaken to 
unravel their functions and mechanisms down to the molecular level. The 
discovery of novel classes and subtypes of GPCRs, especially among the large 
group of orphan receptors, also confirms the importance of GPCRs in modern 
medicine. Despite more than four decades of research in this field, there are still 
many important discoveries to be made, and many dividends may be reaped from 
such progress with the aid of modern techniques and novel approaches.
1.1.1 Historical Perspective
The discovery of GPCRs stretches back to 1957, when Sutherland and Rail 
(Rail et al. 1957; Sutherland et al. 1958) characterized the properties of the 
enzyme adenylate cyclase, which was activated by the hormones adrenaline and 
glucagon and by sodium fluoride. Initially, adenylate cyclase was thought to be a 
protein complex in which the hormone ligand directly activated the enzyme via a 
site on a regulatory subunit. It was not until the late 1960s that Birnbaumer and
Rodbell (1969) concluded that the hormone receptors are distinct from the 
enzyme from studies of fat cell adenylate cyclase.
At about the same time, a crucial role for guanine nucleotides on hormone 
binding and activation of adenylate cyclase was uncovered (Rodbell et al. 1971). 
Pfeuffer and Helmreich (1975) separated a GTP-binding protein from the 
adenylate cyclase complex, which when added back to an insensitive cyclase, 
restored activation by GTP and sodium fluoride (Ross and Gilman 1977). This 
protein is now widely known as G^a subunit, due to its stimulatory effect on 
cyclase.
The GTPase activity of Gga was first noted by Cassel and Selinger (1977) 
when they stimulated adenylate cyclase of turkey erythrocyte membranes with 
adrenaline. This GTPase activity was inhibited by cholera toxin, which activated 
adenylate cyclase by an unknown mechanism. Further experiments led them to 
postulate that hormone activated receptor interacted with Gga to release bound 
GDP and subsequently bind GTP (Cassel and Selinger 1978), thus enabling the 
Gga subunit to activate adenylate cyclase. Gga activity was terminated when the 
bound GTP was hydrolysed to GDP. Cholera toxin was able to ADP-ribosylate 
Gga which inhibited the hormone stimulated GTPase cycle and hence 
constitutively activate adenylate cyclase (Cassel and Selinger 1977).
The cellular effectors of the other partner in the heterotrimeric subunits, the 
Gpy dimer, were only discovered in the late 1980s. Early evidence came from 
Clapham’s group in 1987 who showed direct activation of a muscarinic 
acetylcholine regulated channel in cardiac atrial cells by Gpy dimer (Logethetis 
et al. 1987). There was initial contention about whether such effects were due to 
Ga or Gpy subunits, but it is now widely accepted that Gpy dimers do regulate a 
wide range of effectors (Capham et al. 1997). The crystallography studies of Gpy 
subunit showed a “propeller" structure (Sondek et al. 1996).
On the receptor front, the bovine opsin receptor was the first GPCR cloned 
(Nathans et al. 1983), using oligonucleotide probes designed from the amino acid
sequence of bovine rhodopsin. When the mammalian p2"3 drenergic receptor 
cDNA was cloned in 1986 (Dixon et al. 1986), it was apparent from the deduced 
sequence that it exhibited a structure similar to that of the rhodopsins, and 
suggested the existence of a family of signal receptors. The application of new 
molecular cloning techniques, such as polymerase chain reaction (PCR) and 
homology screening, enabled rapid progress in the isolation of GPCR genes. This 
included many novel members for which physiological ligands are not identified, 
and hence they are named “orphàn receptors”.
Sustained agonist activation of GPCR resulted in diminished cellular 
response, a phenomenon known as desensitisation in the laboratory (Shear et al. 
1976) or drug tolerance in the clinic. Initial research focused on the role second 
messenger activated kinases, such as protein kinase A (PKA) and protein kinase 
C (PKC), played in the uncoupling of Ga from GPCR (Hausdorff et al. 1990). 
However, understanding of the regulation of desensitisation was given new 
impetus with the discovery of a group of receptor kinases known as G protein 
receptor kinases (GRKs). Rhodopsin kinase (now known as GRK1) was the first 
kinase in the family to be discovered, by Kuhn in 1978. He and other co-workers 
realised that rhodopsin phosphorylation is light-dependent, and results in the 
desensitisation of the receptor. A similar kinase, known as (3-adrenergic receptor 
kinase (or GRK2) was also shown to phosphorylate (3-adrenergic receptors 
(Benovic et al. 1986). Furthermore, a protein known as (3-arrestin was able to bind 
to the GRK phosphorylated receptor to cause uncoupling of the receptor from their 
Ga subunits (Lohse et al. 1990). (3-arrestin is an isoform of visual arrestin, 
originally discovered by Pfister (Pfister et al. 1985) that binds to GRK 
phosphorylated rhodopsin.
The identification of new proteins regulating the GPCR pathway continued 
into the 1990s with the discovery of regulators of G protein signalling (RGS). 
These proteins are equivalent to the GTPase activating proteins (GAPs) of small 
G proteins such as RasGAP, in that they accelerate the GTP hydrolysis rate and 
hence “switch-off” the activated conformation of G proteins (Berman et al. 1998). 
A eukaryotic RGS homologue, SST2 was initially shown to exist in the yeast
Saccharomyces cerevisiae when Chan and Otte screened for mutant haploids 
hypersensitive to pheromone-induced cell cycle arrest (Chan et ai. 1982). It was 
only in 1995 that a human homologue, GAIP was found through a yeast two- 
hybrid system by using Gisa as bait (DeVries et ai. 1995). GAIP contains the core 
RGS domain which is also found in products of BL34/1R20 and GOS8  cDNAs, 
now known as RGS1 and RGS2 respectively. Using homologous screening and 
expressing the cDNAs in SST2 gene deficient yeast cells, RGS3 and RGS4 were 
found (Druey et al. 1996). There are at least 19 RGS proteins identified to date.
This enormous progress in the identification and understanding of GPCRs 
and their signalling pathways, with their profound implications for human diseases, 
enabled the development of new therapies. It is without doubt that many of our 
most useful medicines were developed from such intensive research. As we 
continue to uncover the intricacies of GPCR signalling and understand their 
regulation and involvement with other signalling pathways, it is undeniable that 
such research will be important and relevant in our endless battle against 
diseases.
1.1.2 Structural Features of GPCRs
Analysis of the amino acid sequence of GPCRs indicated seven 
hydrophobic domains which were shown to transverse the plasma membrane. 
Hence, GPCRs are also known as seven transmembrane receptors. They have an 
extracellular N-terminal segment, seven transmembrane segments (TM) of 20 to 
27 amino acids which are linked by three intracellular (1C) and three extracellular 
(EC) loops, and ending in an intracellular C-terminal segment (Figure 1.1).
The N-terminal segment contains one to nine glycosylation consensus 
sequences (Asn-X-Ser/Thr), where X is any amino acid except Pro or Asp. N- 
glycosylation at the asparagine residue of this sequence targets the receptor to 
the plasma membrane (Rands et al. 1990). Variability in the overall length of 
GPCRs also occurs primarily in this domain (7-595 amino acids). This domain 
plays a role in ligand binding, especially for large polypeptides and glycoprotein
hormones. There is a weak correlation between the length of the domain and the 
size of the ligand (Ji et a i 1998).
Interestingly, there is a new family of single transmembrane domain 
proteins known as receptor-activity-modifying proteins (RAMPs) that control the 
transport and glycosylation of certain GPCRs (McLatchie et af. 1998). Co­
expression of RAM PI wit-h calcitonin-receptor-like receptor (CRLR) presents the 
receptor at the cell surface as a mature glycoprotein and a calcitonin-gene-related 
peptide (CGRP) receptor. However, co-expression of RAMP2 with CRLR caused 
core-glycosylation of the receptor, and presented it as an adrenomedullin 
receptor. Thus, RAMPs have the capacity to regulate the pharmacological profile 
of GPCRs, and hence may have extensive physiological implications.
The transmembrane domains are arranged in a counter-clockwise 
orientation (TM 1 to 7; see Figure 1.1) when viewed from the extracellular surface, 
based on the structure of animal rhodopsin (Unger et al. 1997). Using chimeric 
a2/P2“3 drenergic receptors to identify intramolecular interactions between specific 
amino acids on the transmembrane domains, Mizobe et al. (1996) also found a 
similar counter-clockwise arrangement of the adrenergic receptors. The 
orientation of the TMs gives rise to specific stereo and geometrical selectivity of 
the ligands that bind to the TM core. This core is formed from the closed loop 
arrangement of the TMs, and is packed tightly tggether by extensive hydrogen 
bonds and salt bridges within and between the TMs (Pebay-Peyroula et al. 1997). 
The greatest degree of amino acid similarity (20 to 90%) occurs in the TM 
segments. Finally, the TMs are not orientated perpendicular to the plane of the 
plasma membrane; but with TM3 tilted at -30° and TMs 1,2 and 5 tilted slightly 
(Unger et al. 1997).
Figure 1.1 Structure of a typical G protein coupled receptor
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The intracellular loops allow interaction of heterotrimeric G protein subunits 
and other regulatory proteins with the receptor. The first and second loops are 
relatively well conserved among the GPCRs, but the third intracellular loop is quite 
divergent. Both the second and third intracellular loops have been shown to be 
crucial for coupling to Ga subunits, especially residues close to TM5 and TM6  in 
the third loop (Burstein et al. 1995). The third intracellular loop also may contain 
sites for phosphorylation by second messenger regulated kinases.
The first and second extracellular loops contain cysteine residues that form 
a disulphide bond in receptors for rhodopsin, p2~adrenergic, muscarinic, 
thyrotrophin-reieasing hormone, thromboxane A2 , gonadotrophin releasing 
hormone and many others. The disulphide bonds are thought to play a crucial role 
in maintaining the structural integrity of GPCRs. For example, in congenital blue 
cone monochromacy, a point mutation of an opsin gene leading to the loss of a 
conserved cysteine residue in the second intradiscal loop causes congenital 
colour blindness (Nathans et al. 1989). Furthermore, the importance of the 
cysteine residues involved in disulphide bond formation is shown by the 
conservation of cysteine residues in corresponding locations in the majority of 
GPCRs. The first or second extracellular loop may also contain sites for N-linked 
glycosylation.
The intracellular C terminal segment varies considerably in length (12-359 
amino acids). It is often thioacylated at the cysteine residue of a palmitoylation 
consensus sequence, which anchors the carboxyl tail of the receptor to the 
plasma membrane, and gives rise to a fourth intracellular loop (O’Dowd et al. 
1989). The C terminal domain is usually rich in serine and threonine residues that 
are potential sites for phosphorylation by GRKs and second messenger regulated 
kinases.
1.1.3 Regulation of GPCR
Binding of an extracellular ligand (or primary messenger) to the GPCR 
activates the receptor which then initiates a series of signalling cascades in the 
interior of the cell. These signalling cascades, if not kept in check, may result in
abnormal functioning of the cell, as shown by the constitutively activated mutant 
receptors. Furthermore, in the case of the photoreceptors, it is important that the 
activated receptor be reverted back quickly to its normal state so that the eye can 
perceive continuous changes in light intensity. It is therefore crucial that 
mechanisms exist to regulate the activated GPCR so that it can continue to 
function.
A) Desensitisation
Receptor desensitisation refers to the phenomenon whereby receptors 
become refractory to further stimulation after an initial response, despite the 
continued presence of a stimulus of constant intensity (Shear et al. 1976). 
After exposure to agonists, GPCR-Ga interactions become attenuated due to 
rapid uncoupling of receptors from their cognate G proteins. It can be 
classified into homologous desensitisation (where only the activated GPCR 
is affected) and heterologous desensitisation (where other GPCRs on the 
same cell are also affected) (Hausdorff et al. 1990).
Phosphorylation of the GPCR is an important mechanism whereby both 
types of desensitisation mediate their effects. The G-protein coupled 
receptor kinases (GRK) are involved in the homologous desensitisation 
process. The GRK family consists of 6  members to date, which are divided 
into 3 subfamilies; (i) GRK1 (also known as rhodopsin kinase), (ii) GRK2 
consisting of GRK2 & 3 (also known as pARKI & pARK2 respectively), and 
(iii) GRK4 consisting of GRK4, 5 & 6  (Pitcher et al. 1998). They are 
ubiquitously expressed with the exception of GRK1 (exclusively in retina) and 
GRK4 (significant levels only in testes).
GRKs phosphorylate serine and threonine residues predominantly in the 
third intracellular loop and C-terminal segment of the agonist bound receptor. 
So far, there is no clear GRK phosphorylation consensus sequence, 
although there is evidence that GRK1 and GRK2  prefer acidic residues 
flanking the serine or threonine sites, while GRK5 and GRK6  prefer basic 
residues (Pitcher et al. 1998). For GRKs to phosphorylate GPCRs, they must
be first localised to the plasma membrane. GRK1 is farnesylated (C15 
isoprenylated) on the last cysteine residue with subsequent 
carboxylmethylation, while GRK4 and GRK6  are palmitoylated (C16 
acylation). GRK2 and GRK3, however, are recruited to the activated receptor 
by binding to the dissociated Gpy subunit via the pleckstrin homology (PH) 
domain in their carboxyl termini. GRK5 has also been shown to bind 
phospholipids with its carboxyl and amino terminal sequences (Krupnick et 
al. 1998).
The GRK phosphorylated receptor recruits a class of cytoplasmic inhibitory 
proteins known as arrestin isoforms, composing of only 3 members: visual 
arrestin, p-arrestin 1 and p-arrestin 2. The arrestin protein inhibits functional 
coupling of the GPCR to its Ga by binding to the third intracellular loop and 
carboxyl terminus of the receptor, and hence terminates the GPCR signalling 
process (Lohse et al. 1990).
Second messenger kinases like PKA and PKC play important roles in the 
heterologous desensitisation of GPCRs (Hausdorff et al. 1990). These 
serine/threonine kinases are mobilised by the feedback effect of activated 
Ga subunits dissociated from the agonist-occupied receptors. In the case of 
PKA, also known as cAMP dependent protein kinase, agonist treatment of 
the Gsa coupled GPCR raises cAMP levels-, in the cell which then causes 
phosphorylation of the receptor on PKA consensus sequences (Lys/Arg-Arg- 
X-X-Ser) (lismaa et al. 1995). Similarly, agonist stimulation of a Gqa coupled 
GPCR results in elevation of inositol trisphosphate (IP 3) and diacylglycerol 
(DAG) levels due to the activation of phospholipase C (PLC) by dissociated 
Gqa subunits. DAG enhances the activity of PKC, which phosphorylates PKC 
consensus sequences of the receptor. As phosphorylation by second 
messenger regulated kinases is not selective for the activated receptor, other 
GPCRs that carry appropriate sequences may be phosphorylated too. 
Hence, the response of other GPCRs to their respective ligands are also
diminished at the same time, giving rise to the phenomenon of heterologous 
desensitisation (Hausdorff ef a/. 1990).
B) Internalisation /  Sequestration
Sustained agonist treatment of GPCR was also shown to result in 
redistribution of the receptor from the plasma membrane into the interior of 
the cell (Bohm at ai. 1997). This phenomenon is known as receptor 
internalisation or sequestration, and is independent of the very rapid receptor 
desensitisation process described before. In the case of sequestered p2- 
adrenergic receptors, they were co-localised in intracellular vesicles with 
transferrin receptors, and hence demonstrated the involvement of the 
endosomal sorting pathway (Von Zastrow et al. 1992).
Sequestration of GPCRs does not appear to require coupling to Ga, and is 
independent of second messenger kinase phosphorylation (Koenig et al. 
1997). However, evidence is accumulating that receptor phosphorylation by 
GRKs may play an important role, especially in the recruitment of arrestins. 
Immunofluorescence studies show that the activated P2AR, p-arrestin and 
clathrin all co-localise into intracellular punctate accumulations upon addition 
of agonist (Goodman et al. 1996). This result correlates well with the 
arrestin/clathrin interaction observed in vitro. Thus, p-arrestin and arrestinS 
act as adaptor proteins by targeting the desensitised receptor to clathrin 
coated pits.
Although the sequestration of GPCR is distinct from desensitisation, recent 
studies have indicated that it may play a role in resensitisation (recovery from 
desensitisation) (Lefkowitz 1998). The first direct evidence came from the 
lack of resensitisation of P2-adrenergic receptors, when their internalisation 
through clathrin coated pits was inhibited by treatment with concanavalin A 
or sucrose (Pippig et al. 1995). Furthermore, the central idea that 
dephosphorylation and subsequent recycling of functional receptors to the 
plasma membrane was essential for resensitisation, was confirmed by the 
ability of calyculin A (an inhibitor of protein phosphatases) and monensin (an
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inhibitor of intracellular trafficking) to block resensitisation of the P2- 
adrenergic receptors (Pippig et ai. 1995). Finally, déphosphorylation may 
require other conditions to be present, like acidification of vesicles in the 
case of P2AR, and the dissociation of arrestin from photoactivated rhodopsin 
(Krupnick et al. 1998).
C) Downregulation'
Prolonged agonist treatment'(hours) of a GPCR can result in downregulation 
of receptor levels where there is an irreversible loss from the plasma 
membrane due to both internalisation and degradation, and also reduction in 
mRNA levels (Flausdorff et al. 1990). The requirements for downregulation 
are still not very clear, although there seems to be a requirement for 
functional coupling with Ga, as S49 lymphoma eye' cells lacking endogenous 
Gga exhibit very little agonist-induced downregulation (Mahan et al. 1985). 
The role of serine/threonine is conflicting, with some studies suggesting that 
phosphorylation by second messenger regulated kinases, but not GRK are 
essential in down regulating P2 -adrenergic recepotors (Hausdorff et al. 1991). 
However, tyrosine residues in the C terminal segment of the P2-adrenergic 
receptor appear to be crucial (Valiquette et al. 1990). What is clear so far is 
that there is instability of receptor mRNA, resulting in reduction in steady 
state levels. Cellular recovery to the normal level of receptor expression has 
been shown to take days or weeks and is dependent on new protein 
synthesis (lismaa et al. 1995).
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1.2 The Heterotrimeric G proteins
The heterotrimeric G proteins refer to G alpha (Ga), G beta (Gp) and G 
gamma (Gy) subunits, which associate together with a seven transmembrane 
receptor to form a functional GPCR unit at the plasma membrane of the cell. Upon 
agonist activation of the receptor, Ga subunit releases its bound GDP and 
exchanges it for GTP (due to the higher intracellular concentration of GTP versus 
GDP). The GTP bound Ga suburîit then dissociates from the GPy dimer, allowing 
both to activate their effectors. Termination of signalling occurs with the hydrolysis 
of GTP by the Ga subunit, which subsequently reassociates with the receptor and 
GPy dimer. Such a simple mechanism underlies the transduction of signalling by 
all receptors in the GPCR superfamily. Differences in cellular effects among the 
GPCRs therefore are determined by the subunits: their GTP exchange rates, GTP 
hydrolysis rates, cellular localisation, activation of effectors, and regulation by 
various proteins.
1.2.1 G Alpha Subunit
There are 20 different mammalian Ga subunits to date, classified into 4 
subfamilies according to the similarity of their amino acids (56% to 95%). As seen 
in Table 1.1, there are only 16 gene products, with splice variants of Gga and Goa, 
and their size ranges from 39 to 52 kDa (lismaa et al. 1995). Members of the 
same subfamily may activate the same effector (e.g. adenylate cyclase or 
phospholipase C) although this is not absolute.
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Table 1.1 Classification of Ga subunits, their distribution and effectors
Subtype Expression Effectors
G.=a Subfamiiv
Ggtt (4 splice variants) Ubiquitous tAdenylate Cyclase,
tCa^"^ Channels, iN a^ Channels
Goifa Olfactory tAdenylate Cyclase
Gia Subfamiiv
Gjia Widespread tAdenylate Cyclase, etc
G|2a Ubiquitous tAdenylate Cyclase, etc
Gisa Widespread tAdenylate Cyclase, etc
Goa ( 2  splice variants) Neuroendocrine tK"* Channels, tCa^"*" Channels
GgustC(- Taste Buds tcGMP Phosphodiesterase
G tia Retinal Rods tcGMP Phosphodiesterase
G t2Ct Retinal Cones tcGMP Phosphodiesterase
G^a Neuroendocrine tAdenylate Cyclase, etc
Gga Subfamiiv
Gqa Widespread tPhospholipase C
G iia Widespread tPhospholipase C
G-j^a Widespread tPhospholipase C
G-j^a Circulatory tPhospholipase C
Gi?a Subfamiiv
G i2a Ubiquitous RhoGEF & others
Gisa Ubiquitous RhoGEF & others
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The crystal structures of Gta and G,ia bound with various nucleotides has 
yielded tremendous amounts of structural information (Sprang 1997). Basically, 
the structure of Ga consists of two domains: a GTPase domain (also known as G 
domain) and an a helical domain. The GTPase domain consists of 5 a helices 
surrounding a 6  stranded p sheet. This domain contains the guanine nucleotide 
binding pocket (making up a motif for binding GTP and Mg^^) and sites for binding 
the receptor, downstream effectors, and GPy subunit. The 5 helices are 
designated a l to a5, while the strands of the p sheet are designated pi to p6  
(Figure 1.2). The five polypeptide loops in the GTPase domain (consisting of the 
various helices and p strands), form the guanine nucleotide-binding site. These 
five loops (G1 to G5) are also the most highly conserved elements across the G 
protein superfamily, which consists of both the heterotrimeric Ga and the small G 
proteins.
Three segments of G^a undergo substantial rearrangement upon GTP 
hydrolysis (Mixon et a!. 1995). These are switch 1 (the loop between a l helix and 
the p2  strand; involved in Mg^^ coordination), switch 11 (the loop preceeding a2  
helix, and the helix itself), and switch 111 (the loop connecting helix a3 to strand 
P5). In the GTPyS bound state (Figure 1.2 top figure), basic residues in switch 11 
form ionic interactions with complementary residues in the switch ill loop. 
Flowever, upon GTP hydrolysis, both switch II arid switch 111 are disordered or 
collapsed and hence these contacts are severed (Figure 1.2 bottom figure). As 
both switch II and 111 are the proposed effector-binding regions in the activated Ga, 
the collapse in their structure also abrogates interactions with effectors (Sprang 
1997).
14
Figure 1.2 Structure of Gjia
.2+The structures of G ^a complexed with GTPyS.Mg (top) or GDP (bottom). In the 
top figure, the a helical domain (left) and G domain (right) of G jia are shown 
together with the switch segments (darkened) (adapted from Sprang 1997).
Switch IIIaGhelical domain ^ (xD
(XB _  -  . T - r
G domain
a4
a3
aE
aP
1c) (35
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The a helical domain is unique for the heterotrimeric Ga subunits but its 
function is unclear. The interface between the helical domain and the GTPase 
domain creates a narrow crevice within which the guanine nucleotide is bound, 
although most of the GTP or GDP contacts are made with the 5 loops (G1 to G5) 
of the GTPase domain. The a helical domain was shown to influence the 
spontaneous GDP release rate of Ga and hence was postulated to act as a “lid" to 
bury the guanine nucleotide deep between it and the GTPase domain (Hamm et 
al. 1996). Furthermore, it may also play a role in GTP hydrolysis as it helps to 
orient the critical arginine 174 residue of Gta whose side chain interacts with the 
guanine nucleotide terminal phosphate (Rens-Domiano et al. 1995).
The role of Ga subunits may extend beyond the GPCR family, as a number 
of other non-seven transmembrane receptors have been shown to activate G 
proteins. Examples are short peptides of the insulin-like growth factor II receptor 
coupled to Gi2a and epidermal growth factor receptor coupling with a Gia-like 
subunit (Spiegel 1992). The precise roles which Ga subunits play in the signalling 
pathways of these receptors are still not very clear, although a recent study has 
implicated G|2a as a positive regulator of insulin action (Moxham et al. 1996). 
However, the importance of Ga subunits in GPCR signalling can be seen by the 
extensive studies of the various Ga subfamilies.
A) Gsa subfamily
The Gga subfamily is so named due to the ability of these G proteins to 
stimulate the enzyme adenylate cyclase upon binding of GTP. Adenylate 
cyclase catalyses the formation of cyclic adenosine mono-phosphate (cAMP) 
from adenosine triphosphate. cAMP acts as a second messenger in the cell 
to activate cAMP dependent protein kinase (PKA), a serine / threonine 
kinase with diverse functions. The activity of cAMP is terminated by cAMP 
phosphodiesterases, which hydrolyse cAMP to 5’~AMP.
Gga is expressed in almost all cells, but has 4 splice variants, known as 
Gga1, Gga2, GgaS, and Gga4 (Bray et a!. 1986). Ggal and Gga3 are identical
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except that GgaS lacks a single stretch of 15 amino acids (from exon 3). 
Gsa2 and Gga4 are identical to Ggal and Gga3 respectively but have 3 
additional nucleotides (GAG) at the 5’ end of exon 4. The longer forms 
(Ggal & Gga2) are known as Gga long (Gga(L)) while the shorter forms 
(Gga3 & Gga4) are known as Gga short (Gga(S)). Gga can activate all 9 
mammalian adenylate cyclases.
Goifa is selectively expressed in the cilia cells of the olfactory bulb and thus in 
vivo only couples to the very large class of olfactory receptors (estimated at 
400). It is grouped under the Gga subfamily due to its high homology with 
Gga and its ability to activate the olfactory specific adenylate cyclase type 111. 
Activated Goita elevates cAMP and also phospholipase 0, leading to the 
opening of a cyclic nucleotide-gated cation channel (Parmentier et al. 1994).
Membrane association of Gga subunit is mediated by reversible 
palmitoylation of a Met-Giy-Cys motif at the amino terminus (Wedegaertner 
et al. 1995). The 16-carbon saturated fatty acid forms a thioester bond with 
the cysteine residue, and imparts significant hydrophobicity to the protein, 
which can affect both protein-lipid and p rote in-protein interactions. An 
example is the co-fractionation of palmitoylated Ga subunits with caveolin, a 
protein maker for caveolae (specialised invaginations of the plasma 
membrane). Since palmitoylation is reversible, there are suggestions that it 
may be regulated, as shown by enhanced pa Imitate turnover when Gga is 
activated. Indeed, an acyi-protein thioesterase enzyme was recently 
identified and found to be regulated by the activation of the G protein 
(Duncan et al. 1998).
Members of the Gga subfamily are ADP-ribosylated by cholera toxin (CTX) 
from Vibrio cholerae at a crucial arginine residue (arginine 201 in Gga(L)) in 
the GTPase domain. These ADP-ribosylated subunits are constitutively 
active, as their GTP hydrolysis rates are dramatically diminished (Cassel et 
al. 1977). As a result, there is a persistent activation of adenylate cyclase
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and a net increase in intracellular cAMP levels. The clinical symptom of 
infection by Vibrio cholerae is excessive loss of body fluids and ions, 
secreted by cells in the small intestine. As CTX specificially activates Gga 
subunits but not others, it is therefore very useful in studying Gga regulated 
signalling pathways.
Receptors that couple to Gga subunits are very widespread, ranging from (3- 
adrenergic, glucagon, secretin, VIP, corticotropic releasing factor, and certain 
members of the vasopressin, adenosine, dopamine, 5-HT and PG 
subfamilies of GPCRs. It is therefore not surprising that mutations in Gga 
would give rise to severe clinical disorders that is more generalised than 
mutations involving a locally expressed receptor. For example, in pseudo­
hypoparathyroidism type la, loss of function mutations of the Gga gene 
cause resistance to several hormones, in McCune-Albright syndrome, 
mutation on the arginine 2 0 1  residue of Gga during embryogenesis led to 
pleiotropic endocrine, skin and bone manifestations of this disorder.
B) G\a subfamily
The Gja proteins were originally identified as inhibitory regulators of 
adenylate cyclase (Katada and Ui 1982a). Hoyvever, after the reclassification 
of G protein family by amino acid sequence homology, the G\a subfamily 
now includes other members (Goa, Gta, Ggusta) that do not inhibit adenylate 
cyclase. A more common characteristic, apart from Gza, is their susceptibility 
to ADP-ribosylation catalysed by pertussis toxin (PTX) from Bordetella 
pertussis (Katada and Ui 1982b). This occurs on the last cysteine residue 
and results in uncoupling of Ga from the receptor. PTX is therefore used 
routinely in the laboratory to “knockout” the signalling effects arising from 
receptors coupled to members of the Gja subfamily (except G^a).
PTX was previously known as islet-activating protein, and was discovered by 
Katada and Ui in 1977, when they found that perfusion of the pancreas with
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the toxin abolished a-adrenergic-induced hyperglycemia, and enhanced (3- 
adrenergic stimulation. It was subsequently shown to specifically modify the 
inhibition of adenylate cyclase (Katada and Ui 1981), and ADP-ribosylate a G 
protein of about 41 kDa (Katada and Ui 1982a and 1982b). This conclusively 
proved the existence of a separate G protein apart from Gga, which has 
molecular mass of .45 or 52 kDa, that is involved in inhibiting adenylate 
cyclase.
The demonstration of direct inhibition of adenylate cyclase (type II and IV) by 
Gja subunits (G^a, Gjga, Gjga) was only achieved in 1993 in an in vitro 
reconstitution study (Taussig et ai. 1993). This inhibition is non-competitive 
with respect to activation by Gga, and hence indicates separate sites of 
interaction for Gja and Gga subunits (Birnbaumer 1995). Besides their effect 
on adenylate cyclase, Gja subunits also activate potassium channels; an 
inwardly rectifying K^ channel and an ATP-sensitive K"^  channel. A role for 
Gj2a in regulating insulin action had been found in transgenic mice deficient 
in G|2a expression (Moxham et al. 1993). In further studies of cells from 
these mice, adipose tissue and liver deficient in Gj2a were found to produce 
hyper-insulinaemia, impaired glucose tolerance and resistance to insulin in 
vivo (Moxham et al. 1996). Furthermore,, protein-tyrosine phosphatase 
activity was increased and insulin-stimulated tyrosine phosphorylation of 
insulin-receptor substrate 1 was attenuated in vivo. This suggested that G#a 
is a positive regulator of insulin action (Moxham et al. 1996).
Goa is found predominantly in neuroendocrine tissues, accounting for about 
1 % of brain membrane protein. There are 2 splice variants of it, known as 
Goia and Go20t, which arise from differential RNA splicing of a single GqO 
gene. Their C-terminal 113 aa are encoded by alternative use of duplicated 
exons 7 and 8  (Kaziro et al. 1991). The positions of the splice junctions of 
the human Goa gene are identical to those of the human Gi2a and Gjsa gene 
in the coding region. As the splice variants differ only in their C-terminal
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region, it is possible that they may interact with different receptors, indeed, in 
rat pituitary GH3 ceils, Goia and Go20t have been shown to inhibit Ca^^ 
channel by coupling to muscarinic and somatostatin receptors respectively 
(Kleuss et al. 1991).
Ggusta is involved in the perception of sweet and bitter taste at the taste buds 
of the tongue (McLaughlin et ai. 1992). The G protein involved in the 
transuction of signal from rhodopsin and opsin receptors is Gta, also known 
as transducin. There are two isoforms of transducin, Gtia found in rod cells 
(coupling with rhodopsin) and Gt2a found in cone cells (coupling with opsin 
receptors) (Lerea et al. 1986). 80% of their amino acid sequence is identical. 
All these G proteins found in sensory organs are believed to couple to cGMP 
phosphodiesterase. Ggusta and Gta can be ADP-ribosylated by both PTX 
and CTX.
Gza is found primarily in neurons, particularly cells with long axonal 
processes. It has a very slow rate of guanine nucleotide exchange, and an 
unusual Mg^ "^  ion dependence when compared to Gga and G-,a proteins 
(Casey et al. 1990). In addition, its intrinsic guanosine triphosphatase 
(GTPase) activity is at least 100 times slower compared to other Ga 
subunits. The functions of Gza are only beginning to be discovered, with 
studies showing that it may Inhibit adenylate cyclase (type I and V) and also 
it can couple to a number of Gja coupled receptors (Fields et al. 1997). An 
interesting study demonstrated a potential role of Gza subunits with p opioid 
receptor when the anti-nociceptive effects of p but not ô opioid agonists were 
diminished in rats injected intracerebroventricuiarly with antisense 
oligonucleotides, which resulted in reduced expression of Gza protein in 
various parts of the brain (Sanchez-Blazquez et al. 1995). Finally, G%a is 
phosphorylated by PKC in vitro, which blocks its interaction with G(3y subunit 
(Kozasa and Gilman 1996).
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Members of Gja subfamily are both palmitoylated (at cysteineS) and 
myristoyiated (at glycine2) except Gta which is only myristoylated. N- 
myristoylation of Ga subunits results in the addition of the saturated 14- 
carbon fatty acid myristate to the N-terminal glycine residue of Gja, G^a, 
Gza, and Gta (Wedegaertner et ai. 1995). Myristoyiation, but not 
palmitoylation, seerhs to be essential for both membrane localisation and 
interaction with Gpy and adenylate cyclase (Taussig et al. 1993). Many 
studies have also showed that preventing myristoyiation by mutation of 
glycine to alanine also prevented palmitoylation of members of the Gja 
subfamily (Wedegaertner et al. 1995).
C) Gqa subfamily
Direct activation of phospholipase C-p (PLC-p) is a common feature of the 
Ga's of this subfamily. However, the potency and specificity of activation of 
the various PLC-p isoenzymes differ among the members of this subfamily. 
Phospholipase C catalyses the breakdown of phosphatidylinositol 4,5- 
bisphosphate (PIP2 ), a minor lipid component of the plasma membrane, to 
inositol trisphosphate (IP3 ) and diacylglycerol (DAG). IP3 is water soluble and 
capable of diffusing through the cytosol to exert its effects by binding to the 
IP3 receptors on a subcompartment of the smooth endoplasmic reticulum. 
The IP3 receptors regulates Ca^ "^  flow from the endoplasmic reticulum to the 
cytosol. DAG, on the other hand, is lipophilic and hence remains associated 
close to the plasma membrane. PKC is activated by both DAG and Ca^^, and 
hence its activity is usually enhanced in Gqa signalling (lismaa et al. 1995).
Gqa and G ^ a  subunits differ by less than 1 2 % in their amino acid 
sequences, especially in their amino terminal domains. This region is 
involved in determining the specificity of interaction with the Gpy subunit and 
the relative rate of nucleotide exchange and hydrolysis. This may give rise to 
differences in regulation of effector isoforms, plus variations in the amplitude 
and duration of signal between the two subunits (Simon et al. 1991).
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Receptors that couple to Gqa or G na include those for TXA2 , bradykinin, 
thrombin, bombesin, angiotensin, histamine, vasopressin and others. 
Interestingly, recent evidence points to the need for tyrosine phosphorylation 
before receptor activation of Gqa/Gna subunit (Umemori et al. 1997).
The importance of Gqa in platelet activation was highlighted in a study by 
Gabbeta et al. (1997) when they found the level of Gqa was less than 50% of 
normal in a patient with abnormal platelet responses. GTPase and 
[35s]GTPyS binding were also diminished in platelet membranes upon 
stimulation with thrombin, platelet-activating factor, or the thromboxane A2 
analogue, U46619. These result were further confirmed by Gqa-deficient 
mice, which had increased bleeding times and were protected from collagen 
and adrenaline-induced thromboembolism (Offermans et al. 1997a). This 
clearly demonstrated the crucial role of Gqa in activation of platelets, which 
cannot be replaced by other subunits.
Other members of the Gqa subfamily include G i4a, which is found in stromal 
and epithelial cells, and G-iea, which is found only in some cells derived from 
the haematopoietic lineage. Despite the very limited expression of Giea, a 
large number of receptors were shown to be able to couple to this subunit 
following its heterologous expression, and there has even been a suggestion 
that it can function as a universal G protein adapter (Milligan et al. 1996).
The N-termini of Gqa and G na differ from other Ga subunits in that they 
contain a unique, highly conserved 6  aa extension (MTLESI) and (MTLESM) 
respectively. Deletion or mutation of this N-terminal extension in Gqa was 
recently shown to allow coupling with non-Gqa-coupled GPCRs (Kostenis et 
al. 1997 & 1998). Palmitoylation of Gqa members occur on cysteine residues 
at the 9th or 10th positions. Gqa subunits are not myristoylated.
22
D) G i 2a subfamily
Although 6 1 2 a and 6 1 3 a proteins are ubiquitously expressed, their functions 
are only recently beginning to be understood. There is evidence implicating 
their involvement in regulating a range of signalling pathways. For example, 
both subunits stimulate Na"'/FI'" exchanger (NHE), via PKC dependent 
(G-i2 a), and independent pathway (Gisa). G13Œ interacts with the Rho 
proteins involved in cellular ^ctin cytoskeletal effects, and hence stimulates 
NFIE mediated by the Rac/Cdc42 Jun N-terminal Kinase pathway (Hooley et 
al. 1996). Moreover, G120C was implicated in pathways that regulate cell 
growth, and was shown to activate NHE through a pathway dependent on 
Ras and the phosphatidylcholine-phospholipase / PKC network (Wadsworth 
et al. 1997). Further evidence that G12OC and G i3a regulate distinct, non- 
complementary signalling pathways was apparent in G i3a gene knock-out 
studies in mice (Offermanns et al. 1997b). Fibroblasts from these mice were 
also defective in thrombin-stimulated cell migration, and hence confirmed the 
role of G i30t in Rho dependent cytoskeletal effects.
G i2 Œ was recently found to directly stimulate Bruton's tyrosine kinase (Btk) 
and G apl^, a RasGAP, in vitro and in vivo (Jiang et al. 1998). G i2 a interacts 
with a conserved domain composed of the pieckstrin-homology domain and 
the adjacent Btk motif, present in both Btk and Gapl*^. Overexpression of a 
constitutively active G i2a (Q229L) in DT40 lymphoma cells led to increased 
kinase activity of endogenous Btk. Similarly, overexpression of G i20 t (Q229L) 
in COS-7 cells reduced the stimulation of Ras by EGF. The Rho guanine 
nucleotide exchange factor p i 15 RhoGEF, was found to be a direct effector 
of G i3 tt (Hart et al. 1998). Activated G i3a bound tightly to p i 15 RhoGEF and 
stimulated its capacity to catalyze nucleotide exchange on Rho. In contrast, 
activated G i2a inhibited stimulation of p i 15 RhoGEF by G 13a. Therefore,
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Gap1^ and p115 RhoGEF appeared to provide a link between signalling in 
heterotrimeric and monomeric G proteins.
A range of GPCRs are known to couple to the G-i2ct subfamily. The thrombin 
receptor was among the first GPCR shown to activate both subunits in 
platelet membranes (Offermanns et al. 1994). Using a cotransfection 
approach, Mao et al. (1998) found that thromboxane A2 , lysophosphatidic 
acid (LPA), and endothelin receptors induce serum response factor in a 03 
exotoxin-dependent manner. C3 exotoxin {Clostridium butulinum C3 
transferase) is a specific RhoA inactivator that ADP-ribosylates RhoA, but 
not Cdc42 or R ad . As activated Gq/na and G12/13a but not Gja or Goa can 
regulate SRF activity, these cotransfection studies were done in a fibroblast 
cell line derived from mice lacking Gq/na. Therefore, GPCRs that induce C3- 
dependent SRF activation in this cell line would suggest coupling with G 
proteins of the G i2a subfamily.
A final point to note of these Ga subunits is that their rate of nucleotide 
exchange is very slow (k = 0.01 to 0.02 min'^) compared to most other G 
proteins except G^a (Fields et al. 1997).
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1.2.2 G Beta and Gamma Subunits
The Gpy complex is made up of two polypeptides, Gp and Gy, but 
functionally it is a monomer as the two subunits cannot be dissociated except with 
dénaturants. At present, 6  different Gp and 12 different Gy subunits have been 
identified (Clapham ef al. 1997). Gp and Gy subunits are very widely expressed, 
with the exception of y1, present only in the photoreceptor cells, and y2 and y3, 
restricted to the brain. While many Gpy pairs can form, not all combinations are 
possible. The ability of Gpy subunits to regulate effectors was relatively recently 
recognised (from 1987). As there are potentially more combinations of Gpy than 
Ga subtypes, there is a possibility that Gpy may play a role as important as Ga in 
mediating GPCR signalling.
Structurally, the GPy complex has been described as a “propeller” (Figure 
1.3) based on crystallography studies (Sondek et al. 1996). Gp subunit is made up 
of 2  structurally distinct regions, an amino terminal segment and a repeating 
sequence. The amino terminal segment comprises about 20 amino acids in an a 
helix. The repeating sequence consists of 7 WD repeating motifs made up of 
small anti-parallel p strands arranged in a ring, forming a propeller structure with 7 
blades.
The WD-repeat comprises a highly conserved core of about 40 amino 
acids, bounded by glycine-histidine and tryptophan-aspartate (WD), and a variable 
length region between WD and the next G FI. Each blade of the propeller is made 
up of 4 twisted p strands; the conserved core making up the inner 3 while the 
variable length region forms the outer strand. Finally, the circular structure is held 
closed by the seventh blade, which is made up of both the N-terminal region (the 
outer strand) and the C-terminal region (the inner 3 strands), forming a kind of 
molecular “velcro snap” (Clapham et al. 1997).
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Figurel .3 The propeller structure of Gpy subunit
Seen from the surface that faces Ga. Gp subunit is in solid gray; Gy subunit is in 
black stripes. The blades are numbered so that the first core W D repeat occurs in 
blade 1 (adapted from Clapham et al. 1997).
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The N-terminus of Gy forms a coiled-coii with the amino a-helix of Gp, with 
the rest of the polypeptide extending across the wider surface of Gp, contacting 
residues in blades 5, 6 , and 7 of the propeller structure (Sondek et al. 1996). 
Docking of the Ga subunit to Gpy involves the Ga N-terminal a helix (tethered to 
the plasma membrane by either palmitoylation or myristoyiation, or both) binding 
to the side of the Gp propeller structure parallel to the central tunnel (Lambright et 
al. 1996). Furthermore, the switch II region of Ga, which changes conformation 
upon binding GTP, is positioned directly over the central tunnel. This crucial 
hydrophobic region (switch II) of Ga is believed to be hidden within the Ga subunit 
upon GTP exchange, and therefore prevented from interacting with the top of the 
Gp propeller (Neer et al. 1996). This results in dissociation of the Ga and Gpy 
subunits, exposing sites for interaction with effectors.
Gpy interferes with the function of Ga subunit, especially in the dissociation 
of bound GDP from the Ga protein, a pre-requisite step for GTP exchange. This 
effect is Mg^^ dependent; at low concentration of Mg^^ (less than 5mM) Gpy dimer 
inhibits the GTPase activity of Goa as it slows the dissociation of GDP. At higher 
concentrations, the rate of dissociation of GDP from the Gqapy heterotrimer is 
greater than the Goa monomer (Higashijima et al. 1987). Since the intracellular 
Mg^^ concentration is about ImM, it is postulated that the predominant effect of 
Gpy in the cell would be to slow the GTPase activity of Ga by stabilizing the 
inactive, GDP-bound state (Clapham et al. 1997). A further effect of Gpy subunit 
on Ga is in enhancing the binding of Ga protein to its appropriate receptor 
(Higashijima et al. 1987). This is likely due to the isoprenylation of Gy subunit 
(farnesylation for y1 ; geranylgeranylation for other y-subtypes) at the carboxyl 
terminus, which localises the Gpy dimer to the plasma membrane.
The discovery that Gpy subunits can activate the muscarinic channel in 
pacemaker cells marked the first evidence of direct regulation of an effector by 
Gpy dimers (Logothetis et al. 1987). However, the widespread interest in 
unravelling how Gpy subunits participate in GPCR signalling started only when 
adenylate cyclase and phospholipase were found to be involved. Adenylate
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cyclase type I activity can be inhibited by Gpy, while adenylate cyclase type II and 
type IV have been shown to be stimulated by Gpy subunits when the cyclases are 
also activated by Gga (Tang et al. 1991). Such difference from Ga regulation of 
effectors also extend to the activation of PLC-p, where high nanomolar and even 
micromolar concentrations of Gpy dimers are required, compared to the low or 
sub-nanomolar concentrations for Ga subunits (Birnbaumer 1992). Since AC and 
PLC are also regulated by Ga subunits, such convergence of signalling on the 
same effector may represent a further modulation of signals within the cell arising 
from agonist activation of different GPCRs. However, there are also effectors 
(direct and indirect) specific for Gpy dimers; PLA2 , GRK2 & GRK3, phosducin, 
phosphoinositide-3 kinase, mitogen activated kinase cascade proteins (e.g. She, 
Raf-1, Ras exchange factor), Btk, and plasma membrane Ca^^ pump (Clapham et 
al. 1997).
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1.3 Receptor G-protein Coupling
The coupling of GPCRs with heterotrimeric G proteins is generally specific. 
This is partly due to the differential tissue expression of GPCR and G proteins. For 
example, transducin (Gta) is expressed in rod cells, which accounts for why only 
rhodopsin transmits extracellular signals via this Ga subunit. However, in a vast 
majority of cells, the presence of different Ga subunits implies that the GPCR and 
the Ga must contain specific domains that enable them to “recognise" or couple 
to each other. This coupling specificity of GPCR with their cognate Ga had long 
been a topic of great interest, as this directly affects the activation of secondary 
effector's, and ultimately the final physiological response.
1.3.1 Receptor domains essential for coupling
Various approaches including receptor chimeras, deletions, point 
mutations, and short peptides that mimic or inhibit receptor interactions with Ga 
have been employed to identify critical regions of the receptor that coupled to G 
proteins. These studies pointed to the importance of intracellular domains, 
especially the C-terminal residues of 1C2, the N- and C-terminal portions of IC3, 
and the C-terminal tail (Bourne 1997).
Extensive studies using rhodopsin and iPa-adrenergic receptors were 
among the first to establish the involvement of the second and third 1C loops in 
GPCR / Ga interactions. For the rhodopsin receptor, biochemical, mutagenesis, 
and peptide competition studies identified the residues 143-150 of IC2 and 
residues 236-239, 244-249 of IC3 as domains essential for activation of Gta 
(Konig et al. 1989). Similar segments in the P2-adrenergic receptor, namely the N- 
terminal and C-terminal portions of 1C3, plus the C-terminal cytoplasmic domain 
proximal to TM7 were found to be critical for activation of Gga (Savarese et al. 
1992). The shortest segment of the intracellular loop shown to confer specificity in 
G protein coupling was mapped to a 4 aa epitope on the M2 muscarinic 
acetylcholine receptor (Liu et al. 1995). This epitope was predicted to be located
29
at the junction between 1C3 and TIVI6 , and can specifically recognise the C- 
terminal 5 aa of a subunits of the G\a subfamily.
Most GPCRs share similar Ga coupling domains with the rhodopsin and p2 “ 
adrenergic receptors. In instances where the coupling domains are not entirely 
similar, substituting regions of the cytoplasmic domain may confer additional 
coupling capacity to the receptor. For example, in chimeric constructs of 
muscarinic acetylcholine (Mi and- M2 ) and (3i-adrenergic receptors (Wong et al.
1994), each parental receptor activates a single G protein exclusively: Mi 
muscarinic (Gqa), M2 muscarinic (G ja), and -adrenergic (Gga). However, when 
the IC3 of both the Mi and M2 muscarinic receptor was replaced by the 
corresponding sequence from the pi-adrenergic receptor, these chimeric 
receptors were able to activate all 3 types of G a  subunits. This effect was 
abolished when both IC2 and 1C3 was substituted with that of pi-adrenergic 
receptor as only Gga can be activated.
The importance of receptor C-terminal tail in GPGR/Ga coupling was 
shown by the difference in G protein coupling of bovine EP3  splice variants, where 
they differ only in their intracellular C-tails (Namba et al. 1993). Of the EP3 
receptor splice variants, EP3A activates the Gja sqbfamily, both EP3 B and EP3 C 
activate Gga subfamily, while the EP3 D activates Gja, Gga, and Gqa subfamilies. 
Such differences in G protein activation is not directly related to the length of the 0 
terminal: EP3A has the longest 0  terminal, EP3C the shortest, while both EP3 B and 
EP3 D have similar number of residues. However, it is interesting to note that the 
gonadotropin-releasing hormone receptor appears to completely lack a carboxyl 
terminal tail (Tsutsumi et ai. 1992) which suggests that this region is not essential 
for Ga coupling in all GPCRs.
Despite the above evidence alluding that the GPCR intracellular domains 
are essential for coupling to Ga, it must be mentioned that the overall 
conformation of the GPCR is rather flexible or plastic, and hence G protein
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coupling can be affected by regions beyond the intracellular domains. For 
example, a point mutation in the extracellular loop of the luteinizing-hormone 
receptor abolished its ability to activate Gga but preserved its ability to stimulate 
Gqa (Gilchrist et al. 1996). Furthermore, point mutations in the TM3 of aig- 
adrenergic receptor caused selective and constitutive activation of Gqa, but not 
Gja (Perez et al. 1996). •
1.3.2 G-protein domains essential for coupling
There are at least 3 regions of Ga postulated to contact the receptor, with 
the strongest evidence pointing to the C-terminus. Similar approaches: chimeras, 
point mutations, and short peptides were employed to delineate the regions of Ga 
crucial for interacting with GPCR.
The importance of the extreme C-terminus was evident very early when 
pertussis toxin was shown to covalently modify a cysteine residue (4th aa from the 
C-terminus) of the Gja family (except G^a) and hence caused uncoupling of the 
ADP-ribosylated Ga from the GPCR (West et al. 1985). This was followed by the 
discovery of an une (uncoupled) mutation in which a proline residue was 
substituted for arginine at the 6 th aa from the C-terminus of Gga (Sullivan et al. 
1987). This mutated Gga was shown to respond normally to agents that act 
directly on Gga such as cholera toxin, AIF4 ' ion, and hydrolysis-resistant guanine 
nucleotides. However, activated GPCRs failed to transduce extracellular signal 
through the mutated Gga to activate adenylate cyclase.
In another study, a peptide mimicking the last 11 residues of Gta not only 
inhibited stimulation of Gta by rhodopsin, but also mimicked the ability of Gta to 
induce a spectral change in rhodopsin (Hamm et al. 1988). These and other 
studies using chimeric G proteins (Conklin et al. 1993a), antibodies (Simonds et 
al. 1989), and structural studies (Hamm 1991) further established the role of the 
Ga extreme C-terminus (last 5 to 11 aa) in receptor coupling. Despite all this 
evidence, it should be noted that the C-terminus of Ga is not the only region
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interacting with the GPCR. This was shown by the fact that transducin has almost 
the same last 2 0  residues as Gja and Goa subunits, yet the a2-adrenergic receptor 
activated Gja and Goa but not transducin (Cerione et al. 1986).
Evidence that the N-term in us of Ga was also involved in GPCR coupling 
was shown by a study that a photo-affinity peptide corresponding to the 103 region 
of the a2A-adrenergic receptor can be cross-linked to the amino terminus of Gga 
(Taylor et al. 1994). This confirmed previous work by Hamm et ai. (1988) on the 
inhibtion of interaction of Gta with rhodopsin using a synthetic N-terminal peptide 
of Gta. Furthermore, a chemical cross-linker attached mastoparan to a cysteine 
residue near the extreme N-terminus of Goa (Higashijima et al. 1991). Mastoparan 
is a wasp venom peptide that activates G proteins of the Gja subfamily. It is 
predicted to form an amphipathic a helix that mimics the GPCR 1C2 and 1C3 
regions.
A third region of Ga that may contact the receptor surface was mapped to 
residues 311 to 328 of Gta (Hamm et al. 1989; Hamm 1991). This peptide 
behaved like the last 1 1  residues of Gta in inhibiting Gta activation by 
photorhodopsin and at the same time induced spectral changes in 
photorhodopsin. The analogous region in Ras was postulated to be the G5 region, 
where the guanine ring interacts with the side chains in this region (Conklin et al. 
1993b). There is currently no further study on the interaction of this domain with 
GPCRs.
1.3.3 Divergent Signalling in GPCRs
Although the majority of GPCRs transduce signals in a linear pathway (i.e. 
via a single effector system), there is emerging evidence that a number of 
receptors can couple to more than one Ga protein, and hence activate multiple 
effectors. Such divergent signalling can also be observed for multiple receptor 
subtypes that are pharmacologically indistinguishable. Alternatively, the Gpy 
subunit may also regulate a different effector from that of the activated Ga
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subunit, and hence mediate secondary effects apart from that arising from the Ga 
(Milligan 1993).
The prototypical GPCR that exhibits promiscuity in Ga coupling is the a2A- 
adrenergic receptor. Overexpression of this receptor in CHO (Chinese Hamster 
Ovary) cells indicated its association with Gja and Gga subunits from co- 
immunoprecipitation studies (Eason et al. 1992). This was further supported by 
the observation that agonist stimiHated adenylate cyclase following pertussis toxin 
pretreatment. Furthermore, in co-expression studies, the a2A-adrenergic receptor 
was observed to couple to Gja, Gqa, and Gga subunits upon stimulation by 
agonists, which also demonstrated that their effective concentration at 50% 
response (EC50) varied between the different Ga (Chabre et al. 1994). We should 
however, be cautious in interpreting the significance of these results as 
overexpression studies tend to produce enforced coupling between the GPCR and 
the Ga (Kenakin 1997). Indeed, in the study by Eason et al. (1992), elevation of 
cAMP only occurs at more than 5 pmol/mg of a2A-adrenergic receptor and at high 
agonist concentration (micromolar).
An endogenously expressed GPCR that shows pleiotropic cellular 
responses is the human thyrotropin (TSH) receptor, expressed in human thyroid 
cells (Laugwitz et al. 1996). Upon receptor activation, G proteins of all 4 families 
(Ggtt, G ja, Gqa, and G i2a ) incorporated the photo-reactive GTP analogue [a- 
P]GTP azidoanilide. This incorporation occurred at similar levels of the 
physiological ligand, TSH, which indicates that the TSH receptor couples equally 
well with the various G a . This represents a naturally occurring general G a -  
activating receptor and suggests that such promiscuous coupling may also be 
found in other GPCRs. Other GPCRs that couple to more than one G a  subunit 
include the P2“3 clrenergic receptor (Xiao et al. 1995), the luteinizing hormone 
receptor (Herrlich et al. 1996) and many others. An unusual mechanism for the 
switching of G a  coupling in the p2-adrenergic receptor was discovered recently 
(Daaka et al. 1997). In that study, Gga was shown to be initially activated by the
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(32-adrenergic GPCR. Sustained agonist occupation subsequently resulted in the 
activation of PKA due to the elevated cAMP levels. The activated PKA then 
phosphorylated the j3 2-adrenergic receptor and enabled coupling with the Gja 
subunit. It is currently not known how many GPCRs might make use of such a 
mechanism to switch coupling between different G proteins.
The bovine EP3  prostaglandin receptor splice variants differ at their C- 
terminus and were also shown to regulate different secondary effectors (see 
section 1.3.1). Similarly, for the human EP3  receptor isoforms, there are 
differences between the subtypes in their ability to mobilise Ca^^. Although all the 
human EP3  receptor isoforms are capable of inhibiting adenylate cyclase, under 
conditions of high levels of expression, activation of the same receptor can also 
lead to stimulation of cAMP formation (Schmid et al. 1995). This suggests that the 
level of receptor expression, or the host cell, can affect the apparent differential 
coupling to various Ga. Indeed, all six C-terminal splice variants of the human EP3  
receptors displayed similar binding and Ga-coupling characteristics when 
expressed in BHK-21 cells, with careful control for receptor density (Gudermann et 
al. 1996). Other examples of differential Ga-coupling between splice variants 
include the receptors for pituitary adenylate cyclase-activating polypeptide 
(PACAP), dopamine, calcitonin, serotonin and many others.
The last form of divergent signalling was observed from the activation of a 
single Ga subunit but with the secondary effect arising from the dissociated Gj3y 
partner. Such divergent signalling has been observed in a large number of 
receptors, including the IVI2 and M4 muscarinic, serotonin, D2 dopamine, 
somatostatin and certain subtypes of the a2-adrenergic receptors (Milligan et al. 
1993; Hildebrandt et al. 1997). A common characteristic of such signalling is that 
the effects mediated by Gpy subunits require considerably higher agonist 
concentrations compared to that mediated by Ga subunits (Birnbaumer 1992). 
Moreover, these effects are usually dependent on receptor abundance and host 
cell.
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1.4 Prostaglandin Receptors
1.4.1 Prostaglandins and their biosynthesis
Prostaglandins (PGs) refer to a group of bioactive lipids with very diverse 
physiological functions. They were first discovered in 1930 by Kurzrok and Lieb 
(1930) in human seminal fluid, and shown to contract human uterus. This 
observation was further confirmed by other investigators and as they were thought 
to be produced by the prostate gland, the bioactive lipid(s) were named 
prostaglandin. By the 1970s most prostaglandins were isolated, and their 
importance in human physiology beginning to be realised. There was also much 
enthusiasm about their potential as drugs, especially with the discovery of TXA2 
and PGI2 , which regulate platelet aggregation and thrombosis. The vast array of 
agents acting on prostaglandin receptors is a testimony to that enthusiasm in the 
70s and 80s.
Prostaglandins and thromboxanes (TXs) are derived from arachidonic acid, 
release from phospholipids of cell membranes by the action of phospholipase A2 
(PLA2 ) (Campbell 1990). The released arachidonic acid can activate 2 enzyme 
systems: cyclooxygenase and lipoxygenase. Gyclooxygenase converts
arachidonic acid into cyclic endoperoxides (PGG2 and PGH2) that can be further 
converted to other PGs and TXs. Lipoxygenase catalyses arachidonic acid into 
hydroxyl fatty acids that can be further converted to ieukotrienes (LTs). LTs are 
involved in inflammatory responses, especially in the chemotaxis of neutrophils 
and eosinophils. Figure 1.4 shows a simplified schematic diagram of the 
biosynthesis of PGs, TXA2 , and LTB4. PGs are named with alphabets from A to I 
depending on the substitutions on the cyclopentane ring, with a suffix 1 to 3 
denoting the number of double bonds in the side chains. TXs are similarly named, 
but has substitutions on the cyclohexane ring instead. LTs are not considered as 
part of the prostaglandin family and will not be discussed in detail.
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Figure 1.4 Biosynthesis of prostaglandins
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1.4.2 Prostaglandin Receptor Family
The mammalian prostaglandin receptor family consists of 5 subfamilies: 
DP, EP, FP, IP and TP, classified in accordance with their affinity for the various
PGs: PGÜ2 , PGE2 , PGp2a, PGI2 , and TXA2 respectively (Coleman et al. 1994). 
There are no receptors for certain PGs as they are either unstable or 
intermediates of prostaglandin synthesis.
cDNAs of all known members in the PG receptor family have been cloned 
(Pierce et ai. 1995). Interestingly, molecular cloning of these receptors led to the 
unexpected discovery of isoforms generated by alternative mRNA splicing. Some 
of these receptor isoforms can even couple to different effector systems. 
Phylogenetic analysis of PG receptor sequences led Narumiya et ai. to the 
conclusion that they evolved from a precursor EP receptor into two subfamilies 
(see Figure 1.5) that differ with respect to their G protein coupling (Toh at al. 
1995). The various receptor subfamilies will be briefly mentioned, while the IP 
prostanoid receptor will be discussed in a separate section.
Figure 1.5 PG Receptor Phylogeny
Adapted from Kedzie et ai. 1998
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A) DP
The DP receptor is the least ubiquitous of the PG receptor family (Hirata et 
al. 1994). It is distributed largely in blood platelets, vascular smooth muscle, 
and nervous tissue including the central nervous system. Responses 
mediated by DP receptors are predominantly inhibitory in nature including 
the inhibition of -platelet aggregation and inhibition of autonomic 
neurotransmitter release. The study of DP receptors has been facilitated by 
the availability of a number of rather selective and potent agonists and 
antagonists (Coleman et al. 1994). The use of these agonists and PGD2 
itself have shown that DP receptors can couple to Gga to stimulate adenylate 
cyclase.
B)EP
There are 4 subtypes of EP receptors to date with splice variants for the EP3 
subtype (Pierce et al. 1995). EPi receptors mediate smooth muscle 
contraction of the trachea, gastrointestinal tract, uterus and bladder. Their 
expression is not very high compared to other EP subtypes, and is species 
dependent. Occupancy of EP-j receptors appears to mobilise Ca^ "^  from 
intracellular stores independent of IP3 . EP2 receptors are more widespread 
and mediate a wide range of responses like relaxation of smooth muscle, 
inhibition of mediator release in inflammatory cells, and activation of sensory 
afferent nerves. They are most highly expressed in ileum, then thymus, lung, 
spleen, heart and uterus of mouse tissue. Studies done so far imply that it is 
coupled to adenylate cyclase through Gga (Coleman et ai. 1994).
EP3 receptors are the most ubiquitous of all EP subtypes, with 6  splice 
variants in human (Pierce et al. 1995). These splice variants share the same 
amino termini and TMs and start to differ from the 11th residue of the C 
terminal domain. Probably because of the many isoforms, EP3 receptors 
mediate very diverse functions like contraction of smooth muscle, inhibition 
of neurotransmitter release in autonomic nerves, inhibition of lipolysis,
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inhibition of acid secretion from gastric mucosal cells, and also inhibition of 
water reabsorption from renal medulla. The EP3  receptor agonist 
misoprostol, an anti-gastric ulcer drug, is perhaps the most useful therapeutic 
agent from amongst the large library of compounds acting on PG receptors. 
As mentioned before, splice variants of the EP3  receptor are promiscuous in 
their coupling to Gjx, and hence activate a number of effector systems 
(Namba et al. 1993).
Finally, the EP4 receptor was identified recently as having similar antagonist 
but not agonist (butaprost) binding properties as the EP2 receptor, and it also 
activates the same effector system. Due to their similar characteristics, a 
cDNA of the EP4 isoform was initially mistaken as that of EP2 (Pierce et ai.
1995).
C )F P
FP receptors mediate quite a range of functions including luteolysis of the 
corpus luteum and contraction of iris sphincter. It is also found in ocular 
tissue, and acts to lower intra-ocular pressure; hence agonists of FP 
receptors were found to be useful in the treatment of glaucoma. These 
effects were associated with elevation of intracellular Ca^ "^  and PI turnover, 
suggesting coupling with the Gqa subfamily‘of G proteins (Coleman et al. 
1994).
D) TP
Thromboxane was initially found to act on thrombocytes (platelets), which 
contain TP receptors. These receptors mediate inflammatory responses like 
vasoconstriction, platelet aggregation, bronchoconstriction etc. They are 
found in vascular smooth muscle, platelets, and airway smooth muscles 
(Hirata et al. 1991). They may also play a key physiological role in the 
closure of umbilical vessels at birth. Futhermore, TP receptors could be 
involved in wound healing and scar formation, and also in thymocyte 
differentiation and development. There are many antagonists of varied
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structures but none are currently in clinical use. Second messenger studies 
on TP receptors suggest that it is coupled to Gqa subunits to activate 
phospholipase C and mobilise Ca "^" (Coleman et al. 1994).
1.4.3 Prostacyclin (IP) Receptor
The cDNA of the human IP receptor was cloned only in 1994 by 
Abramovitz's group (Boie et al. 1994). It encodes a protein of 386 amino acids 
with a predicted molecular mass of 40, 961 daltons (Figure 1.6). When expressed 
in Xenopus oocytes and challenged with agonist, it stimulated the cAMP-activated 
Cr channel. Other expression studies also indicate that the IP receptor is 
functionally coupled to adenylate cyclase activation via Gga (Smyth et al. 1996). 
Furthermore, the IP receptor was reported to elevate IP3  and Ca^ "^  via a pertussis 
toxin-insensitive G protein (Namba et al. 1994). This effect is seen at much higher 
agonist concentrations than required for elevation of cAMP and its physiological 
relevance is currently unclear. It seems possible that the elevation of IP3  is 
mediated via Gpy subunits rather than Gqa, due to the characteristic higher 
agonist concentrations required in Gpy signalling processes. IP receptor mRNA 
was found most abundantly expressed in kidney, with lesser amounts in lung and 
liver (Boie et al. 1994).
The human IP receptor has two putative N-Îinked glycosylation sites on its 
N-terminal domain and the first extracellular loop (see Figure 1.6). The receptor 
shares 23 residues in common with other prostanoid receptors and another 10 
residues in common with all GPCRs (Boie et al. 1994). Of interest is that the IP 
receptor has phenylalanine at position 292 in TM7 instead of the tyrosine which is 
present in virtually all other GPCRs. This tyrosine residue forms part of the N/D- 
PXXY sequence where it was shown recently that receptors carrying the NPXXY 
but not the DPXXY motif may form functional complexes with ADP-ribosyiation 
factor (ARF) and RhoA (Mitchell et ai. 1998). There are two PKC phosphorylation 
consensus sequences in the C terminus of the IP receptor (see Figure 1.6), but
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recent study by Smyth et al. showed that serine 328 is the primary PKC 
phosphorylation site (Smyth et al. 1998).
A) Physiological functions and potential therapeutic roles
The IP prostanoid receptor was first identified in platelets, and was shown to 
stimulate adenylate cyclase upon activation by PGI2 (Gorman ef al. 1977). It 
opposes the functions of the TP receptor, and therefore acts to counteract 
the pro-inflammatory responses of thromboxanes. Hence, agonists acting on 
IP receptors have great potential as inhibitors of platelet aggregation and 
thrombosis. This effect is probably mediated by elevation of intracellular 
cAMP via Gga subunit. However, as IP receptors are also found in arterial 
smooth muscle, and no subtypes of IP receptors have been found to date, 
agonists that prevent thrombosis caused profound vasodilation effects at the 
same time.
IP receptors are also involved in mediating inflammatory hyperalgesia. Due 
to their presence in sensory neurones, they sensitise or directly activate the 
nerve endings upon the release of prostanoids generated by cells in 
response to mechanical, thermal or chemical injury and inflammatory insult 
(Bley et al. 1998). This hyperalgesic effect of IP receptors was further 
confirmed by studies in transgenic mice lacking the receptor (Murata et al. 
1997). Therefore, selective antagonists of the IP receptor may act as 
potential blockers of inflammatory pain. This approach is currently explored 
by major pharmaceutical companies (Bley et al. 1998).
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Figure 1.6 Diagram of the human IP prostanoid receptor
Consensus sequences for PKC phosphorylation are shown in black, while N- 
linked glycosylation sites are indicated in the N terminus and first extracellular loop 
with a Y (Adapted from Smyth et al. 1996).
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B) Agonist Studies
The endogenous ligand, PGI2 is chemically unstable, and has a very short 
duration of action. Although PGEi and its 6 -keto analogue are also 
moderately potent at the IP receptor, most prostaglandins are non-selective 
for the various PG receptors. Due to the potential therapeutic role of IP 
receptor agonists as anti-platelet agents, a range of chemically stable, 
potent, and selective compounds were developed by various companies in 
the last decade.
The first compound to combine chemical stability with high IP receptor 
agonist potency is iloprost, developed by Sobering in the early 1980s, and is 
a close analogue of PGI2 (Figure 1.7). It is not only at least as potent as PGI2 
but also more selective at the IP receptor (except for EPi subtype). 
Moreover, it is far more stable with an extended duration of action in vivo. 
Another compound developed by Sobering is cicaprost, which is slightly more 
potent than iloprost but with almost no activity at other PG receptors 
(Coleman et ai. 1994). Other selective compounds include octimibate, BMY 
45778, BMY 42393, taprostene, TEl-9063, ONO-1301 etc. A recent study 
showed the rank order of potency for PGs and PG analogues for the human 
IP receptor expressed in COS cells as: iloprost »  carbacyclin »  PGE2 >
PGp2a = PGD2 (Boie et al. 1994). Despite enormous efforts, there are still no 
clinically useful IP agonists; the probable reason could be their strong 
vasodiiative effects.
Recent binding studies on chimeric mouse IP/DP (mlP/DP) receptors 
showed that TM6  to TM7 of mIP receptor confers the specificity to bind IP 
agonists such as PGEI and iloprost (Kobayahi et al. 1997). This was 
because when the region from TM6  to the carboxyl terminus of mIP receptor 
was replaced with the corresponding segment from mDP receptor, the 
chimeric receptor was able to bind IP and DP agonists indiscriminately.
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When only the carboxyl terminus of miP receptor was substituted with that of 
mDP receptor, binding was confined to IP agonists strictly.
A further proof of the importance of TM7 of PG receptors in agonist binding 
comes from a point mutation study by Kedzie et al. (1998). By mutating 
leucine 304 to tyrosine in the human EP2 receptor, they were able to show 
functional activation' of the mutant receptor by both EP receptor agonist 
(PGE2) and IP receptor agonist (iloprost). This study further confirmed the 
proposed PG receptor phytogeny (see Figure 1.5) in that PG receptors 
evolved functionally from an ancestral EP receptor before the development 
of distinct binding epitopes. This mutant receptor therefore represents a 
molecular “missing link” in the evolution of the IP receptor from EP2 receptor 
(Kedzie et al. 1998).
Currently, there is no specific antagonist that blocks the IP receptor, and their 
therapeutic potential is therefore not clear. However, we can expect some 
compounds to be developed very soon judging from the interest shown in it.
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1.5 Research Objectives
The primary aim of this study is to increase the G protein output of a Gga- 
coupled GPCR to a level that can be detected by assays that monitor G protein 
activation and termination. This will allow the measurement of agonist activity at 
the earliest point of the GPCR signalling cascade.
Currently, the measurement of guanine nucleotide exchange and the 
subsequent hydrolysis in the GPCR activated Gga protein is besieged with various 
obstacles (Wieland et al. 1994; Gterschik et al. 1994). Although such phenomena 
were first observed in the Gga proteins (through the stimulation of turkey 
erythrocyte membranes with adrenaline by Casse! and Seiinger 1977), the activity 
obtained is still relatively low compared to that of the Gja subfamily. Therefore, 
agonists acting on Gga-coupled GPCRs are usually assayed via its secondary 
effector, the adenylate cyclase enzyme. The assay of this activity is reliable and 
highly sensitive (Wong 1994), but it can be affected by various factors including 
the type and level of adenylate cyclase, interference from Gja and GPy signalling, 
and also receptor expression level. These factors differ between the cell lines 
used and can affect the pharmacological analysis of receptor agonists even with 
recombinant systems (Kenakin 1997).
As the IP prostanoid receptor regulates various important functions in the 
body and was also shown to be an important mediator of inflammatory pain, this 
receptor is thus of high interest to the pharmaceutical industry and may be a 
potential target for high-throughput screening. Current functional assays that 
monitor effector activity are not compatible with high-throughput screening formats 
that monitor Ga activity. Moreover, the ability to monitor Ga activity will avoid the 
pitfalls associated with analysis of effector activity. By studying the G protein 
signalling characteristic of the human IP prostanoid receptor, it is hoped that novel 
assay systems may be developed that allow the monitoring of agonist-promoted 
Ga activity.
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CHAPTER 2 MATERIALS AND METHODS
2.1 Materials
All reagents used in this study were of analytical or similar grade and were 
purchased from the following suppliers;
2.1.1 General Reagents
Alexis Corporation Ltd., Bingham, Nottingham, U. K.
DTT
Amersham International pic., Buckinghamshire, U. K.
Enhanced chemiluminescence reagent 
BDH
Ammonium persulphate, glucose, glycine, Na2HP04
Boehringer Mannheim U. K. Ltd., Lewes, East Sussex, U. K.
App(NH)p, aprotinin, creatine phosophokinase, GDP, GTPyS and restriction 
enzymes
Calbiochem-Novabiochem Ltd., Beeston, Nottingham, U. K.
Geneticin (G-418)
Fisher Scientific Equipment, Loughborough, U. K.
Acetic acid, DM80, EDTA, HEPES, hydrochloric acid, KCl, KH2 PO4 , K2 HPO4 , 
MgCl2 , NaCI, NaaCOs, NaHCOs, NaH2 P0 4 , sucrose, SDS, trichloroacetic acid
FMC BioProducts, Rockland, USA
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Agarose
Fuji Photo Film Co. Ltd., Tokyo, Japan 
X-ray film
Genosys, Cambridge, U. K.
Oligonucleotides
Gibco BRL Life Technologies Inc, Paisley, U. K.
Lipofectamine™, TRIS, 1 kb DNA ladder, oligonucleotides
Invitrogen, San Diego, CA, U. S. A.
pcDNA3
Merck Ltd., Poole, Dorset, U. K.
Agar, NaOH
Oxoid Ltd., Hampshire, U. K.
Tryptone, yeast extract
Premier Beverages, Stafford, U. K. =
Marvel
Promega Ltd., Southampton, U. K.
Restriction enzymes, DNA purification kits - Wizard™ Minipreps and Wizard™ 
Maxipreps systems
Qiagen Ltd., West Sussex, U. K.
QlAquick Gel Extraction Kit
Sigma Chemical Company, Poole, Dorset, U. K.
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Alumina, ampicillin, cholera toxin, DOWEX AG50 W-X4 (200-400 mesh), forskolin, 
imidazole, mineral oil, pertussis toxin, TEMED, thimerosai, TRIGINE
Stratagene Ltd., Cambridge, U. K.
Pfu DNA Polymerase
Whatman International Ltd., Maidstone, U. K.
Brandell GF/C Glassfibre filters
2.1.2 Radiochemicals
Amersham International pic., Buckinghamshire, U. K.
[^H]Adenine (specific activity; 20 Ci/mmol)
[^H]lloprost (specific activity; 11.5 Ci/mmol)
Du Pont NEN Ltd., Stevenage, Hertfordshire, U. K.
[y^^PjGTP (specific activity; 30 Ci/mmol)
[^^S]GTPyS (specific activity; 1250 Ci/mmol)
2.1.3 Tissue Culture
American Tissue Culture Collection, Rockville, U. S. A.
Human Embryonic Kidney (HEK293) cells
Costar Scientific Corporation, Buckinghamshire, U. K.
Dishes 10 cm diameter. Flasks 25 cm^ and 75 cm^, Plates 6 , 12 and 24 wells, 
Disposable cell scraper
Gibco BRL Life Technologies Inc, Paisley, U. K.
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Glutamine (2000mM), Newborn calf serum, NaHCOs (7.5% % ), Optimem-1 
medium
Sarstedt, Numbrecht, Germany 
Cryovials
Sigma Chemical Company, Poole, Dorset, U. K.
Dulbecco’s Modified Eagle’s Medium (DMEM), Minimum Essential Medium (MEM) 
Sterilin Bibby Ltd., Stone, Staffordshire, U. K.
Pipettes 5 ml, 10 ml and 25 ml
2.1.4 Standard Buffers
Tris Buffered Saline (TBS)
NaCI 150 mM
Tris/HCl 20 mM
pH adjusted to 7.5
This was usually made up from 20 ml of 1M Tris (pH 7.5) and 30 ml of 5M NaCI 
for a 1 litre solution.
Tris Buffered Saline with Tween (TBST)
As for TBS but with Tween 2 0  (0.1% %) added
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Tris-EDTA Buffer (TE)
Tris/HCl 10mM
EDTA 0.1 mM
pH adjusted to 7.5
This was usually made up as a 10X stock solution and diluted when required. 
Phosphate Buffered Saline (PBS)
K C l 2 .7  m M
K H 2 P O 4  1.5 m M
N a C I 140 m M
N a H 2 P 0 4  8  m M
pH adjusted to 7.4
This was made as a 10X stock solution and diluted when required,
Laemmli Buffer (2X)
DTT 0.4M
SDS 0.17M
Tris/HCl (pH8 ) 50mM
Urea 5M
Bromophenol Blue 0.01% ' /^y
This was stored in aliquots at -20°C until required.
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2.1.5 Antisera 
Anti-FLAG M6
Mouse monoclonal antibody that binds to N-terminal methionine-FLAG proteins.
- purchased from Kodak IBI Ltd., New Haven, U. S. A.
Anti-Ga antisera
These antisera were generated against synthetic peptides described in Goldsmith 
et al. 1988. Conjugates of these peptides with keyhole-limpet haemocyanin were 
injected subcutaneously into New Zealand White rabbits. Bleeds were obtained 
from the ear artery. Amino acid sequence of the synthetic peptides derived from 
the various Ga are listed below;
Antiserum Peptide Sequence Ga Residues Specific for;
OS RMHLRQYELL last 1 0  aa of Gga Gga
SG KENLKDCGLF last 1 0  aa of Gta Gta,Gj-ja, Gj2a
CQ QLNLKEYNLV last 1 0  aa of Gqa Gqa, G-|-ja
lie LDRIAQPNYI 159 - 168 àa of G^a Gj-ia
Anti-mouse IgG
Goat polyclonal antibody conjugated with horseradish peroxidase, purchased 
from Sigma Chemical Company, Poole, Dorset, U. K.
Anti-rabbit IgG
Donkey polyclonal antibody conjugated with horseradish peroxidase, produced by 
the Scottish Antibody Production Unit, Lanarkshire, U. K.
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2.2 Cell Culture
All tissue culture manipulations were done in laminar flow hoods designed 
for cell culture work, with regular cleaning and servicing schedules. Aseptic tissue 
culture techniques were followed strictly, and antibiotics usage was limited to 
medium for maintenance and selection of stable cell lines. Any contaminated cells 
were disposed and dealt with promptly. Finally, mycoplasma testing of all cell lines 
are done twice a year.
2.2.1 Routine Cell Culture
The primary cell line used for the present study is Human Embryonic 
Kidney (HEK293) cells. It was grown in continuous monolayer culture in 75 cm^ 
sterile tissue culture flasks in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 2 mM L-glutamine and 10% Newborn Calf Serum (NBCS). 
Flasks of cells were incubated in cell culture incubators (Jencons Nuaire) in a 
humidified atmosphere of 95% air / 5% CO2 at 37°C.
Confluent cells were detached from the flasks by the addition of 1.2 ml 
trypsin solution (0.1% trypsin, 0.025% ' /^y EDTA, and 10 mM glucose) after the 
removal of medium. When all the cells were detached, trypsinisation was 
terminated by the addition of 5 volumes of grgwth medium. The cells were 
centrifuged at about 800 x g for about 5 min. The cell pellet was finally 
resuspended in growth medium and plated out as required. For routine 
maintenance of cell line, HEK293 cells were split 1:16 to 1:20 per week.
2.2.2 Transient Transfections
Transient transfections of DNA into HEK293 cells were achieved using 
Lipofectamine™ reagent (Gibco Life Technologies) according to the 
manufacturer’s instructions.
Briefly, a 75 cm^ flask of confluent HEK293 cells was split into five or six 
100 mm diameter tissue culture dishes the day before transfection. On the day of
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transfection, the confluency of cells should be between 60 to 80%. For each dish, 
about 5 pg of DNA was used, diluted in 0.4 ml of Optimem-1 medium. 
Lipofectamine™ was also diluted in Optimem-1 medium to give a 0.1 mg/mi 
solution. Equal volumes of the diluted DNA and Lipofectamine™ were then mixed 
together (i.e. 0.4 ml of DNA suspension + 0.4 ml of Lipofectamine™ suspension) 
and incubated at room temperature for about 30 min. In the meantime, cells on 
the dish were rinsed once in Optimem-1. Finally, 5.2 ml of Optimem-1 medium 
was added to the DNA / Lipofectamine™ mixture, mixed well, and then added to 
cells on the dish.
After 5 h incubation in a cell culture incubator, 6  ml of DMEM containing 
20% NBCS was added to the dish, and left overnight in the incubator. On the 
following morning, the DNA / Lipofectamine™ mixture was removed and replaced 
with about 1 0  ml of growth medium. The cells were incubated for another 24 to 48 
h before they were harvested or assayed.
2.2.3 Generation and Maintenance of Stable Ceil Lines
Generation of stably expressing cell lines involved selecting isolated 
colonies of cells (also known as clones) that incorporated the transfected DNA into 
their chromosomes. This is possible only under the presence of a selection 
antibiotic that kills all cells except those that have resistance conferred to them 
from the antibiotic resistance gene present in the transfected DNA.
The transfection protocol is the same as that for transient transfections 
(section 2.2.2). 48 h after DNA transfection, cells were split 1:3 into 100 mm 
diameter dishes, together with a dish of untransfected HEK293 cells with similar 
confluency (as control). Antibiotic (Geneticin G-418 in the case of pcDNA3 vector) 
containing medium was added to all dishes. A very high concentration of G-418 
was used initially (up to 1.5 mg/ml) to select for resistant clones, and the medium 
changed every 3 days to maintain maximum selection pressure. After 7 to 10 
days, when all the untransfected HEK293 cells in the control dish were dead, 
isolated clones of cells in the transfected dishes were picked. The clones (about 
24 for each type of DNA transfected) were detached from the dish by scraping
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with sterile blue tips and simultaneously drawing up about 0.5 ml of medium. The 
clones were grown in 24 well plate in 1 ml of G-418 (800 pg/ml) per well, with 
regular change of medium every 4 days.
After another 7 to 10 days, each confluent clone was split into a 25 cm^ 
flask, at the same time dispensing a very small fraction into a well of a 6  well plate. 
When clones in the 25 cni^ flask were confluent, cells were harvested for assaying 
their receptor levels. Once the desired clones were obtained, cells growing in the 6  
well plate were expanded in medium containing lower concentration of G-418 (400 
jLig/ml). Routine culture of stable cell lines were in DMEM or MEM (for HEK293 
stably expressing FhiPR-Gi/Gs) medium containing 350 to 400 pig/ml G-418. All 
mediums were prepared as in section 2 .2 .1 .
2.2.4 Preservation of Ceil Lines
stable cell lines were preserved in the earliest passage possible. They 
were also tested for mycoplasma contamination before preservation. Cells in 75 
cm^ flasks were grown to confluency before trypsinisation as in section 2.2.1. After 
centrifugation, the cell pellet was suspended in 1 ml of NBCS with 10% DMSO (as 
a cryo-protectant). The cell suspension was transferred into 1.5 ml cryovials, and 
labelled clearly. These were subjected to a slow freezing process; the first 3 to 6  h 
in a -20°C freezer, then overnight in a -80°C freezer, and finally long term storage 
in liquid nitrogen tanks.
Preserved cell line can be resuscitated by thawing the cryovial in room 
temperature, and resuspending in 10 ml of pre-warmed medium. The cell 
suspension was then centrifuged at 800 x g for about 5 min to remove all traces of 
DMSO. The cell pellet was finally resuspended in about 13 ml of medium and 
grown in 75 cm^ flask.
2.2.5 Treatment with Toxins and Agonist
Stable or transiently expressing cells were treated with toxins in vivo. 
Cholera toxin was used at 2 0 0  ng/ml final concentration, diluted in a small volume
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of medium. It was added directly into the flasks under aseptic environment, 
followed by incubation for the appropriate amount of time. Pertussis toxin was 
added in the same manner, but at a final concentration of 25 ng/ml.
Pretreatment of cells with the agonist iloprost was done exactly the same. 
Iloprost was normally used at a final concentration of 1 pM.
2.2.6 Cell Harvesting
Cells were harvested by first removing the growth medium and rinsing once 
in cold PBS buffer. Using a disposable cell scraper, the cells were scraped off the 
base of the flask or dish with a small volume of PBS buffer. The cell suspension 
was collected into 10 ml or 50 ml tubes and centrifuged at 800 x g at 4°C for about 
5 min. The cell pellets obtained were stored at -80°C until required for membrane 
preparation.
2.3 Molecular Biology
Molecular biological manipulations were performed in a manner where 
contamination of DNA and DNAse were kept to a minimum. This involved 
autoclaving all materials (e.g. pipette tips, eppendorfs, bottles, buffers, water etc), 
swapping the bench and pipetters with 70% alcohol, and using gloves for all 
procedures.
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2.3.1 Reagents for Molecular Biology 
Gel Loading Buffer (6X)
For 10 ml:
Bromophenol Blue (2%) 1.25 ml
Sucrose 4 g
These were dissolved in autoclaved water to a final volume of 10 mi. The buffer 
was stored in aliquots at -20°C.
TAE Buffer
Tris-acetate 40 mM
EDTA 1 mM
This was prepared as a 50X stock solution by adding 242 g of Tris / HCI, 57.1 ml 
of glacial acetic acid, and 100 ml of 0.01 M EDTA (pH 8 ) to deionised water in a 
final volume of 1 litre. This was diluted in deionised water when required.
Liquid Broth (LB)
For 1 litre:
Bacto-tryptone 10 g
Bacto-yeast extract 5 g
NaCI lOg
These were dissolved in deionised water and pH adjusted to 7. Sterilised by 
autoclaving at 126°C for 11 min.
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LB Ampiciilin Agar Plates
This has the same components as LB but with bacto-agar (1.5% % ) added. After 
autoclaving, it was left to cool before ampiciilin was added to a final concentration 
of 50 pg/ml. The liquid LB agar was poured into 10 cm diameter petri dishes, and 
allowed to solidify before storing at 4°C. LB ampiciilin agar plates can be stored for 
up to 3  weeks without any loss of antibiotic activity.
2.3.2 Transformation
The transfer of DNA into E.coli, known as transformation, allows multiple 
copies of the DNA to be produced as the bacteria replicates. The strain of E. coli 
used for transformation is DH5a, which used in conjunction with the vector 
pcDNA3, allows high copies of the plasmid to be made per bacteria.
A) Preparation of competent bacteria
Before the £. coli can be used for DNA transformation, it must be “made 
receptive or competent” for foreign DNA entry. This usually involved treating 
the bacteria to various chemicals.
Solution 1 (for 100 ml)
Potassium acetate (1 M) 3 ml
RbClz (1 M) 1 0  ml
CaCl2 (1 M) 1 ml
MnCIa (1 M) 5 ml
Glycerol (80% %) 18,75 ml
The final volume was made up to 100 ml with deionised water and pH 
adjusted to 5.8 with 100 mM acetic acid. The solution was filter-sterilised and 
stored at 4°C.
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Solution 2 (for 40 ml)
MOPS (100 mM; pH 6.5) 4 ml
CaCl2 (1 M) 3 ml
RbCl2 (1 M) 0.4 ml
Glycerol (80% %) 7.5 ml
The final volume was made up with deionised water and pH adjusted to 6.5 
with HCL It was filter sterilised and stored at 4°C.
A conical flask with 250 ml of LB was inoculated with 5 ml of an overnight 
culture of DH5a E. coli, and allowed to incubate at 37°C with shaking for 4 to 
5 h until the optical density (at 550 nm) of the culture reached 0.48. The E. 
coli culture was then chilled on ice for 5 min, and the bacteria collected by 
spinning in a chilled centrifuge at low speed (-3000 rpm). The pellet was 
resuspended in 100 ml of solution 1 for 5 min on ice. The bacteria cells were 
pelleted as before, and then resuspended in 5 ml of solution 2 for 15 min on 
ice. The DH5a bacteria is now ready for transformation or can be stored at - 
80°C in aliquots until required.
B) Transformation of DNA
Each plasmid DNA (10-50 ng) was incubated with 50 pi of competent 
bacteria in a sterile non-plastic tube for 15 min on ice. The DNA / bacteria 
mix was then subjected to heat shock at 42°C for 90 seconds, and plunge 
straight back into ice for another 2 min. 450 pi of LB was added and the 
bacteria cells allowed to recover in a 37°C shaking incubator for 45 min. 100 
to 200 pi of this mix was plated out on LB ampiciilin agar plate, left briefly on 
the bench for the agar to absorb the liquid, and finally incubated at 37°C 
overnight. Colonies picked from the plate can be cultured in LB for further 
DNA extraction, or the plate can be kept at 4°C for up to 2 weeks.
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Transformed E. coli LB culture can also be kept as glycerol stocks by mixing 
1 volume of culture with 1 volume of 50% %  glycerol in a sterile eppendorf 
tube, and stored at -80°C. Cells kept as glycerol stocks are viable for up to 2 
years.
2.3.3 DNA Preparation
DNA was purified using the^Promega Wizard™ Miniprep and Maxiprep kits 
according to the manufacturer’s instructions. A brief description of the Miniprep 
protocol will be given.
The miniprep kit was used when less than 10 pg of DNA is required. A 5 ml 
overnight culture of the transformed E. coli was first set up, 3 ml of it was 
transferred into two 1.5 ml eppendorf tubes and spinned at 12,000 rpm in a 
bench-top centrifuge for 2  min. 200 pi of Cell Resuspension Solution (50 mM 
Tris/HCI pH 7.5, 10 mM EDTA, 100 pg/ml Rnase A) was added to resuspend the 
cell pellet, followed by 200 pi of Cell Lysis Solution (0.2 M NaOH, 1% SDS). The 
tube was gently inverted a few times until the suspension clears. 2 0 0  pi of 
Neutralisation Solution (1.32 M potassium acetate pH 4.8) was added, mixed as 
before, and then spinned at 12,000 rpm for 5 min.
The clear supernatant thus obtained was transferred to a new 1.5 ml 
eppendorf tube and to it added 1 ml of Wizard™ Minipreps DNA Purification 
Resin. This DNA / resin mix was transferred to a disposable syringe attached to a 
Wizard™ Minicolumn. The mix was pulled through the column by vacuum, 
followed by 2 ml of Column Wash Solution. The resin which binds the DNA was 
now trapped in the column, and can be dried by continuing the vacuum for 
another 30 seconds. Finally, DNA was eluted off the resin by applying 50 pi of 
preheated autoclaved water (65-70°C) onto the Minicolumn for 1 min. This was 
collected in an eppendorf tube by fitting the Minicolumn on top and spinning the 
whole assembly for 1 min at about 5000 rpm in a bench-top centrifuge. The DNA 
solution thus obtained can be stored at -20°C for up to 3 years or more. A similar 
protocol for the Maxiprep kit was used.
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2.3.4 Polymerase Chain Reaction
PGR mix: Template DNA (0.1 pg/pl) 2 pi
Primer 1 (25 pmol/pl) 1 pi
Primer 2 (25 pmol/pl) 1 pi
Deoxynucleotides trixphosphate (2.5 mM) 5 pi
Pfu polymerase buffer (10X) 5 pi
Autoclaved water to 50 pi
The above mix was added into autoclaved thin-walled PCR tubes, with a drop of 
mineral oil overlayed on top. It was initially heated at 95°C for 10 min to denature 
the DNA double strand so that primers can hybridise onto the complementary
sequences of the DNA. 0.8 pi of native Pfu enzyme was then added and the PCR
cycles initiated in a Hybaid OmniGene temperature cycler.
PCR cycles:
Dénaturation Annealing Extension Cycles
95°C; 45 sec 50-60°C*; 1 min 72%; 2.5 min 30
95%; 45 sec 50-60%*; 1 min 72%; 10 min 1
* annealing temperature was empirically determined, and was set at 50, 55 or 
60%.
At the end of the PCR cycles, the lower aqueous layer was withdrawn carefully 
and transferred into a clean tube.
2.3.5 Agarose Gel Electrophoresis
The DNA required for agarose gel electrophoresis was first diluted to the 
appropriate concentration with autoclaved water. Gel loading buffer (6 X) was
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added in the ratio 1:5 with the diluted DNA. Agarose gel was prepared by heating 
the appropriate amount of agarose in 30 ml TAE buffer in the microwave oven for 
90 seconds. Concentrations of 0.8 to 1% %  agarose were used depending on the 
size of the DNA fragments to be separated. 5 pi of ethidium bromide (10 mg/ml) 
was mixed well with the liquid agarose before pouring into the chamber of the 
electrophoresis kit (Gibco Horizon 58 with Model 200 power pack). The 
appropriate combs were inserted to form wells in the gel. After the gel had set, 
TAE buffer was added to a level that fully covered it. The prepared DNA was then 
loaded into the wells and the electrophoresis started. The gel was finally examined 
under UV light and an electronic image printed.
2.3.6 DNA Purification from Agarose Gel
Purification of DNA fragments from agarose gel was performed using the 
QIAquick Gel Extraction kit (Qiagen, West Sussex, U. K.). Briefly, the desired DNA 
fragment on the agarose gel was first excised with a clean, sharp scalpel and 
transferred to a 1.5 ml eppendorf tube.
The gel slice was weighed and Buffer 0X1 was added at a volume 3 times 
the gel weight. The tube was incubated at 50°C for 10 min to dissolve the gel. 1 
volume of ispropanol was added to the sample and mixed by inverting. The 
sample was then transferred to a QIAquick column fitted on top of a 2 ml 
collection tube. The whole assembly was centrifuged for 1 min at about 13,000 
rpm in a microcentrifuge, discarding the flow-through. 0.5 ml of 0X1 was added to 
the QIAquick column, and centrifuged as before to remove all traces of agarose 
from the column. The column was washed with 0.75 ml of Buffer PE by repeating 
the centrifugation and discarding the waste. The column was further dried by 
repeating the centrifugation after discarding the waste from Buffer PE.
The QIAquick column was removed from the 2 ml collection tube and 
placed onto a clean and autoclaved 1.5 ml eppendorf tube. 50 \x\ of water was 
added to the QIAquick column, stand for 1 min, and centrifuged for 1 min at
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13,000 rpm. The eluant contained the desired DNA fragment and can be either 
stored at -20°C or used immediately.
2.3.7 DNA Sequencing
Sequencing of DNA was done by the Molecular Biology Support Unit 
located at the Anderson College, Institute of Virology, University of Glasgow. An 
ABI dye-terminator kit was used for the PCR reaction, while a Perkin Elmer ABI 
377 DNA sequencing machine was used for the electrophoresis and analysis of 
DNA sequences.
2.3.8 Construction of FLAG-hlPR (FhlPR)
The cDNA for human IP prostanoid receptor was a kind gift from Dr. M. 
Abramovitz of Merck Frosst, Quebec, Canada. The FLAG epitope is an 8  amino 
acid sequence (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys), where high affinity and 
selective antibodies are commercially available. Since there is currently no 
antibody raised against the human IP prostanoid receptor, tagging the N-terminus 
of the receptor with the FLAG epitope will be useful for immuno-detection and 
immuno-locaiisation purposes.
The set of PCR oligonucleotide primers used were:
Sense oligonucleotide 5’ - AAGGATCCGCCACCATGfGACTACAAGGACGACG- 
ATGATAAG)GCGGATTCGTGCAGGAACC - 3’; the underlined bases refer to 
restriction sites for BamH^ and A/col respectively, and FLAG epitope bases are in 
parenthesis.
Antisense oligonucleotide 5’ - AAGAATTCTCAGCTTGAAATGfTCAIGCAGAG -3’; 
the underlined bases refer to EcoRI restriction site, and the stop codon is in 
parenthesis.
PCR amplified fragment was purified by agarose gel (1% % ) 
electrophoresis followed by gel extraction. It was digested with BamH\ and EcoRI 
before ligating to pcDNA3 vector through these restriction sites. Introduction of the 
A/col site at the start codon allowed the selection of positive clones upon A/col
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digestion and agarose gel electrophoresis. The cDNA construct, known as FhlPR 
cDNA, was fully sequenced.
2.3.9 Construction of Receptor-Ga Fusion cDNA
The construction of cDNAs encoding fusions between the human IP 
prostanoid receptor with the various G a  necessitates removal of the stop codon in 
the receptor cDNA. Furthermore, a new restriction site had to be introduced, so 
that the 5 ’ end of the G a  cDNA can be ligated in frame with the 3’ end of FhlPR 
cDNA. It appeared that a Xho\ sequence would be an ideal linker, as it was not 
present in the receptor nor all the G a  (G^a, Gj^a, G ia/G ga) cDNAs. Furthermore, 
the Xbal site of pcDNA3 (which is downstream of Xho\) is available for ligating to 
the 3' end of G a  cDNAs, as this sequence is also not present in either the receptor 
or the G a  cDNAs.
An oligonucleotide primer for FhlPR without the stop codon was designed:
Antisense oligonucleotide 5’ - CCGCTCGAGGGAGCAGGCGACGCTGGC -3’; the 
underlined bases refer to Xho\ restriction site.
PCR was repeated with the original sense oligonucleotide for FhlPR and this new 
antisense oligonucleotide, using FhlPR cDNA as the template. The amplified 
fragment was again purified by gel electrophoresis and extraction. Restriction 
enzymes BamHl and Xho\ were used to digest the fragment which was then 
ligated to pcDNA3 via these restriction sites. This cDNA was used for subsequent 
receptor-Ga fusion cDNA constructs.
A) FhlPR-Gsa cDNA
To link the Gga cDNA with the IP receptor cDNA, the 5’ end was changed to 
a Xho\ site, while the 3’ end was changed to Xba\ site. Hence, a set of PCR 
primers were designed:
Sense oligonucleotide 5 ’ - CCGCTCGAGATGGGCTGCCTCGGCAACAG - 
3 ’: the underlined bases refer to X /70I restriction site.
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Antisense oligonucleotide 5’ - TGCTCTAGAfTTA)GAGCAGCTCGTATTGGC 
- 3’: the underlined bases refer to Xba\ restriction site and the stop codon is 
in parenthesis.
The template is rat Gga(HA), obtained from Drs M. J. Levis and H. R. 
Bourne, University of California at San Francisco, CA, U. S. A. It encodes the 
long isoform of Gga in which the haemagglutinin (HA) epitope (VPDYA) was 
constructed between amincr- acid residues 76-82. PCR and purification of 
amplified fragment were done as in section 2.3.4 & 2.3.7 respectively. The 
purified fragment was digested with Xho\ and Xbal restriction enzymes and 
cloned into the corresponding sites of FhlPR (no stop codon) in pcDNA3.
B) F h lP R -G iia  cDNA
A similar strategy was used in the construction of the FhlPR-Gna fusion 
cDNA. A set of PCR primers specific for the Gjia cDNA were used:
Sense oligonucleotide 5' - CCGCTCGAGGGCTGCACACTGAGCGCTG - 3’; 
the underlined bases refer to Xbol restriction site.
Antisense oligonucleotide 5’ - TGCTCTAGAAGC(TTA)GAAGAGACCACA- 
GTC - 3’i the underlined bases refer to Xbal restriction site and the stop 
codon is in parenthesis.
The template used is G^a cDNA. PCR, gel extraction, digestion, and cloning 
were as for the above protocol.
C) Fh lP R -G ii/G s6a  cDNA
To construct the fusion cDNA of a chimeric G protein (Gii/Gs6 cc) with the 
receptor, the chimeric G protein cDNA was first constructed (courtesy of 
Daljit Bahia). This was done by substituting the last 6  amino acids of G^a 
with that of Gga using PCR primers:
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Sense oligonucleotide 5’ - ACGTGAATTCGCCACCATGGGCTGCACACTG- 
AGCGC - 3’; the underlined bases refer to EcoRI restriction site.
Antisense oligonucleotide 5’ - CCACGTGAATTCTTA(TAAGAGTTCATA- 
TTGCCT)TAGGTTATTCTTTAT - 3’; the underlined bases refer to EcoRI 
restriction site, and bases in parenthesis refer to substitutions for Gga bases.
From this Gji/Gg6 a cDNA, restriction sites at both the 5’ and 3' ends were 
mutated to Xho\ and Xbal respectively. The same strategy as that of other 
Ga cDNAs was utilised to clone the chimeric G protein cDNA in frame with 
that of the human IP prostanoid receptor. The sense oligonucleotide primer 
for the FhlPR-Gjia fusion cDNA was used, while a new antisense 
oligonucleotide primer was designed:
5’ - TGCTCTAGATTA(TAAGAGTTCATATTGCCT)TAGG - 3’; the underlined 
bases refer to the Xbal restriction site and bases in parenthesis refer to Gga 
bases.
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2.4 Assays
2.4.1 Radioligand Binding
The expression of IP prostanoid receptors in stable cell lines and transient 
transfected cells were assessed by [^HJIIoprost binding studies. These were 
performed in borosilicate glass tubes in triplicates, containing the following mix:
Membrane protein (1 mg/ml) 20 p.1
Assay buffer (50 mM Tris/HCI at pH 7.5, 5 mM MgCl2 ) 60 \i\
[^HJIIoprost (> 10 nM) 10 pi
lloprost ( -1 0  pM) or assay buffer 10 pi
Total volume: 100 pi
Reactions were incubated for 30 min at 30°C. Binding was stopped by 
addition of 2.5 ml ice cold wash buffer (50 mM Tris/HCI at pH 7.5, 0.25 mM 
EDTA), followed by vacuum filtration through GF/C filters to remove free 
radioligand from the membrane. The filters were washed 3 times in ice-cold wash 
buffer, air dried, and inserted into vials containing 5 ml of liquid scintillant. After an 
overnight incubation, the vials were counted in a Beckman LS6500 scintillation 
counter using the ^H counting channel. Specific binding was determined by 
subtracting the counts performed in the absence of unlabelled lloprost (total 
counts) from that with it (non-specific counts). Receptor expression level (fmol/mg) 
was calculated by taking into consideration the specific activity of [^Hjiloprost (34 
dpm/fmol) and the amount of membrane protein used per tube.
The binding affinity of the receptors for lloprost was similarly assayed, using 
a concentration of [^H]iloprost close to Kd (-3.4 nM) and increasing concentrations 
of unlabelled lloprost (from 10'^^ to 10'^). Non-specific binding was taken as the 
counts when maximum concentration of unlabelled iloprost was used.
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2,4.2 Adenylate Cyclase Catalytic Activity
The catalytic activity of adenylate cyclase was assayed in accordance to 
Wong (1994), based on the use of [^Hjadenine. Cells were split into the wells of 
24-well plate and incubated in medium containing [^H]adenine at 0.5 pCi/weli for 
16-24 h.
The following day, cells were washed once in assay medium make up of IX  
DMEM, 2 mM L-glutamine, 20 mM HEPES (pH 7.4), 1 mM 3-isobutyl-1- 
methylxanthine, and 1% penicillin/streptomycin. Various concentrations of iloprost 
were first diluted in assay medium, and added to the wells for the required 
duration. During the incubation period, the plate was placed on a heated block 
connected to a 37°C water bath. At the end of incubation, the assay medium was 
aspirated and 0.5 ml of ice-cold stop solution (5% ^/v TCA, 1 mM ATP, 1 mM 
cAMP) added to each well. The plate can be stored at -20°C or at 4°G if the 
columns to separate the nucleotides were ready.
Separation of cAMP from the other adenine nucleotides is based 
essentially on the method of Salomon et al. (1974). The Dowex and alumina 
columns were set up in accordance to Farndale et al. (1991). Basically, a rack of 
Dowex columns and a rack of alumina columns with precise alignment of the 
column positions were used. Columns were improvised from 5 ml syringes fitted 
with glass wool at the base to form a retaining mesh for the resins. Dowex resins 
were washed extensively in deionised water, followed by 3 washes in 1 M HCI, 
and again with water. It was finally resuspended 1:1 with deionised water in a 
beaker and kept in uniform suspension using a magnetic stirrer. 2  ml of this 
suspension was pipetted into the columns, giving a 1 ml bed volume. Alumina 
resins were washed once in water and once in 0.1 M imidazole (pH 7.3). It was 
similarly resuspended in deionised water and pipetted into the columns. The 
columns were plugged to prevent the resins from drying when not in use. Before 
using the columns, the Dowex columns must be primed by passing through 2 
washes of 1 M HCI, followed by 2 washes of deionised water; the alumina
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columns were washed twice with 0.1 M imidazole (pH 7.3) and once with 
deionised water.
The separation of [^HjcAMP from the rest of the labelled components (e.g. 
[^H]ATP, [^H]ADP, [^H]AMP, [^HJadenine etc) starts with the Dowex columns. 
Dowex 50 resins are negatively charged and hence are not expected to bind any 
of the components. However, the passage of cAMP is preferentially retarded in 
the column, probably by a non-specific interaction with the Dowex resin, and 
hence allow other labelled components to be washed away (Farndale et al. 1991). 
The alumina resin instead binds cAMP less avidly than other adenine nucleotides 
as th e . cyclisation leads to the loss of vicinal hydroxyls on the ribose ring. 
Imidazole, which competes for the purine binding site, can therefore displaced 
cAMP from alumina columns.
The separation protocol involved firstly pipetting the sample (in stop 
solution) into the Dowex column, followed by 3 ml of deionised water. The eluant 
was collected in vials containing about 5 ml of liquid scintillant. This fraction 
contained predominantly [^H] labelled adenine nucleotides except f  H]cAMP. The 
rack of Dowex columns was next placed on top of the alumina columns, taking 
care to ensure that the eluant from the upper Dowex columns go straight into the 
alumina columns. The Dowex columns were next washed with 5 X 2 ml of 
deionised water into the alumina columns, discarding the washings. This step 
displaced cAMP from the Dowex to the alumina columns. The rack of Dowex 
columns was then removed, and 3 X 2 ml of 0.1 M imidazole (pH 7.3) added to the 
alumina columns. This eluant was collected in vials containing 9 ml of liquid 
scintillant, and labelled as the [^H]cAMP containing fraction. Both sets of vials 
were counted in Beckman scintillation counter using the ^H counting channel. 
Results were expressed as the ratio of [^H]cAMP to total [^H]adenine nucleotides 
(X I00).
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2.4.3 High Affinity GTPase
High affinity GTPase assay was performed essentially as described in 
Gierschik et al. (1994). Assay mix (for 100 tubes) was prepared as follows:
Components Volume (ul) Final concentra
Creatine Phosphate (0.4 M) 250 20 mM
Creatine Phosphokinase (2.5 U/ml) 2 0 0 0.1 U/ml
ATP (0.04 M; pH 7.5) 250 2 mM
App(NH)p (0.04 M) 25 0.2 mM
Ouabain (0.01 M) 1 0 0 0 2 mM
NaCI (4 M) 250 200 mM
MgCl2 (1 M) 50 10 mM
DTT (0.1 M) 2 0 0 4 mM
EDTA (0.02 M; pH 7.5) 50 0.2 mM
Tris/HCI (2 M; pH 7.5) 2 0 0 80 mM
GTP (0.1 mM) 50 1 pM
Deionised water to final volume of 5000 pi
32,5 i-iCi [y P]GTP (50 nCi per assay) was added to the above mix and left on ice 
until ready to be added to the reaction tubes.
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The assay was performed in 1.5 ml eppendorf tubes containing the following:
Membrane protein (at 0.5 mg/ml) 20 pi
Agonist or water or GTP * 10 pi
Deionised water 20 pi
Assay mix  ^ 50 pi
Total volume: 100 pi
* the assay was set up under 3 different conditions: agonist driven, basal, and 
non-specific activities, depending on whether agonist (at various concentrations), 
water, or GTP (1 mM) were added respectively.
The assay tubes were set up in triplicates and incubated at 37°C for 20 
min. 900 pi of ice-cold charcoal slurry (5% activated charcoal in 10 mM H3 PO4 ) 
was added to each tube to terminate the reaction. The charcoal was pelleted by 
spinning the tubes at 13,000 rpm for 5 min in a chilled microcentrifuge. 500 pi of 
the supernatant (containing Pi) was withdrawn and transferred into vials for 
Cerenkov radiation counting in a Beckman radioisotope counter. High affinity GTP 
hydrolysis rate (pmol/min/mg) was obtained by subtracting the counts from GTP (1 
mM) control tubes, and taking into consideration thb specific activity of [y^^P]GTP, 
the concentration of unlabelled GTP in the assay (0.5 pM), the membrane protein 
concentration, and finally the incubation time.
To measure enzymatic parameters like Michaelis Menton constant (K^) 
and maximum velocity (Vmax) of the GTPase activity, the assay can be carried out 
under various concentrations of GTP (the substrate). The assay mix was prepared 
as above with the omission of unlabelled GTP. A series of GTP dilutions was then 
prepared at 10X the concentration required in the final assay. The assay consisted 
of the following components:
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Membrane protein (at 0.5 mg/ml) 20 pi
Agonist or water 10 pi
GTP at various concentrations 10 pi
Deionised water 10 pi
Assay mix (without unlabelled GTP) 50 pi
Total volume: 100 pi
The assay included a zero and a high concentration (1 mM) of unlabelled 
GTP which gave the GTPase rate at the concentration of [y^^P]GTP and that of 
non-specific respectively. The assay was performed as before and results 
calculated in the same manner. The data can be plotted on appropriate graphs, 
e.g. Eadie-Hofstee plot or Lineweaver Burke plot, to determine Km and Vmax 
values.
2.4.4 GTPyS Binding
[^^SjGTPyS binding studies were performed according to Wieiand and 
Jakobs (1994). A 4X binding assay mix was first made up, consisting of 80 mM 
HEPES (pH 7.4), 20 mM MgCIa, 400 mM NaCI, and 20 pM GDP (freshly added). 
The reaction was done in borosilicate glass tubes, with the following components:
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Membrane protein (1 mg/ml) 20 pi
Agonist or water or GTPyS * 10 pi
[^°8 ]GTPy8 * (0.3 to 0.5 nM) 10 nl
Binding assay mix (4X) 25 pi
Deionised water 35 pi
Total volume: 100 pi
* The assay was performed under 3 conditions: agonist driven, basal, and non­
specific. This depended on whether agonist (at various concentrations), water, or 
unlabelled GTPyS (200 pM) were added respectively.
+ [^ ®8 ]GTPy8  was diluted in 10 mM Triclne (pH 7.5) and 1 mM DTT to 100 nCi/pl, 
allquoted, and stored at -80°C. The amount used In the assay was kept constant 
at 50 nCi/assay by taking into account the decay of the radioisotope.
The tubes were incubated at 25% for 60 min. Binding was stopped by the 
addition of 2.5 ml ice cold wash buffer (20 mM Tris/HCI at pH 7.4, 5 mM MgCl2), 
followed by vacuum filtration through GF/C filters to remove unbound [^^SjGTPyS 
from the membrane. The filters were washed 3 times in ice-cold wash buffer, air 
dried, and inserted into vials containing 5 ml of liquid scintillant. These were 
counted in a Beckman scintillation counter using the counting channel.
The specific incorporation of [^%]GTPyS into the membranes was 
calculated by subtracting the non-specific counts in tubes containing high 
concentration (20 pM final concentration) of unlabelled GTPyS.
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2.5 Other Protocols
2.5.1 Preparation of Cell Membranes
Plasma membrane-containing P2 particulate fractions were prepared from 
cell pastes that had been stored at -80°C since harvesting. Cell pellets were 
resuspended in TE buffer and rupture of the cells was achieved with 25 strokes of 
a hand-held Teflon-on-glass hqmogenizer. Unbroken cells and nuclei were 
removed by centrifugation at low speed (2 , 0 0 0  rpm) in a refrigerated 
microcentrifuge. The supernatant fraction was then centrifuged at 75,000 rpm for 
30 min in a Beckman Optima TLX Ultracentrifuge (Palo Alto, CA) with a TLA100.2 
rotor. The pellets were resuspended in TE buffer to a final protein concentration of 
1-3 mg/ml and stored at -80°C until required.
2.5.2 Western Blotting
A) Preparation of SDS-PAGE gel
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) 
was usually performed with 10% acrylamide resolving gels. It was prepared 
as follows:
Water . 8.3 ml
Tris/HCI (1.5M, pH 8 .8 ), SDS (0.4% % ) 6  ml
Acrylamide (30% % ), bisacrylamide (0.8% % ) 8  ml
Glycerol (50% % ) 1.6 ml
Ammonium persulphate (10% % ) 90 pi
TEMED 8  pi
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The is sufficient for a single gel cast in a Hoefer Gel Caster with two 180 X 
160 mm glass plates and 1.5 mm spacers. The gel was layered with 0.1% 
SDS and allowed to polymerise at room temperature for about 90 min.
After the resolving gel had polymerised, the SDS layer was washed off and 
the stacking gel prepared as follows;
Water 9.75 ml
Tris/HCI (0.5IVI; pH 6 .8 ), SDS (0.4% % ) 3.75 ml
Acrylamide (30% % ), bisacrylamide (0.8% % ) 1.5 ml
Ammonium persulphate (10% % ) 150 pi
TEMED 8  pi
This was layered on top of the resolving gel with a 15 well teflon comb left at 
the top and allowed to polymerise for about 60 min, after which, the gels 
were used immediately or stored at 4°C overnight.
B) Electrophoresis of SDS“PAGE
The buffer for electrophoresis of SDS-PAGE consists of 25 mM Tris/HCI, 192 
mM glycine and 0.1% %  SDS, make up to 2 litre for each electrophoresis 
tank. The gels were assembled into a Hoefer vertical gel electrophoresis kit, 
and buffer filled into the lower reservoir till the electrophoresis wire was fully 
immersed. Sufficient buffer was also poured into the upper reservoir, taking 
care not to overfill.
Protein samples (30 pg) were diluted 1:1 in laemmili buffer (2X) and heated 
to boiling for 5 min on a heating block prior to loading onto the gel. A 
Hamilton syringe was used to load samples into the wells of the gel. At least 
a sample of prestained protein markers was loaded into each gel. Any empty
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wells were loaded with laemmili buffer at a volume similar to the protein 
samples.
Electrophoresis of each 10% SDS-PAGE gel was usually at 10 mA constant 
current overnight (about 16 h) or 35 mA constant current for about 4 h; the 
voltage was set at least 300 V and the power at least 10 W. The current was 
doubled for two gels:
C) Protein transfer onto mèmbrane
After electrophoresis, the glass plates with the gel were dismantled from the 
electrophoresis kit. 5 litre of transfer buffer was prepared, consisting of 25 
mM Tris/HCI, 192 mM glycine, and 20% %  methanol. Nitrocellulose 
membranes and Whatman filter papers were also cut to the size of the gel, 
and pre-wetted in transfer buffer.
After the glass plates were separated from the gel, a nitrocellulose 
membrane was gently rolled over to cover it, taking care to avoid any air 
bubbles between them. This gel-nitrocellulose combination was then 
sandwiched between two pieces of Whatman filter paper and assembled into 
an LKB Transphor apparatus. The nitrocellulose membrane was positioned 
nearer to the positive end relative to the gel. All the transfer buffer was 
poured into the transfer tank.
Protein transfer from the gel to the membrane was performed at about 1.5 
mA for 90 to 120 min, depending on the number of gel transfers in the 
apparatus. The protein transferred to the nitrocellulose membrane can be 
visualised by temporarily staining with a solution consisting of 0 .1 % %  
Ponceau S and 3% %  trichloroacetic acid. The stain can be removed in 
TBST buffer.
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D) Incubation with antibodies
Prior to incubation of the membrane with antibodies, it was covered with 5% 
non-fat milk (Marvel) in TBS overnight at 4°C. This was necessary to remove 
any non-specific interaction between the membrane and the antibodies.
All antibodies were diluted in 3% Marvel in TBS and kept at 4°C with a trace 
of thimerosai. Membranes were incubated with each antibody for 1 to 2 h at 
room temperature with shaking. The membranes were washed extensively 
(at least 3 to 4 times) with TBST before the next antibody was added. 
Antibodies were reused for no more than 5 times or 3 months whichever 
earlier.
Dilutions of the various antibodies used were as follows;
Primary antibody Dilution Secondary antibody Dilution
M5 FLAG 1 : 1 0 0 0 Anti-mouse IgG 1 : 2 0 0 0
CS 1 : 2 0 0 0 Anti-rabbit IgG 1 : 2 0 0 0
SG 1 : 2 0 0 0 Anti-rabbit IgG 1 : 2 0 0 0
CQ 1 : 2 0 0 0 Anti-rabbit IgG 1 : 2 0 0 0
I1C 1 : 1 0 0 0 Anti-rabbit IgG 1 : 2 0 0 0
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E) Enhanced chemiluminescence
Visualisation of horse-radish-peroxidase conjugated antibodies on the 
nitrocellulose membrane was performed by enhanced chemiluminescence 
(ECL) according to the manufacturer’s instructions (Amersham, U. K.). 
Briefly, membranes were washed extensively with wash buffer before 
incubation with the ECL reagent. After 3 min, excess reagent was drained 
off, and the membrane sandwiched between two pieces of clear plastic 
sheet. Care was taken to ensure that no air bubbles were trapped between 
the membrane and the plastic sheet.
The nitrocellulose membrane was then put into a film cassette and a light- 
sensitive film inserted in the darkroom. The film was developed in an 
automatic film developer (Kodak Xomat) after an appropriate exposure time.
77
CHAPTER 3
Selective Activation of a Chimeric Gn/Gs 
G Protein a  Subunit by the Human IP 
Prostanoid Receptor
CHAPTER 3
Selective Activation of a Chimeric Gn/Gg G Protein 
a  Subunit by the Human IP Prostanoid Receptor
3.1 Introduction
GPCRs transduce extracellular signals into the cell by activating 
heterotrimeric G proteins. There are currently 2 0  G a , 6  Gp and 12 Gy subunits 
known. The association of G protein and GPCR is rather specific, and occurs only 
when specific domains and conformations are present on both the receptor and G 
protein. The coupling of G a  subunit with GPCR has been particularly well studied, 
and specific domains essential for coupling have been defined. Much of this work 
was made possible through the generation of chimeric G proteins, where codons 
of a G a  cDNA were replaced by those of another. Such chimeras represent 
continuous open reading frames that contain domains from 2  different Ga 
subunits. This is possible because of the high sequence homology between G a  
subunits, which permit specific domains to be interchanged without altering the 
likely overall structure of the protein. As G a  proteins differ substantially in their 
handling of guanine nucleotides, activation of effectors, coupling to GPCRs, and 
regulation by other proteins, the substitution of certain domains will therefore 
generate chimeric G proteins that differ from the "parental" G protein. Careful 
analysis of such chimeras has yielded useful information regarding the functions 
and properties of the replaced domains, and their impact on the overall 
characteristics of the chimeric protein.
The use of chimeric G proteins in G P C R  research dates back to 1988 when 
Masters et al. constructed a Gj2 a (1-212 aa) / Gga (235-394 aa) hybrid 
polypeptide. This was possible by digesting a conserved BamHl restriction 
endonuclease site in the cDNA of mouse Gi2a, that neatly separated domains I 
and II from domain III (the carboxyl terminus). The domains I and II fragment of
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Gi2 a was then ligated to the domain III fragment of mouse Gga, forming a single 
reading frame that encoded 60% of Gi2a and 40% of Gga. This cDNA was 
introduced via a retroviral vector into S49 eye' cells, which lack endogenous Gga. 
They found the ability of the chimeric Gi2a/Gga protein to mediate Pa-adrenergic 
receptor stimulation of adenylate cyclase was similar to that of the wild type Gga. 
Hence, they concluded that the carboxyl terminus of Gga contains structural 
features essential for interactions with the receptor and the effector enzyme, 
adenylate cyclase.
In the following year, a chimeric G a  protein, Gga (1 -3 5 6  aa) / G|2a  (3 2 0 -3 5 5  
aa), known as G ag/i(38) was constructed by Woon et al. (1989). It involved 
replacing the last 38  amino acids of Gga with the last 36 amino acids of G;2a . This 
chimeric G protein showed 1.5 to 2 .5  fold constitutively elevated cAMP levels and 
a 3 to 4 fold increase in PKA activity when expressed in Chinese hamster ovary 
(OHO) cells. Furthermore, in the presence of isobutylmethyl-xanthine, a cAMP 
phosphodiesterase inhibitor, cAMP levels in clones expressing the Gag/i(38) 
construct were 10 to 15 fold higher than Gga expressing clones. There was also 
an indication of enhanced GDP dissociation rate as the lag time for maximal 
adenylate cyclase activation by GTPyS was diminished. However, the constitutive 
activity of this chimeric G protein appeared to be cell line dependent, as 
expression in COS-1 cells did not show any constitutive activity (Osawa et al. 
1990a).
In a further extension of the work on Gj2a (1-212 aa) / Gga (235-394 aa), 
Osawa et al. also replaced the last 38 amino acids of this hybrid polypeptide with 
the last 36 amino acids of Gj2a  as in the Gag/i(38) construct. Interestingly, this 
Gj2a (1-212 aa) / Gga (235-356 aa) / G|2a (320-355 aa) protein did show 
constitutive adenylate cyclase activity when expressed in COS-1 cells (Osawa et 
al. 1990a). The Gga domain for adenylate cyclase activation was therefore 
mapped to isoleucine 235 to arginine 356. Besides replacing the carboxyl terminal 
residues of Gga with Gja, Osawa et al. also studied the effect of replacing the
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amino terminal residues. They found that a chimeric G protein Gj2a (1-54 aa) / 
Gga (55-395 aa) gave constitutive adenylate cyclase activity when expressed in 
COS-1 cells (Osawa et al. 1990b). This and other N-terminal G;2 (%/Gga constructs 
led them to the conclusion that the N-terminus of Gga possesses an attenuator 
regulatory function.
The importance of C-terminal residues of Ga proteins in receptor coupling 
was further demonstrated by Conklin et al. (1993a) when they generated Gqa/Gj2 a 
chimeric proteins by replacing 1 to 23 amino acids of the C-terminal region of Gqa 
with that of G|2a. When these chimeric G proteins were coexpressed with Ai 
adenosine or D2 dopamine receptors (both are Gja coupled GPCRs), functional 
coupling in HEK293 cells was shown by elevation of agonist stimulated PLC 
activity. The substitution of at least 3 carboxyl terminal residues was required to 
switch the receptor specificity of the chimeric protein from Gqa coupled GPCR to 
Gja coupled GPCR (the Ai and D2 receptors) (Conklin et al. 1993a). Maximum 
coupling efficiency was seen when 4 to 9 carboxyl terminal residues were 
substituted. This suggested that more residues may actually hinder receptor 
coupling or affect the activation of PLC. Expression of chimeric Gqa/Gj2a proteins 
with 4 to 11 substitutions also caused a 2 fold increase in basal PLC activity, 
which was indicative of weak constitutive activity..,
The benefit of switching the receptor specificity of a G protein was exploited 
in a study of Gisa subunit by Voyno-Yasenetskaya et al. (1994). Gisa was 
identified as the Ga subunit responsible for regulating the activity of Na" -^H  ^
exchanger (NHE) from transient expression studies of a mutationally activated 
Gisa. However, as no GPCR was known to directly activate this subunit at that 
time, a chimeric protein approach was used to activate Giga with a Gja coupled 
GPCR. Hence, a Giaa (1-372 aa) / G^a (351-355 aa) protein was constructed by 
replacing the last 5 carboxyl residues of Giaa with those of G%a. This enabled the 
D2 dopamine receptor to couple to the G-^a/Gza chimera and activate NHE using
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quinpirole, a D2 receptor agonist, while a dopamine antagonist, butaclamol, 
blocked the effect (Voyno-Yasenetskaya etaL 1994).
The critical carboxyl terminal residues involved in receptor coupling were 
further defined to be at the -3 and -4 position from the C-terminus of Ga, using 
mutation studies of the Gqa/Gza chimera (Conklin et al. 1996). However, in a 
study of other chimeric G proteins with substitutions of their extreme C-terminus, it 
was apparent that not all G PC Re were able to couple as efficiently. For example, 
replacement of 5 C-terminal aa of Gqa with the equivalent G^a sequence 
permitted V2 vasopressin receptor but not P2 -adrenergic receptor (both Gs 
coupled GPCRs) to stimulate phospholipase C. Similar replacement of aa 
with Gqa permitted bombesin and V ia  vasopressin receptors but not the oxytocin 
receptor (all Gqa coupled GPCRs) to stimulate adenylate cyclase (Conklin et al.
1996).
Further evidence that the extreme carboxyl terminus of Ga protein is not 
sufficient for receptor coupling comes from studies of chimeras Gisa (1-372 aa) / 
Gza (351-355 aa) and G i2 « (1-372 aa) / Gza (351-355 aa) (Tsu et al. 1997). 
Signais from aminergic (a2-adrenergic and dopamine D2 ) receptors but not 
peptidergic (opioid and formyl-methionine peptide) receptors were transduced by 
these chimeras, despite the known Gja and G%a coupling ability of these 
receptors. Furthermore, G^a (1-319 aa) / Gta (315-355 aa) but not a Gta (1-314 
aa) / G^a (320-355 aa) chimera couples to 5-opioid receptor to activate adenylate 
cyclase type II via Gpy dimers, which appears to contradict the importance of the 
C-terminus in receptor coupling. Similarly, C5a chemoattractant factor receptor 
was not able to activate a G ^ a  (1-237 aa) / G^ea (241-374 aa) chimera although it 
can stimulate PLC activity via full length Giea (Lee et al. 1995). Instead an 
additional segment encompassing residues 220-240 of G-iga was required for 
functionality. Interestingly, N-terminal residues of G^^a were sufficient to endow a 
Giea (1-209 aa) / G ^a  (207-359 aa) chimera with specificity for C5a induced
81
activation, although it exhibited only 40% coupling capacity of full length Giecc (Lee 
et al. 1995). Therefore, these conflicting results indicated that not all G proteins 
couple to GPCRs solely via the carboxyl-terminal residues. Hence, the carboxyl 
terminus of Ga may not be the only determinant for receptor coupling.
Despite these various setbacks, it is still possible that the majority of known 
GPCRs activate G proteins via the extreme C-terminus (see Section 1.3.2). This 
probably prompted Komatsuzaki et al. (1997) to devise a system that reports the 
G proteins coupled to a GPCR by using a series of Gga / Gya chimeras (Gya = any 
G a ). These chimeras were constructed by replacing the last 5 aa of Gga with 
those of Gj-|/2 a, Gga, Gza, Gqa, G i2 C(., G-{3a, G-i^a, and G-jga. This was designed 
to allow the chimeric G protein to couple to the receptor under study, and hence 
determine the G protein(s) that are normally activated via measurement of 
adenylate cyclase activity. Indeed, the SSTR3 somatostatin receptor recognised 
the C-termini of G ji/2a, but not Goa or G%a, and those of G i^ a  and G iea , but not of 
Gqa or G iia . These results were further confirmed by assaying for SSTR3 agonist 
stimulated PI turnover when G # a  or G ie a  were co-transfected (Komatsuzaki et al.
1997). Hence, such a G protein reporting system, at least in the case of the 
SSTR3 somatostatin receptor, gave a similar result as co-transfection experiments 
and with the ease of using only a single assay end point. More studies will need to 
be undertaken to confirm whether this approach is applicable for other GPCRs.
This study aimed to extend the use of chimeric G proteins to assay for 
agonist function at the G protein level for the human IP prostanoid receptor. 
Activation of an agonist-occupied GPCR results in the exchange of GDP for GTP 
in G a  subunits. The activated G a  subunit has an intrinsic ability to hydrolyse GTP 
to GDP, due to the presence of a GTPase domain. This timer-controlled hydrolysis 
of the terminal phosphate of GTP determines the duration of the signal as GTP- 
bound G a  adopts a conformation that can activate downstream effectors. 
However, G a  subunits exhibit different rates of GTP exchange (koff) and GTP 
hydrolysis (kcat) (Fields et al. 1997). As such, assays that examine the GPCR- 
induced exchange of GDP for GTP or a poorly hydrolysed analogue like GTPyS as
82
in [^^S]GTPyS binding assays (Wieland et at. 1994), and the subsequent 
hydrolysis of GTP as in high affinity GTPase assays (Gierschik et al. 1994) are 
useful only for a subset of G proteins, in particular the pertussis toxin-sensitive 
subfamily of Gja-like G proteins (Milligan 1988). The direct demonstration of 
guanine nucleotide binding and hydrolysis in other Ga subunits, is often difficult to 
demonstrate in membrane systems, mainly due to a combination of intrinsically 
low GTP exchange and hydrolysis function of these subunits (Wieland et al. 1994; 
Gierschik et al. 1994). To assay the activation of these non Gja-like subunits, it is 
important to reduce basal activity to a minimum, for example through the use of N- 
ethylmaleimide, a sulfhydryl group alkylating agent. N-ethylmaleimide is also a 
potent inhibitor of receptor-stimulated GTP hydrolysis by pertussis toxin-sensitive 
G proteins (Gierschik et al. 1994). In the [^^SjGTPyS binding assay, pretreatment 
with unlabelled GTPyS can reduced agonist-independent binding of radiolabelled 
GTPyS, and pretreatment together with N-ethylmaleimide was found to give the 
best result in [^^S]GTPyS assays of turkey erythrocyte membranes in response to 
p-adrenergic receptor agonists (Wieland et al. 1994). Despite these treatments, 
the level of agonist stimulated activity in both assays is still a fraction of that 
obtainable by Gja-like subunits.
As the IP prostanoid receptor is a Gga-coupled GPCR, conventional 
methods for assaying G protein activation are not ideal. Although studies on 
chimeric G proteins had yielded conflicting results, it may still be possible that the 
majority of GPCRs transduce signals to G proteins solely through residues at the 
carboxyl terminus of Ga. If this is also true for the IP prostanoid receptor, then it 
may be possible to utilise a chimeric Gja/Gga protein, which has the high GTP 
exchange and hydrolysis capability of Gja, but the coupling specificity of Gga. 
Therefore, a G^a (1-349 aa) / Gga (389-394 aa) protein (known as Gn/GgGa) was 
constructed. The backbone of this chimeric G protein is essentially Gjia, while the 
last 6  carboxyl residues are from Gga. It was constructed by Mr Daljit Bahia, a 
Ph.D. student in the laboratory, as part of a series of G^a (1-349 aa) / Gxa (last 6  
aa) chimeras. These chimeras were constructed with the intention of testing their
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coupling capacity with various GPCRs. This approach will hopefully allow non-Gja 
coupled GPCRs to produce robust agonist-dependent regulation of high affinity 
GTPase and GTPyS binding.
For ease of immunodetection, the human IP prostanoid receptor (hIPR) 
was FLAG™ epitope tagged on the N-terminus by PCR. The cDNA of this FLAG™ 
tagged receptor (FhlPR) was then stably transfected into HEK293 cells. cDNA of 
the G proteins Gji/Gs6 a, G jia or.Gga was transiently transfected into a clone of 
HEK293 cells stably expressing the FhlPR. GTPyS binding and high affinity 
GTPase assays were utilised to monitor activation of the expressed Ga by the 
agonist, occupied FhlPR. Toxins that ADP-ribosylate Ga subunits, cholera and 
pertussis toxins, were also employed to delineate receptor coupling with the 
various G proteins. Some of the results to be presented have been published in 
Molecular Pharmacology (^998) 54, 249-257.
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3.2 Results
Characterisation of HEK293 clones stably expressing FhlPR
Incorporation of the FLAG™ epitope (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) 
at the N-terminus of hIPR was successfully completed using PCR (see section
2.3.8). Transient transfection of this cDNA (5 pg) into HEK293 cells gave very low 
expression of the receptor, as assessed by [^Hjiloprost binding (data not shown). 
The transient expression of FhlPR was not increased by using larger amounts (up 
to 20 pg) of cDNA. Therefore, antibiotic selection of stably expressing HEK293 
clones was embarked on very early in the project.
25 HEK293 clones stably expressing the FhlPR were expanded and 
screened by [^Hjiloprost (-10 nM) binding studies. Three of the highest expressing 
clones were studied in detail: clones 13, 16 and 17. Membranes of these clones 
and parental HEK293 cells were prepared and their level of FhlPR expression was 
reassessed by [^Hjiloprost binding (Figure 3.1). Parental HEK293 cells expressed 
negligible amounts of IP prostanoid receptors (<20 fmol/mg; n=5). Clone 13 
showed the highest level of specific [^Hjiloprost binding at 2957 + 144 fmol/mg 
membrane protein (n=5), followed by clone 17 at 1660 + 251 fmol/mg (n=3) and 
clone 16 at 1010 + 29 fmol/mg (n=3).
The functionality of the expressed FhlPR in HEK293 clones was assessed 
by the ability of agonist to elevate cAMP in intact cells. This secondary messenger 
effect of the IP prostanoid receptor was first discovered in platelets through the 
action of prostacyclin (PGI2) by Gorman et al. (1977). In this study, the assay for 
adenylate cyclase activation was performed essentially according to the method of 
Wong (1994) in which [^Hjadenine was used to label the cellular pool of adenine 
nucleotide. The cells were split into 12 well plates and incubated overnight with 
[^Hjadenine at 1 jaCi per well. Iloprost (1 pM) was used to stimulate the receptor 
while forskolin (50 p.M) which directly activates adenylate cyclase, was used to 
assess the level of maximum cyclase activity. After 20 min incubation, the [^H]-
labelled adenine nucleotides were separated as described in Section 2.4.2. All 3
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clones exhibited substantial increases in cAMP when stimulated by agonist 
(Figure 3.2). However, agonist stimulated cAMP production in clone 16 cells was 
consistently lower than the rest; a possible reason being the poorer expression of 
FhlPR (see Figure 3.1). As clone 13 cells demonstrated maximal adenylate 
cyclase response to both iloprost and forskolin, and also expressed the FhlPR at 
high level, it was selected for detailed analysis.
Agonist saturation binding studies were performed on clone 13 cells at up 
to 50 nM [^H]iloprost (Figure 3.3A). A Scatchard plot showed 2-affinity binding 
(analysed by EBDA™; Elsevier-BIOSOFT 1987) with dissociation constant (Kd) of 
1.6 + 0,4 nM and maximum receptor level (Bmax) of 971 + 83 fmol/mg membrane 
protein (n=3) for receptors showing high-affinity binding and Kd of 11.4 + 2.3 nM 
and Bmax of 3202 ±515  fmol/mg (n=3) for low-affinity binding sites (Figure 3.3B).
"unt of [^H]iloprost that can be realistically used in 
' nM, this limited the accuracy of the Bmax and Kd
 ^
^  V  ites. Therefore, it was decided that agonist
^  K  )vide a better assessment of the overall binding
\  ^  ^  ^ clone 13 cells. From Figure 3.4, we can see that
^  ^Hliloprost (3.4 nM) in a concentration-dependent 
% Y" ^  ............... - -------------------------------------------- ---------T •- 'T e 13 cells, with IC50 of 6.1 ± 0.7 nM and Bq of 1817
4:; ' 'malism of DeBlasi et al. (1989) to these data, the Kq
V /I and Bmax was estimated at 3260 ±  6 8  fmol/mg. The
slope of the aispicauo.. ,^. .. ^ jp h  is shallow (Hill coefficient = 0.64 ± 0.05), which is 
a strong indication of binding to more than one site.
Immunodetection of FLAG™ epitope in the IP prostanoid receptor was 
demonstrated in Figures 3.5A and 3.5B. Immunoblotting the membranes of 
HEK293 cells transiently expressing the FhlPR with the anti-FLAG™ monoclonal 
antibody M5 confirmed expression of a FLAG™-tagged protein (Figure 3.5A) 
which was absent in membranes of mock transfected HEK293 cells. The 
predominant FLAG antibody reactive species migrated through SDS-PAGE with 
an apparent molecular mass of around 45 kDa. Although somewhat slower
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migrating polypeptides were observed in the transiently transfected cells, these 
were more evident in membranes of clone 13 cells that expressed the receptor 
stably and at higher levels (Figure 3.5B). These probably represent differentially 
glycosylated forms of the FhlPR which presented as a broad complex or multiple 
bands ranging from 41 to 61 kDa in mass. In contrast, membranes of parental 
HEK293 cells from which clone 13 was derived did not show any immunoreactivity 
to M5 anti-FLAG™ antibody.
Agonist-stimulated adenylate cyclase activity in clone 13 cells was 
assessed in greater detail by studying the dose-dependent effect of iloprost 
(Figure 3.6). Clone 13 cells were seeded into poly-o-lysine coated 24 well plates 
and incubated overnight with [^Hjadenine at 0.5 pCi per well. Iloprost 
concentrations from 10’ ^^  to 10"^ M were used to stimulate the cells for 20 min. 
The ECso of iloprost to stimulate adenylate cyclase in clone 13 cells was 
estimated at 1.4 ±  0.3 X 10'^° M (n=3). This result correlated well with that 
observed for a hemagglutinin-tagged hIPR with EG50 of 0.1 nM (Smyth et al. 
1996).
Sustained agonist treatment of cells can caused downregutation of the 
activated G protein(s). Therefore, iloprost (1 pM) pretreatment of clone 13 cells 
was attempted at various time points. Membranes of these treated cells were 
resolved in SDS-PAGE and immunoblotted with various anti-Ga antisera. The 
progressive loss of endogenous Gga with time when incubated with iloprost was 
clearly seen in Figure 3.7A. As stimulation of IP prostanoid receptor elevates 
cAMP, it is not surprising that Gga was downregulated. The long Isoform of Gga 
was observed to be downregulated faster than the short isoform, probably due to 
its lower endogenous expression. However, such a time-dependent pattern of 
downregulation was not apparent for Gii/2a or Gq/na subunits (Figures 3.7B & 
3.70 respectively). Ga subunits in parental HEK293 cells were not downregulated 
upon iloprost treatment (1  |iM for 16 h) (data not shown).
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Construction and immunological characterisation of a Gn/Gs6a chimeric 
protein
The C-terminal decapeptide of Gga differs from Gjia in 8  residues (Figure
3.8). Conklin et al. (1993a) had previously shown maximum coupling efficiency 
when 4 to 9 carboxyl terminal residues were substituted. It was therefore possible 
that substituting the last 6  residues of Gj-ia with those of Gga may confer the 
protein with the ability to interact with the IP prostanoid receptor. Such a chimeric 
protein (G ji/G g6a) was constructed using a PCR-based strategy, where the last 6 
codons of Gjia cDNA were altered to encode the respective amino acids of Gga 
by changing as few bases as possible (see Section 2.3.9C).
To determine that this cDNA encoded a correct chimeric Gn/GgGa protein, it 
was transiently transfected into COS-7 cells, and the membranes assessed by a 
series of immunoblots. Antiserum IIC  specific for an internal domain (159-168 aa) 
of Gj-ia was firstly used. This detected strong immunoreactivity in membranes of 
Gii/Gg6 a transfected but not mock (pcDNA3) transfected cells (Figure 3.9A). This 
41 kDa polypeptide co-migrated with an immunreactive protein from membranes 
of rat brain cortex, which express high levels of Gjia. However, SGI antiserum, 
specific for the C-terminal decapeptide of Gn/aa, failed to detect the same 
polypeptide in membranes of Gn/GgGa transfected* cells (Figure 3.9B), although it 
did detect a low level of endogenous G|i/2a in COS-7 cells and a high level of 
authentic Gji/2a in rat brain cortex. Therefore, this showed that the "Gna-like" 
polypeptide in Gji/Gg6 a transfected cells had an altered C-terminus that failed to 
interact with an antiserum specific for the terminal decapeptide of Gji/2a.
Confirmation that the chimeric G protein had acquired the immunoreactivity 
of the carboxyl-terminus of Gga can be seen from a CS immunoblot. CS antiserum 
was raised against the C-terminal decapeptide (RMHLRQYELL) of Gga. It 
immunoreacted with a polypeptide in Gn/GgGa transfected cells (Figure 3.9C; left 
panel). Endogenous levels of Gga were also detected in the Gn/GgGa transfected
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cells (upper band). The same CS immunoreactive polypeptide also interacts with 
11C antiserum (Figure 3.9C; right panel). Thus, this “Gjia-like” polypeptide is the 
chimeric G;i/Gg6 a protein. A minor point to note here is that although only 6  
carboxyl residues of Gga were substituted into the corresponding segment of G^a, 
the seventh carboxyl terminal residue - leucine 348, is conserved between G^a 
and Gga. Therefore the last 7 residues of Gga, found in the Gji/Gg6 a chimera 
were sufficient for recognition by the CS antiserum.
Transient expression of Ga proteins in clone 13 cells
To assess the coupling capacity of the chimeric protein with the IP 
prostanoid receptor, cDNAs of Gii/Gg6 a, Gga, G^a, and pcDNA3 were transiently 
transfected into clone 13 cells. Membranes from these cells were prepared and 
high affinity GTPase assays performed under basal and iloprost (1 pM) stimulated 
conditions, at a final GTP concentration of 0.5 pM. This assay detects the rate of 
GTP hydrolysis by Ga subunits, and hence is a measure of both G protein 
activation (koff) and termination (kcat) (Gierschik et al. 1994). As Ga subunits differ 
greatly in their handling of guanine nucleotides, the GTPase assay is therefore 
ideal to detect any "switch" of Ga coupling with the receptor.
As presented in Figure 3.10, transient expression of Gn/GgGa protein in 
clone 13 cells resulted in a very large increase in agonist stimulated high-affinity 
GTPase activity compared to mock transfected cells (unpaired t-test; p<D.05; 
n=3). Transient expression of Gga and G^a in clone 13 cells did not affect the 
level of agonist-stimulated high affinity GTPase inherently present in these cells. 
Furthermore, transient transfection of parental HEK293 cells with Gn/GgGa cDNA 
did not result in any measurable iloprost stimulation of high affinity GTPase 
activity.
Since expression of high levels of protein can cause enforced coupling 
between G proteins and GPCRs which is not seen normally (Kenakin 1997), the 
level of Ga overexpression in clone 13 cells was assessed. In Figure 3.11A, the
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expression level of Gji/Gs6 a protein was similar to G^a protein in transiently 
transfected clone 13 cells. However, Gn/GgGa protein was expressed at least 3 
times higher than Gga protein (Figure 3.1 IB). Although it may appear that the 
elevated GTPase response of Gji/GgGa transfected cells could be attributed to the 
high expression of this protein, a similar level of expression of G^a did not result 
in any increase in GTPase activtiy (Figure 3.10). Thus, the coupling of Gp/GgGa 
protein with the FhlPR was specific and not a direct result of high expression 
levels.
The GTPase assay determines the overall activity of G proteins (a 
combination of activation and termination rates), while the GTPyS binding assay 
gives only an indication of the level of activated G a. This is because incorporation 
of a non-hydroiysable analogue of G T P  (G TP yS ) in G a  would prevent any further 
termination and re-activation processes (i.e. kgat = 0). With this in mind, 
[^^S]GTPyS binding assays were performed on membranes of G n/G gSa  
transfected clone 13 and HEK293 cells, and also in untransfected clone 13 cells 
(Figure 3.12). Expression of Gn/GgGa protein in HEK293 cells did not alter 
agonist-driven binding of [^^S]GTPyS but transfection into clone 13 cells, which 
already express high levels of FhlPR (-3 pmol/mg), enhanced iloprost (1 p.M) 
stimulated binding when compared to untransfected clone 13 cells. Thus iloprost, 
acting via the IP prostanoid receptor, activated a larger amount of G a  when 
Gii/Gg6 a was co-expressed.
Pretreatment with cholera and pertussis toxins
The presence of endogenous G a  subunits affected the proper assessment 
of signalling activity arising from transfected G a. Since activation of the IP 
prostanoid receptor resulted in cAMP production and also downregulation of 
endogenous Gga subunits, it is apparent that uncoupling Gga from the receptor 
will reduce endogenous G a  output and allow a true measure of Gj-i/GgGa
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stimulation. This problem is less acute in 849 eye' cells, which lack endogenous 
Gga, but most cell lines including HEK293, contain relatively high levels of Gga.
Cholera toxin has been shown to catalyse the ADP-ribosylation of Gga at 
arginine 201 and hence diminish its GTP-hydroiysis capacity (Casse! and Selinger 
1977). As a result, ADP-ribosylated Gga is constitutively active and stimulates 
adenylate cyclase in the absence of agonist. Furthermore, ADP-ribosylated Gga is 
rapidly degraded, with extensive loss after 8  h treatment with cholera toxin (Chang 
and Bourne 1989). Using this strategy, clone 13 cells were pretreated with cholera 
toxin (200 ng/ml; 16 h) with the aim of reducing Gga activation by the IP 
prostanoid receptor. Alternatively, pertussis toxin catalyses the ADP-ribosylation of 
the last cysteine residue of G proteins of the G;a subfamily (except G%a) and this 
modification has been shown to prevent G protein interaction with the receptor 
(Fields et al. 1997). Thus, clone 13 cells were also pretreated with pertussis toxin 
(25 ng/ml; 16 h) to assess its effect on endogenous Ga activity. Agonist-stimulated 
(1 pM iloprost) high affinity GTPase assay was performed on membranes of these 
toxin-treated cells (Figure 3.13). The results indicated that pretreatment with 
cholera toxin but not pertussis toxin abolished the agonist-stimulated GTPase 
activity (unpaired t-test; p<0.05; n=3). This confirmed that the low level of agonist- 
promoted Ga activity was derived from activation of endogenous Gga and not Gja.
In the chimeric Gn/GgGa protein both cysteine 351 of G^a and arginine 201 
of Gga are absent (see Figure 3.8), and hence it is postulated to be resistant to 
both cholera and pertussis toxin treatment. Thus, clone 13 cells transiently 
transfected with the various Ga were pretreated with a combination of both 
cholera (200 ng/ml) and pertussis toxins (25 ng/ml) for 16 h, and [^^SjGTPyS 
binding assays performed. This abolished iloprost-stimulated [^^SjGTPyS binding 
in all the transfected cells except those expressing Gj-i/GgGa protein (Figure 3.14). 
This conclusively proved that the chimeric G protein is resistant to treatment with
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both toxins and that the enhancement of [^^S]GTPyS binding in these cells was 
contributed by the G|i/Gs6 a protein.
To ensure that the treatment of clone 13 cells with cholera and pertussis 
toxins had modified all Gja and Gga subunits, immunoblots of the membranes 
were performed. Immunoblotting with antiserum IIC  showed retardation of the 
overexpressed G^a protein in the presence of toxins (Figure 3.ISA), indicating an 
increase in molecular mass arising from the covalent addition of ADP-ribose. This 
was however not observed in cells overexpressing Gji/Gg6 a protein. Pretreatment 
with toxins also resulted in the downregulation of both endogenous forms of Gga 
in all cells (Figure 3.15B), an effect of cholera toxin shown previously by various 
groups (Chang and Bourne 1989; MaCleod and Milligan 1990). As a higher level 
of the long isoform of Ggoc was expressed in cells transfected with Gga(L) cDNA, it 
was downregulated to a lesser extent by toxin treatment. Similar to that observed 
in the 110 immunoblot, the level of CS immunoreactive Gii/Gg6 a protein was 
unaffected by the action of the toxins (Figure 3.15B). These results further confirm 
the resistance of Gn/GgGa protein to both cholera and pertussis toxins under 
conditions where endogenous Gga and Gja subunits were downregulated and 
modified respectively.
As Gji/Gg6 a contains the backbone of Gjia," it would be expected to inhibit 
adenylate cyclase when activated. Clone 13 cells transfected with Gji/Gg6a was 
assessed for cAMP production or inhibition upon stimulation by iloprost (1 pM) or 
iloprost (1 pM) together with forskolin (50 pM). As seen in Figure 3.16, Iloprost 
induced a slightly lower level of stimulation in G}i/Gg6 a tranfected clone 13 cells 
compared to untransfected cells. However, addition of iloprost with forskolin 
resulted in synergistic activation of adenylate cyclase in both sets of cells. As the 
amount of Gja required to alter adenylate cyclase activity is at least 1 0 0 0  fold 
higher than Gga (Taussig et a/. 1993), it is possible that the concurrent activation 
of endogenous Gga could have masked the inhibitory action of Gji/Gg6 a on 
adenylate cyclase. Thus, the cells were pretreated with cholera toxin (200 ng/ml;
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16 h) in an attempt to downregulate endogenous Gga. This had the effect of 
elevating the basal level of adenylate cyclase activity slightly and decreasing the 
response to iloprost in both sets of cells. However, there was still no inhibition of 
forskolin-stimulated adenylate cyclase activity by Gii/Gg6 a protein upon activation 
by iloprost. As Gii/Gg6 a was transiently transfected into clone 13 cells, it would 
mean that only 30 to 40% of all cells would express the protein (manufacturer's 
information leaflet on Lipofectamine™). Therefore, even if Gp/GgOa protein can 
inhibit adenylate cyclase activity, it would exert this effect in only 30 to 40% of 
clone 13 cells. It is thus not possible to properly assess the downstream signalling 
effects of this protein in such a scenario, and hence studies related to this were 
not pursued further.
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Figure 3.1 Stable expression of the FLAG™-tagged human IP prostanoid
receptor in clones of HEK293 cells
Following stable expression of the FhlPR cDNA into HEK293 cells, membranes 
from clones 13, 16, and 17 together with parental cells were prepared and 
assessed using -  10 nM [^H]iloprost The specific binding, of [^HJiloprost was 
obtained by subtracting "non-specific counts (assessed with 5 pM unlabelled 
iloprost) from total counts, and normalised with the amount of membrane protein 
used in the assay. The data represent the mean + SEM of 2 or more independent 
experiments performed in triplicate.
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Figure 3.2 Stimulation of cAMP production by iloprost and forskolin in 
clones of HEK293 cells stably expressing FhlPR
Basal adenylate cyclase activity (stippled bars) and regulation by 1 pM iloprost 
(filled bars) or 50 pM forskolin (hatched bars) were assessed in intact cells of 
HEK293 clones stably expressing FhlPR (clones 13, 16 and 17). The results are 
expressed as the ratio of cAMP over total adenine nucleotides X 100 and 
represent the mean + SD of 2 independent experiments performed in triplicate.
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Figure 3.3A [^H]i!oprost saturation binding studies of clone 13 cells
Membranes of clone 13 cells were incubated with increasing concentrations of 
[^H]iioprost at 30°C for 30 min. Non-specific binding at each [^H]iloprost 
concentration was determined in the presence of 1 0  pM unlabelled iloprost. 
Specific binding of [^HJiioprost was obtained by subtracting non-specific binding 
from the total binding. Specific binding was expressed as fmol of [^H]iloprost 
bound per mg membrane protein by factoring in the specific activity of [^H]iloprost 
(34 dpm/fmol) and the amount of membrane protein used per assay (20 pg). This 
graph is a typical representation of 3 independent experiments performed in 
triplicate.
Figure 3.3B Scatchard plot of agonist saturation binding in clone 13 cells
The binding data of Figure 3.3A was converted into concentrations of bound 
(fmol/mg membrane protein) and free (nM) radioligand at each [^Hjiloprost 
concentration used. This was plotted as Bound/Free versus Bound (Scatchard 
Plot). The slope of the graph gave the negative inverse of Kd (- 1/Kd), while the X- 
intercept is the B^ax- Analysis using EBDA (Elsevier-BIOSOFT 1987) showed 2 
affinity binding. High affinity binding Kd was determined as 1.6 + 0.4 nM, Bmax as 
971 + 83 fmol/mg (n = 3). Low affinity binding Kd was determined as 11.4 + 2.3 
nM, Bmax 3 S 3202 + 515 fmol/mg (n = 3). This graph is a typical representation of 
3 independent experiments performed in triplicate.
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Figure 3.4 Displacement of [ H]iloprost binding in membranes of clone 13
The specific binding of [ H]iloprost (3.4 ±  0.2 nM) to membranes of clone 13 cells 
was displaced by increasing concentrations of unlabelled iloprost. Counts 
obtained in the presence of 1 0  pM unlabelled iloprost were treated as non-specific 
binding. Curve fitting by Kaleidograph™ (v3.02; Abelbeck Software 1993) 
indicated apparent Bmax (also known as Bq) of 1817 + 38 fmol/mg membrane 
protein and IC50 of 6.1 ± 0.7 nM tn = 3). Hill slope of the graph is 0.64 + 0.05. 
Applying the formalism of DeBlasi et al. (1989), Bmax was estimated at 3260 + 6 8  
fmol/mg and Kd estimated at 2.7 + 0.8 nM. The data represent the mean + SEM of 
3 independent experiments performed in triplicate.
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Figure 3.5 Immunodetection of the FLAG™-tagged human IP prostanoid
receptor in transiently and stably transfected HEK293 cells
A. Membranes of mock transfected (lane 1) and FhlPR transiently transfected 
(lane 2) HEK293 cells were resolved by 10% SDS-PAGE, transferred to 
nitrocellulose membrane and immunoblotted with M5 anti-FLAG™ monoclonal 
antibody. The predominant immunoreactive protein in lane 2 migrated with an 
apparent molecular mass of around 45 kDa.
B. Membranes of parental HEK293 (lane 1) and clone 13 (lane 2) cells were 
subjected to the same treatment. M5 immunoreactive proteins ranged from 41 
to 61 kDa in clone 13 cells and presumably represent differentially glycosylated 
forms of FhlPR.
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Figure 3.6 Adenylate cyclase concentration-response curve for iloprost in 
intact clone 13 cells
Intact clone 13 cells were assessed for their ability to stimulate adenylate cyclase 
at various concentrations of iloprost. The results are presented as in Figure 3.2 
but expressed as % maximum stimulation (activity at 1 0  pM iloprost treated as 
100%). Effective concentration at 50% stimulation (EC5 0) was estimated at 1.4 + 
0.3 X 10"^° M (mean + SEM; n =.3). This graph is representative of 3 independent 
experiments performed in triplicate.
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Figure 3.7 Sustained agonist treatment of clone 13 cells results in 
downregulation of G^a but not G11/2OC or Gq/na subunits
Clone 13 cells were incubated with iloprost (1 |aM) for 0, 0.5, 2, 4, 8 , and 16 h. 
Membranes prepared from these cells were resolved by 10% SDS-PAGE, 
transferred to nitrocellulose membrane and immunoblotted using various anti-Ga 
antisera.
A. Immunoblotting with CS antiserum, specific for the carboxyl-terminal 
decapeptide of Gga, demonstrated a time-dependent downregulation of both 
the long and short isoforms of Gga. Downregulation occurs with just 30 min of 
iloprost treatment, leaving only trace amount at 16 h.
B. Immunoblotting with SG antiserum, specific for the C-terminal decapeptide of 
Gji/2 a, did not show any downregulation even after 16 hours of incubation with 
iloprost.
C. Immunoblotting with CQ antiserum, specific for the C-terminal decapeptide of 
Gq/iia, also did not show any time-dependent pattern of downregulation by 
agonist.
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Figure 3.8 Generation of Gii/Gs6a chimeric protein
The carboxyl-terminal decapeptides of Gna and Gga are shown using the single 
letter representation of the amino acids. The ADP-ribosylation sites for pertussis 
toxin (cysteine 351) and cholera toxin (arginine 201) are also indicated. The 
chimeric Gn/GgOa protein contains the last 6 residues of Gga in place of Gjia.
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Figure 3.9 Immunological characterisation of Gii/Gs6a protein
Membranes of COS-7 cells transiently transfected with pcDNA3 (1) or Gn/GgGa 
cDNA (2) were resolved on SDS-PAGE, transferred to nitrocellulose membrane 
and immunoblotted with various antisera. Membranes of rat brain cortex (3) were 
used as positive control for G^a due to its high endogenous expression.
A. Antiserum 110, which recognises an internal domain (159-168 aa) of G;ia, 
identified an immunoreactive protein in Gji/Gs6 a transfected cells that co­
migrated with authentic Gna from rat brain cortex.
B. Antiserum SG1, which recognises the C-terminal decapeptide of Gii/2a, fails to 
identify strong immunoreactivity in mock or Gii/Gs6 a transfected COS-7 cells 
but detected high levels of Gji/2a in rat brain cortex.
C. A polypeptide in G ji/G gG a transfected cells together with endogenous Gga 
display immunoreactivity with CS antiserum, which specifically recognises the 
C-terminal decapeptide of Gga (left panel). The same polypeptide together with 
G jia from rat brain cortex also display immunoreactivity with 11C antiserum 
(right panel). Thus this polypeptide had an internal G^a domain but a C- 
terminal region similar to Gga and hence was identified as the Gn/GgGa protein.
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Figure 3.10 Expression of Gii/Gg6a with FhIPR enhances agonist-stimulated
high affinity GTPase activity
Clone 13 cells were either mock transfected (with pcDNA3) or transiently 
transfected to express Giia, Gga or Gn/GsGa. Parental HEK293 cells were also 
transiently transfected to express Gi-|/Gs6 a. Membranes from these cells were 
assessed for basal and iloprost (1  pM)-stimulated high affinity GTPase activity. 
The stimulation produced by iloprost is displayed, and is as follows (mean + SEM 
pmol/min/mg membrane protein): pcDNA3 (2.9 + 0.6), G^a (3.3 ±  0.3), Gga (3.3 ±
0.8), Gii/Gs6 a (10.6 ± 0.6), and Gji/Gs6 a in HEK293 (-0.4 ± 0.3). These data 
represent 3 independent experiments performed in triplicate.
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Figure 3.11 Immunoblot indicating expression levels of G,a, Gga, and 
Gji/Gs6a in clone 13 cells
Membranes of clone 13 cells transfected as in Figure 3.10 to express Gii/Gs6a 
(1), G jia  (2) and Gga (3) were resolved by 10% SDS-PAGE and immunoblotted 
with antisera I1C (Figure A) or CS (Figure B). Gii/Gg6a and G ^a proteins were 
expressed to similar levels but Gga protein was expressed at less than one third 
the level of Gn/GgGa.
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Figure 3.12 Co-expression of Gn/GgGa with FhlPR enhances agonist-
stimulated binding of [^®S]GTPyS
[ S]GTPyS binding was assessed in membranes of Gn/GgGa transfected clone 
13 cells or HEK293 cells and also of untransfected clone 13 cells. Non-specific 
binding was obtained in the presence of 20 pM unlabelled GTPyS, while agonist- 
stimulated binding in the presence of 1 pM iloprost. Results are presented as 
[^^S]GTPyS bound (cpm) per assay (20 pg membrane protein). Non-specific 
binding was similar in all cells but basal values differed slightly between clone 13 
and parental HEK293 cells. This graph is a typical representation of 3 experiments 
performed in triplicate.
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Figure 3.13 Comparison of the effects of cholera and pertussis toxin on 
agonist-stimulated high affinity GTPase activity in clone 13 cells
Clone 13 cells were treated with either vehicle (50% glycerol) or cholera toxin (200 
ng/ml, 16 h) or pertussis toxin (25 ng/ml, 16 h) before harvest. Membranes from 
these cells were then used to measure basal high affinity GTPase activity and its 
stimulation by iloprost (1-pM). Iloprost stimulated activities are displayed and as 
follows (pmol/min/mg membrane protein): vehicle (2.7 + 0.4), cholera toxin (0.8 + 
0.5) and pertussis toxin (2.7 + 0.2). The data represent mean + SEM of at least 3 
experiments performed in triplicate.
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Figure 3.14 The effects of combined cholera and pertussis toxin treatment 
on agonist-stimulated [^®S]GTPyS binding in clone 13 cells 
transiently expressing various Ga subunits
Clone 13 cells were transfected with the various Ga cDNAs as in Figure 3.10 and 
treated with a combination of cholera toxin ( 2 0 0  ng/ml) and pertussis toxin (26 
ng/ml) for 16 h prior to harvest. Membranes prepared from these and the 
untreated cells were assessed fo t their ability to bind [^^SjGTPyS under basal or 
iloprost (1 pM) stimulated conditions. The stimulation produced by iloprost is 
displayed. This graph represents one of three independent experiments 
performed in triplicate.
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Figure 3.15 Sustained treatment of clone 13 cells with cholera and pertussis 
toxin down regulates levels of Gga and modifies G;a
Membranes from Figure 3.14 were resolved on 10% SDS-PAGE, transferred to 
nitrocellulose and immunoblotted with either 11C antiserum (Figure A) or CS 
antiserum (Figure B) to assess the effect of cholera and pertussis toxins on Ga 
subunits.
A. Retardation of overexpressed Gpa protein in SDS-PAGE was observed in the 
presence of toxins. No noticeable difference was seen in toxin-treated cells 
overexpressing the Gp/GsGa protein.
B. Endogenous levels of Gga were down regulated in the presence of toxins in all 
cells. The levels of Gji/GgSa protein were however unaffected.
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Figure 3.16 Adenylate cyclase response in cells co-expressing FhlPR and 
G|i/Gs6a protein
G|i/Gs6 a was transiently transfected into clone 13 cells and their adenylate 
cyclase activities assessed by stimulation with iloprost (1 pM), iloprost (1 pM) + 
forskolin (50 pM) or forskolin (50 pM). Clone 13 cells were similarly assessed. 
Cholera toxin (200 ng/mlj was also incubated with both sets of cells for 16 h and 
their adenylate cyclase response^to various activators assessed. This graph is a 
typical representation of two independent experiments performed in triplicate.
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3.3 Discussion
The FLAG™-tagged human IP prostanoid receptor is simiiar to the parentai
receptor
Epitope tagging of GPCRs allows easy immunodetection and immuno- 
localisation. Most often, epitope tagging of receptors is on the N-terminus, as it is 
extracellular and hence convenient to work with especially in immunocyto- 
chemistry. However, the N-terminus may also be involved in ligand binding and N- 
glycosylation. The FhlPR stably expressed in clone 13 cells binds iloprost with 
both high and low affinity, in accordance with Boie et al. (1994) who expressed the 
parental human IP prostanoid receptor in C0S-M6 cells. Their Scatchard analysis 
showed that [^H]iloprost binding to the hlPR conformed to a two-site model with 
high affinity and low affinity equilibrium dissociation constants of 1 and 44 nM 
respectively. This is quite similar to the results obtained in this study: high affinity 
Kqj = 1.6 nM; low affinity Kd = 11.4 nM (Figure 3.3), although the accuracy of low 
affinity values obtained in this study is limited by the concentrations of [^H]iloprost 
used. Furthermore, Smyth et ai. (1996) expressed a hemagglutinin epitope 
(YPYDVPDYA) tagged receptor (HAhlPR) and showed similar two-affinity site 
binding for [^H]iioprost (high affinity Kd = 0.4 nM, low affinity Kd = 75 nM). 
Therefore, the incorporation of FLAG™ epitope on the N-terminus of hIPR did not 
affect the binding affinity of the receptor.
N-glycosylation is usually not affected by epitope tagging, but instead may 
cause problems for immunodetecting the epitope. N-Glycosylation involved the 
attachment of oligosaccharides to the amine-group of asparagine residues in the 
extracellular segments of a GPCR. This modification facilitates the movement of 
the amino-terminus and extracellular domains of the receptor through the plasma 
membrane. The processing of N-linked oligosaccharides in the Golgi vesicles is a 
sequential process of removal and addition of sugar residues, with each 
asparagine residue modified differently. There are 3 different structures of 
asparagine-linked oligosaccharides: high mannose, hybrid, and complex. Thus, it 
is not surprising that N-glycosylated GPCRs are often presented as proteins with
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various molecular masses (Figure 3.5B). The immunoblot of HAhlPR was also 
resolved as a broad complex with molecular mass ranging from 44 to 62 kDa 
(Smyth et at. 1996). The single immunoreactive protein in transiently transfected 
HEK293 cells (Figure 3.5A) was likely to be unglycosylated or represented a 
single form of glycosylated receptor. This compared favourably with the expected 
molecular mass of around 42 kDa for the Fl_AG™-tagged human IP prostanoid 
receptor. Deglycosylation of the FhlPR in membranes of clone 13 cells was 
attempted by incubating with N-glycosidase F (Boehringer Mannheim) but was not 
successful (data not shown).
Stimulation of adenylate cyclase activity in clone 13 cells by the IP 
prostanoid receptor agonist iloprost was very robust and rapid. Addition of 0.14 
nM iloprost resulted in 50% stimulation of adenylate cyclase activity (Figure 3.6). 
Furthermore, sustained treatment of clone 13 cells down regulates Gga but not 
Gji/2a or Gq/iia (Figure 3.7). This conclusively showed that the agonist-occupied 
FhlPR activates Gga. The ability of prostanoid agonists to stimulate adenylate 
cyclase and downregulate Gga selectively was previously shown in NG108-15 
neuroblastoma X glioma hybrid cells endogenously expressing the IP prostanoid 
receptor (McKenzie and Milligan 1990). Although there is evidence that stimulation 
of IP prostanoid receptor elevates IP3 level (Namba et al. 1994), this was not 
studied in detail herein. As Gq/iia in clone 13 cells was not downregulated upon 
sustained iloprost treatment (Figure 3.7C), it is unlikely that elevation of IP3 is 
mediated via activation of Gqa or G-^a. Furthermore, most studies showing the 
involvement of inositol phosphate production require quite a high concentration of 
agonist (EC50 = 43 nM in HAhlPR; Smyth et al. 1996). This is in contrast to the 
subnanomolar concentrations required for activation of adenylate cyclase. All 
these observations suggest that G(3y complex and not Gqa subfamily is involved in 
the activation of phosphoiipase C. However, as the results in the current study are 
insufficient and not intended to address this issue, a clear conclusion on this 
matter cannot be drawn.
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Overexpressîon of chimeric Gn/Gs6a protein resulted in enhanced iloprost 
stimulated activity
Chimeric G proteins have been employed extensively to map the functions 
of specific domains in the Ga subunit. In particular, the extreme carboxyl terminus 
of Ga was shown to be essential and even sufficient for transducing signal from 
the receptor (Conklin et'al. 1993a; Voyno-Yasenetskaya et al. 1994). This was 
backed up by substantial evidence showing that modification of particular residues 
in the carboxyl terminus resulted in loss of receptor coupling capacity. This 
included the pertussis toxin catalysed ADP-ribosylation of a conserved cysteine 
residue of Gja (West et al. 1985) and the une mutation (proline 389 to arginine) of 
Ggtt (Sullivan et al. 1987). In contrast, recent studies have shown that the carboxyl 
terminus may not be the only determinant of receptor coupling and that the 
coupling domain varies between different receptors and G proteins (Tsu et al. 
1997; Lee et al. 1995). As the interaction between IP prostanoid receptor and Gga 
had not been studied, it was interesting to investigate the activating capacity of a 
chimeric Gii/Gg6 a protein by the receptor.
The results indicate strongly that the IP prostanoid receptor can activate the 
Gii/Gg6 a protein which resulted in enhanced agonist-stimulated GTPase (Figure 
3.10) and [^^8 ]GTPyS binding (Figure 3.12). This Js because activation of the IP 
prostanoid receptor had never previously shown measurable responses in these 
assays despite strong activation of adenylate cyclase and sufficiently high 
expression of receptors, for example in NG108-15 cells (McKenzie and Milligan 
1990). While it might be argued that endogenous Gga is limiting in these and 
clone 13 cells, this is unlikely to be true. Overexpression of Gga in clone 13 cells 
did not result in increased agonist-stimulated activity in both assays (Figure 3.10 
and 3.14).
The true magnitude of the iloprost-stimulated activity of Gii/Gg6 a was finally 
resolved through the use of cholera and pertussis toxins. Although cholera toxin is 
probably sufficient to remove endogenous Gga coupling with the receptor (Figure
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3.13), the use of pertussis toxin would prevent any non-specific interaction with 
Gja-like G proteins as shown in some studies (Akam et al. 1997). As postulated, 
the Gji/Gs6 a protein was not modified (Figure 3.ISA) nor downregulated (Figure 
3.1 SB) by pertussis and cholera toxin treatment. When used in combination, 
iloprost-stimulated GTPyS binding activities were abolished in all cells except 
those transfected with Gj-i/GgSa (Figure 3.14). Under these conditions, the 
remaining agonist-stimulated activjty must be derived from activation of Gji/Gs6 a.
The high rates of GTP exchange and hydrolysis characteristic of Gna were 
apparently retained in the chimeric Gji/Gs6 a protein. In membranes of Gji/Gs6 a 
transiently transfected clone 13 cells, agonist stimulated GTPase activity was at 
least 3 fold higher while GTPyS binding was about 2 fold higher than mock 
transfected clone 13 cells. Although the expression level of Gj-i/GsSa protein is 
relatively high compared to endogenous Gga (Figure 3.1 SB), it should be noted 
that in transient transfection studies, only a small fraction of cells (30 to 40%) 
would express the protein. Hence, stimulation by iloprost would enable only a 
fraction of the total receptor to activate the chimeric protein in contrast to 
activation of endogenous Gga. The high level of activity is therefore not a result of 
high G ji/G g 6a  expression levels, but rather an intrinsic property of the chimeric G 
protein. Instead, an even greater signal output might be obtained by a cell line that 
stably co-expresses both the receptor and the chimeric G protein.
Conklin et al. (1993a) were among the first to show that it is possible to 
switch the signalling output of a receptor by using chimeric G proteins. In that 
study, Gja-coupled GPCRs like D2 dopamine and A i adenosine receptors 
activated PLC by interacting with a Gqa/Gi2a chimera. Similarly, Voyno- 
Yasenetskaya et al. (1994) had shown that a D2 dopamine receptor can activate 
NHE via a Gisa/Gza chimera. Finally, using a series of G^a/G^a chimeras, 
Komatsuzaki et al. (1997) managed to switch the signalling output of SSTR3 
somatostatin receptor from activation of PLC (via G #a and Giea) to activation of 
adenylate cyclase. In this current study, 1 was able to show the activation of a
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chimeric G protein with high rates of guanine nucleotide activities (koff and kcat) by 
the IP prostanoid receptor, that would normally activate Gga, a G protein with 
intrinsically low guanine nucleotide activities. Therefore, this offers an alternative 
means to analyse agonist pharmacology at the IP prostanoid receptor. By 
activating only the chimeric Gn/GgBa but not full length G^a, the IP prostanoid 
receptor also demonstrated its selective interaction with Gga via the extreme 
carboxyl terminus. It remains to be seen how many more Gga-coupled GPCRs 
share this characteristic.
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CHAPTER 4
Comparison of Signal Transduction Efficiency 
between the Human IP Prostanoid Receptor and 
the Human IP Prostanoid Receptor-Gga Fusion 
Protein
4.1 Introduction
The human IP prostanoid receptor (hIPR) belongs to the family of 
prostaglandin receptors that mediate the functions of prostaglandins and 
thromboxane A2 . The physiological ligand for the hIPR is PGI2 , which is also 
known as prostacyclin. Therefore, the IP prostanoid receptor has also been 
referred to as the prostacyclin receptor. PGI2 mediates important physiological 
functions including inhibition of platelet aggregation and vasodilation, and is also 
thought to play a role in maintaining vascular homeostasis (Moncada et at. 1980). 
These functions were confirmed in a recent study of mice lacking the IP 
prostanoid receptor (Murata et al. 1997). These knock-out mice also exhibited 
reduced inflammatory and pain responses, thereby implicating the IP prostanoid 
receptors in the mediation of inflammatory pain. Indeed, there is also other 
evidence linking the EP and IP prostanoid receptors with nociception, especially in 
post trauma and inflammation settings (Bley et al. 1998). Therefore, antagonists of 
IP prostanoid receptors may have real therapeutic applications, and their 
discovery are high on the agenda of some pharmaceutical companies.
Through secondary messenger studies of endogenous hIPR in human 
platelets (Schafer et al. 1979) and co-expression of the receptor with the cystic 
fibrosis conductance regulator (cAMP-activated Cl' channel) in Xenopus oocytes 
(Boie et al. 1994), the receptor was shown to couple to Gga subunit. Most 
functional receptor studies therefore utilised assays for cAMP, the second 
messenger produced by adenylate cyclase upon binding of activated Gga (Adie et
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al. 1992; Kedzie et al. 1998). This assay takes advantage of the considerable 
signal amplification in the signalling cascade, and is particularly sensitive, as even 
picomolar of activated Gga can stimulate adenylate cyclase (Bourne et al. 1990). 
Constitutively activated Gga can give rise to elevated adenylate cyclase activity, 
for example in a Gga(L) mutant where glutamine 227 was mutated to leucine 
(Q227L) in the GTPase domain (Masters et al. 1989). This mutation diminished 
the GTP hydrolysing ability of Ggq, and hence resulted in a failure of the mutant to 
"switch-off" its activation of adenylate cyclase. Pretreatment of Gga with cholera 
toxin also gave the same effect, when arginine 201, located in the GTPase 
domain, was ADP-ribosylated (Cassel and Selinger 1977). Gga coupled GPCRs 
that are constitutively active, for example a mutant P2-acirenergic receptor 
(Cotecchia et al. 1990), can also elevate cellular cAMP levels by constantly 
stimulating the endogenous pool of Gga.
Previous studies have shown that the levels of receptor, G protein, and 
effector affect the amplitude of the transduced signal (Kenakin 1997). In 
neuroblastoma X glioma hybrid NG108-15 cells transfected to express high and 
low levels of the p2 -adrenergic receptor, a series of p-adrenergic agonists 
displayed higher intrinsic activity and lower EC50 values (from assay of membrane 
adenylate cyclase activity) in a clone expressing a high level of the receptor 
(MacEwan et al. 1995). Similarly, when Gga in NG108-15 cells was reduced by 
35% upon treatment with ethanol (100 mM) for 48 hours, the ability of A2 
adenosine and IP prostanoid receptors to stimulate adenylate cyclase were also 
reduced by ~30% (Mochly-Rosen et al. 1988). Finally, the cellular level of effector 
was also found to have a direct impact on signalling efficacy. Using the same 
NG108-15 cell line discussed above, MacEwan et al. (1996) co-expressed 
adenylate cyclase type II and P2~adrenergic receptor to different levels and found 
the level of adenylate cyclase to be the limiting component for receptor stimulated 
adenylate cyclase activity. Therefore, agonist efficacy in cellular systems may vary 
between cell lines due to differences in the levels and ratios of the signalling 
components. Flowever, an unbiased system of categorising receptor acting
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compounds into full agonist, partial agonist, or neutral antagonist is currently not 
possible.
The assay of agonist function at the level of G protein will remove one 
component of the cascade that interferes with proper interpretation of agonist 
activity. However, for various reasons mentioned in the previous chapter, there are 
numerous obstacles to utilise assays that directly detect Gga activation by an 
agonist occupied GPCR. Interestingly, by using a chimeric G protein (Gii/Gg6 a), 
robust agonist stimulated GTP exchange and hydrolysis by a Gga coupled GPCR 
has been observed (Chapter 3 of this thesis). This offered a potential method to 
assay agonist activity directly at the level of the G protein. Despite this advantage, 
the chimeric G protein approach still fails to address an important parameter in 
signalling: the stoichiometry of receptor and G protein (Kenakin 1997). Through 
the use of a HEK293 clone stably expressing the FhlPR, the level of receptor 
expressed was relatively constant and could be determined by [^H]iloprost 
binding. However, as the chimeric Gji/Gg6 a protein was transiently transfected 
into these cells, its expression level will inevitably vary between different 
transfections. Only very crude determination of its expression level could be 
performed, mainly via immunoblot comparison with known amount of G proteins.
A rather unusual approach to enhance receptor-transducer interaction was 
shown by Bertin et al. (1994) when they fused the amino terminus of Gga to the 
carboxyl terminus of p2 ‘ adrenergic receptor, forming a receptor-Ga fusion protein 
p2AR-Gsa. After transfecting into S49 lymphoma eye' cells a cDNA encoding this 
fusion protein, they were able to restore the defective activation of adenylate 
cyclase by |32-adrenergic receptor. Since these cells lack endogenous Gga 
subunits, the adenylate cyclase activity must have derived from the receptor-fused 
Gga, indicating the functionality of the G protein even when covalently linked to the 
receptor. Moreover, the agonist-dependent activation of adenylate cyclase was 
more potent and productive in the P2AR-Gga transfected 849 eye' cells than in wild 
type 349 cells, thus leading to the conclusion that the covalent link between 
receptor and Gga may increase signalling efficiency over freely interacting
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components (Bertin et al. 1994). This result must however be treated with caution, 
as the overall level of |3 2-adrenergic receptor in p2AR-Gsa transfected S49 eye' 
cells was higher than in wild type S49 cells.
A GPCR-Ga fusion protein was also studied in yeast cells when Medici et 
al. (1997) expressed a fusion protein between the a-factor receptor (Ste2) and the 
Ga subunit (Gpal) into Saccharomyces cerevisiae devoid of endogenous STE2 
and GPA1 genes. In GPA1 gene deleted yeast cells, the free Gpy complex 
constitutively activates the pheromone response pathway which leads to growth 
inhibition, and finally lethality in haploid cells. Medici et al. (1997) observed that 
the fusion protein Ste2-Gpa1, when transformed into Gpal deficient yeast cells, 
can complement efficiently the deletion of the GPA1 gene. Thus the fusion protein 
was able to function as normal Gpal by binding G|3y complex, and hence allowed 
normal growth to resume. Moreover when they transformed the Ste2-Gpa1 protein 
into cells devoid of endogenous Ste2 receptor, they found that these cells 
responded to a-factor inhibition of growth. Therefore, the fusion protein was also 
able to function as a Ste2 receptor (Medici et al. 1997).
All Ga subunits are localised to the plasma membrane by post-translational 
modifications including palmitoylation and/or myristoylation, at sites within their 
amino terminus (Wedegaertner et al. 1995). These acylations may also play a role 
in interactions between the Ga subunit and the receptor and Gpy complex 
(Wedegaertner et al. 1993). Hence, acylation-deficient mutants usually result in 
reduced association with the plasma membrane. Furthermore, co-expression of a 
pertussis-toxin resistant and acylation-deficient G^a (C3S/C351G) with the a2A- 
adrenergic receptor in COS cells failed to result in functional interactions (Wise et 
al. 1997a). However, it was unclear whether this was due to improper targeting, or 
altered receptor and/or G|3y interactions of the mutant G^a. This problem was 
solved when Wise and Milligan (1997b) constructed and expressed a fusion 
protein between the a2A-adrenergic receptor and the acylation-deficient G^a in 
COS cells, and managed to rescue the interactions between the receptor and 
mutant G protein. The GPCR-Ga fusion method therefore ensures co-targeting of
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Ga with the receptor, and enables proper assessment of the capacity of receptor 
and transducer to interact. This is analogous to in-vitro reconstitution experiments, 
but much simpler and more direct.
The usefulness of receptor-G-protein fusions to detect subtle differences in 
Ga protein function was recently exploited by Seifert et al. (1998a). The P2- 
adrenergic receptor was linked to the short (Gga(S)) and long (Gga(L)) splice 
variants of Gga, and expressed ininsect Sf9 cells. The two splice variants differ by 
a stretch of 15 amino acids located at position 72 of the polypeptide, with an 
exchange of glutamine for aspartate in Gga(L). Although Gga splice variants are 
differentially expressed in various tissues, and their levels changed during various 
physiological and pathological processes, the precise cellular role of each splice 
variant is not clear. This difficulty is compounded by the strong similarity between 
the splice variants, and hence their interactions with receptor are influenced 
strongly by their relative expression levels (Kenakin 1996).
By expressing the fusion proteins j32AR-Gga(S) and p2AR-Gga(L) in Sf9 
cells, which have a very low level of endogenous Gga, Seifert et al. (1998a) were 
able to show that P2AR-Gga(L) has low basal adenylate cyclase but high basal 
GTP hydrolysis activity compared to p2AR-Gga(S). Furthermore, when stimulated 
by isoprenaline, a full agonist, P2AR-Gga(L) gave a large output of high-affinity 
GTPase compared to co-expression of P2 receptor and Gga(L). The efficacy and 
potency of partial agonists were also found to be significantly higher for the P2AR- 
Gga(L) fusion protein than P2AR-Gga(S). Finally, a study of guanine nucleotide 
affinity between the two fusion proteins showed that p2AR~Gga(L) had lower GDP 
affinity than the short form, and hence may be more often guanine nucleotide free.
These studies elucidate the substantial benefits in receptor-Ga fusion 
constructs, especially in the enhancement of Gga activation to a point where 
traditional assays for G protein activation can be used. Furthermore, the level of 
expressed Ga can be accurately quantified, and the ratio of receptor and Ga
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constrained to 1:1 when endogenous Ga can be uncoupled from the receptor. 
While the Sf9 cells seem to be ideal for Gga coupled GPCR work, it is not possible 
to select for stably expressing clones of these cells, and hence expression level of 
the fusion protein will vary between transfections. Furthermore, the pattern of 
protein N-glycosylation had been shown to be different from that observed in 
vertebrate cells and is a .major limitation of the baculovirus-insect cell expression 
system (Jarvis efal. 1998).
This study therefore proposed to construct a fusion protein between the 
FLAG™ epitope tagged human IP prostanoid receptor and its cognate Ga, 
generating a protein known as FhlPR-Gga. HEK293 clones stably expressing this 
protein were then selected and characterised. Agonist stimulated activation of G 
protein was then assessed and compared with HEK293 clone 13 cells which 
stably express FhlPR. A comparison of the signal transduction efficiency between 
the freely interacting receptor/Ga and the covalently linked receptor-Ga could 
therefore be made.
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4.2 Results
Construction of IP prostanoid receptor-G^a fusion cDNA
The cDNA encoding the FLAG™-tagged IP prostanoid receptor fused with 
Gga was constructed as described in Section 2.3.9 A. The stop codon in FhlPR 
cDNA was removed by an antisense primer that also encodes a Xho\ restriction 
site. In the meantime, the 5’ and'3' ends of Gga(L)(HA) cDNA were engineered 
with Xho\ and Xba\ sites respectively, which allowed the Gga(L)(HA) cDNA to be 
inserted 3' to the FhlPR (in pcDNA3), forming a continuous open reading frame. 
Figure 4.1 give a schematic representation of the FhlPR-Gga fusion cDNA and the 
protein that it encodes.
The receptor-Ga ligated cDNA was transformed into DH5a E. coii and 
clones were picked from the agar plate after overnight incubation. These were 
screened for the presence of FhlPR and Gga cDNAs by digesting with HindlW and 
Xba\ {BamHl was not used as it is also found in Gga cDNA). Figure 4.2A showed 
that clones SI and S2 contained a digested fragment that migrates in 1% agarose 
gel at the combined length of FhlPR and Gga cDNAs (2.4 kilobases). Further 
digestion of clones 81 and 32 DNAs by Xhol and Xba\ gave a 1.2 kilobase 
fragment, which approximates the mass of Gga cDNA. Thus, both clones 81 and 
82 contained the receptor-Ga fusion cDNA. Clone 81 DNA was subsequently sent 
for DNA sequencing, which confirmed the sequence identity of both the IP 
prostanoid receptor and Gga. This DNA was then used for transfection studies.
Characterisation of HEK293 clones stably expressing the FhlPR~Gsa fusion 
protein
The problem of low expression levels was again encountered in transient 
transfection of the FhlPR-G ga cDNA in HEK293 cells. Geneticin G-418 resistant 
clones were thus selected and expanded. Three clones (clones 41, 4 3  and 4 4 ) 
were selected for further characterisation. Their expression levels were compared
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with clone 13 cells (stably expressing the FhlPR) and parental HEK293 cells. Of 
the three, clone 44 expressed the highest level of receptor (Bmax = 1356 ± 143 
fmol/mg membrane protein; n=5) when determined by [^H]iloprost binding studies 
(-10 nM) (Figure 4.3). Furthermore, it exhibited a relatively high level of iloprost- 
stimulated adenylate cyclase activity (Figure 4.4) and was therefore selected for 
further studies.
Unlabelled iloprost displaced [^H]iloprost (3.4 nM) specifically bound to 
membranes of clone 44 cells in a concentration-dependent manner, with IC50 of
4.8 + 0.5 nM (Figure 4.5; n = 3). Applying the formalism of DeBlasi et al. (1989), 
Kd was estimated at 1.4 + 0.6 nM. This value indicate that the iloprost binding 
affinity in the fusion protein is not significantly different from the isolated receptor 
(Kd = 2.7 ± 0.8 nM) (unpaired t-test p = 0.09; n=3). However, the slope of the 
displacement curve in clone 44 cells is less shallow (Hill coefficient = 0.86 + 0.07) 
than clone 13 cells (Hill coefficient = 0.64 + 0.05). This suggests that the 
proportion of high-affinity binding sites is higher in clone 44 than clone 13 cells..
Immunodetection of the FhlPR-Gga fusion protein was successful with both 
M5 anti-FLAG™ and CS antibodies. Figure 4.6A clearly indicates the presence of 
a FLAG™-tagged polypeptide migrating at the 89 kDa mark in FhlPR-Gga 
expressing cells (lane 1 ) which was not found Mn cells stably expressing the 
FLAG™-tagged receptor (lane 2). Instead, the differentially glycosylated forms of 
FhlPR were seen in membranes from these cells. The same 89 kDa polypeptide 
in lane 1 immunoreacted with GS antiserum (Figure 4.6B) which is specific for the 
carboxyl-terminal decapeptide of Gga. Since both the amino- and carboxyl- 
terminal domains of the fusion protein were shown to interact with the antisera, the 
FhlPR-Gga protein was thus correctly expressed.
A comparison of the effect of sustained agonist treatment on clone 44 and 
clone 13 cells were made (Figure 4.7). Pretreatment with iloprost (1 pM) resulted 
in distinct downregulation of both the short and the long isoforms of endogenous 
Gga in both clones after 2 hours of incubation (Figure 4.7A). These results
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demonstrated that agonist stimulation of FhlPR-Gga protein in clone 44 cells can 
also activate endogenous Gga. As the CS antiserum was shown to immunoreact 
with FhlPR-Gga fusion protein, it can thus be used to monitor the effect of agonist 
treatment on the fusion protein. As observed in the immunoblot, FhlPR-Gga was 
not downregulated by iloprost pretreatment, even up to 16 hours. This was 
confirmed by immunobldtting for the FLAG™ epitope, which showed consistent 
levels of the fusion protein and even a slightly enhanced expression at the longer 
times of iloprost treatment (Figure 4.7B). However, the IP prostanoid receptor was 
slightly downregulated after 2  hours pretreatment, with signs of recovery at 16 
hours of incubation with iloprost. No discernible time-dependent pattern of agonist 
mediated downregulation was observed for the G ^^a (Figure 4.7C) or Gq/^a 
(Figure 4.7D) subunits in either clone.
Clone 44 exhibits enhanced agonist-stimulated GTP hydrolysis and GTP 
exchange functions when compared to clone 13
Clone 44 cells were assessed for iloprost (1 pM) stimulated high affinity 
GTPase activity according to Section 2.4.3. When it was compared to clone 13 
cells, membranes of clone 44 cells exhibited marked elevation of agonist- 
stimulated GTP hydrolysis (unpaired t-test p<0.05; n=5) (Figure 4.8). As it is 
possible that the overall level of Gga in clone 44..is higher than clone 13 due to 
expression of the FhlPR-Gga construct, clone 13 cells were transiently transfected 
with a cDNA encoding Gga(L)(HA) and reassessed for iloprost-stimulated GTPase 
activity. Gga(L)(HA) was overexpressed to a sufficiently high level (Figure 4.9) but 
high affinity GTPase results showed no discernible difference in the level of 
agonist-driven GTPase activity (Figure 4.8). Therefore, elevated agonist- 
stimulated GTP hydrolysis activity in clone 44 versus clone 13 cells cannot be 
attributed to the higher levels of Gga.
The high affinity GTPase assay monitors both the activation (GTP 
exchange) and termination (GTP hydrolysis) of Ga. To define exactly which step 
of Ga activity was enhanced in clone 44 cells, a [^^S]GTPyS binding assay was
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employed. Membranes in Figure 4.8 were reassessed using this assay, utilising 
iloprost (1 pM) to drive the exchange of guanine nucleotides (Figure 4.10). 
Agonist-driven [^^SjGTPyS binding in clone 44 cells (226.5% + 8.7) was more than 
double that of clone 13 cells, which correlated well with results obtained in the 
GTPase assay. Overexpression of Gsa(L)(HA) in clone 13 cells again did not alter 
agonist-stimulated binding of [^^S]GTPyS. These results indicate that the elevated 
Ga activity in clone 44 cells is al^o a result of enhanced GTP exchange. Although 
there is a direct correlation between the levels of receptor expression and agonist- 
activated Ga activity, this is unlikely to account for the greater activity of clone 44 
versus clone 13 cells. This is because clone 44 cells express FhlPR-Gga at about
1.4 pmol/mg of membrane protein, which is less than half of the IP prostanoid 
receptor level (~3 pmol/mg) expressed in clone 13 cells. Therefore, an obvious 
reason for the enhanced level of activity in both the GTPase and [^^SjGTPyS 
binding assays must be the expression of receptor-Ga fusion proteins in clone 44 
cells.
The effect of cholera and pertussis toxins on clone 44 cells
Treatment with cholera toxin but not pertussis toxin was previously shown 
to abolish agonist-stimulated GTPase activity in clone 13 cells (Chapter 3). This is 
due to the ADP-ribosylation of arginine 201 in Gga,; catalysed by cholera toxin, that 
results in diminished GTP hydrolysis capacity (Cassel and Selinger 1977). As the 
fusion protein contains a receptor-linked Gga which is both functional and exhibits 
enhanced activity, it was of interest to examine whether it also acted as a 
substrate for cholera toxin.
Cells of clone 44 were thus incubated with cholera toxin (200 ng/ml) or 
pertussis toxin (25 ng/ml) for 16 h prior to harvest. Membranes from these cells 
were assessed for iloprost-stimulated GTPase activity. Indeed, treatment with 
cholera toxin but not pertussis toxin reduced the high level of agonist-activated Ga 
activity in clone 44 cells (Figure 4.11). The level of activity in the cholera toxin 
treated cells (0.9 + 0.4 pmol/min/mg membrane protein) is as low as that of 
similarly treated clone 13 cells (0.8 + 0.5 pmol/min/mg), indicating almost
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complete abolishment of Gga activity. This is an indirect evidence that the 
receptor-linked Gga can be ADP-ribosylated by cholera toxin, which diminish its 
GTP hydrolysis function. A direct demonstration of this event was attempted using 
[^^P]NAD as co-factor but was unsuccessful due to the non-specific ADP- 
ribosylation of proteins that co-migrated with FhlPR-Gga in SDS-PAGE (results not 
shown).
A rather different scenario was observed when membranes of the toxin- 
treated clone 44 cells were assessed for agonist-driven GTP exchange function. 
Pretreatment with cholera toxin reduced the high level of iloprost-stimulated 
[^^S]GTPyS binding in clone 44 cells, but not completely as in the similarly treated 
clone 13 cells (Figure 4.12). This is in sharp contrast to that observed in the 
GTPase assay where there is almost complete abolishment of Gga activity (Figure 
4.11). The similar reduction of [^^SjGTPyS bound in cholera toxin-treated clone 44 
cells (86.7% + 18.6) and clone 13 cells (78.4% + 16.6) (Figure 4.12), may however 
provide a clue to the cholera toxin resistance of clone 44 cells.
Although ADP-ribosylated Gga has a diminished GTPase function, no study 
had been done to assess its GTP exchange capability. This is partly due to the 
rapid degradation of ADP-ribosylated Gga (Chang and Bourne 1989) and the 
presumed loss of agonist-stimulated exchange function in these proteins. 
However, in the fusion protein construct, the receptor-linked Gga may not be 
degraded as rapidly as endogenous Gga. Indeed, immunoblots with CS antiserum 
demonstrated the continued presence of the fusion protein despite the rapid loss 
of endogenous Gga in membranes of cholera toxin-treated clone 44 cells (Figure 
4.13). It is therefore possible that ADP-ribosylated FhlPR-Gga protein maintains 
the capability to exchange guanine nucleotide in response to agonist, despite a 
diminished GTP hydrolysis function. This also highlights the dual rote of cholera 
toxin in affecting Gga functions: catalysing the ADP-ribosylation process (which 
reduces GTPase activity) and subsequently enhancing the degradation (which 
reduced [^^S]GTPyS bound). Reduction of [^^S]GTPyS bound in both clone 13
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and clone 4 4  cells upon cholera toxin treatment is therefore attributed solely to the 
rapid degradation of endogenous Gga.
Analysis of secondary effector signalling in clone 44 cells
HEK293 clones stably expressing the FhlPR-Gga were shown to elevate 
the production of cAMP in the presence of iloprost (Figure 4.4). In order to 
compare the kinetics of adenyl^ate cyclase activation by receptor-Ga protein 
versus the isolated receptor, the level of cAMP production in intact clone 44 and 
clone 13 cells was monitored over time. The cells were seeded into 24 well plate 
and incubated overnight with [^H]adenine at 0.5 pCi per well. A maximally- 
effective concentration of iloprost (1 pM) and vehicle (assay medium) were added 
to the cells and incubated for various times up to 45 minutes. The reaction was 
terminated on ice and stop solution added at 0.5 ml per well. Separation of the 
adenine nucleotides was according to Section 2.4.2.
Results obtained show that the agonist-stimulated generation of cAMP 
proceed in a seemingly linear fashion for up to 45 minutes in clone 13 cells, but 
only for 20 minutes in clone 44 cells (Figure 4.14). Thus it appeared that the 
Fh lP R -G stt protein was desensitised faster than the FhlPR. The basal level of 
cAMP in both clones was similar and did not increase with time (less than 1% of 
total adenine nucleotides), and hence providers no evidence of significant 
constitutive activity. As adenylate cyclase activity in clone 44 cells appeared to 
wane after 2 0  minutes of agonist stimulation, it was decided that further assays of 
adenylate cyclase activity should not proceed beyond this incubation time. The 
dose-dependent effect of iloprost to stimulate cAMP production in clone 44 cells 
was assessed and compared with clone 13 cells (Figure 4.15). It was found that 
the ECso of iloprost to stimulate adenylate cyclase in clone 44 cells (1.1 + 0.3 X 
1 0 “ M; n=3) was not significantly different from clone 13 cells ( E C 5 0  = 1.4 ±  0 . 3  X 
10'^° M; n=3).
To investigate the secondary effector signalling potential of the FhlPR-Gga 
fusion protein, it was essential to remove endogenous Gga to minimise its
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interaction with adenylate cyclase. Taking advantage of the earlier observation 
that cholera toxin-treated clone 44 cells demonstrated enhance degradation of 
endogenous Gga but not FhiPR-Gga protein (Figure 4.13), clone 13 and clone 44 
cells were similarly treated before assessing their adenylate cyclase response. 
Treatment with cholera toxin reduced the level of iloprost-stimulated cAMP 
production substantially in clone 13 cells (Figure 4.16). This correlated with the 
distinct downregulation of endogenous levels of Gga in these cells after 16 h of 
incubation with cholera toxin (Figure 4.13). Furthermore, the basal level of cAMP 
was also slightly increased in toxin treated clone 13 cells, which can be attributed 
to the constitutive active effect of the remaining ADP-ribosylated Gga, an 
observation shown in previous studies (MaCleod and Milligan 1990).
Cholera toxin treatment of clone 44 cells however resulted in a highly 
elevated basal level of cAMP (Figure 4.16) which is much higher than in similarly 
treated clone 13 cells (paired t-test: p<0.05; n=3). In fact, the basal cAMP level in 
cholera toxin-treated clone 44 cells is at such a high level that iloprost stimulation 
did not result in significant increase in cAMP. This major difference between clone 
44 and clone 13 cells is likely due to the remaining high levels of ADP-ribosylated 
FhlPR-Gga fusion protein but not ADP-ribosylated endogenous Gga after 16 h of 
cholera toxin treatment (Figure 4.13). This provides an indirect evidence that ADP- 
ribosylated FhlPR-Gga and by inference an agonist-occupied FhlPR-Gga, can 
signal to its secondary effector.
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Figure 4.1 Schematic representation of PhlPR-G^a fusion cDNA and
protein
The incorporation of Gsa within the FhlPR cDNA is shown. The last 6 residues of 
FhlPR and the first 6 residues of Gsa are shown. There is an alteration of cysteine 
to glutamic acid at the last residue of the receptor due to the incorporation of Xho\ 
site, required for subsequent ligation with the open reading frame of Gsa(L)(HA).
Xhol Xbal
FhlPR
pcDNA3
T 7 promoter
...VACSLC MGCLGN...
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Figure 4.2 Agarose gel analysis of FhlPR-Gga cDNAs
A. DMAs from E. coli clones (transformed with ligated FhlPR / Gga mix) were 
digested with Hind\\\ and Xba\ and resolved in 1% agarose gel. Clones S1 and 
S2 contain a digested fragment close to the approximate length of 2.4 kb of the 
FhlPR-Gga cDNA.
B. The same DMAs from Figure A were digested with Xho\ and Xbal and resolved 
in 1% agarose gel. As in Figure A, both clones S1 and S2 contain a digested 
fragment that approximates the length of Gga(L)(HA) cDNA (1.2 kb).
A. SI S2 S3 S4 S5 S6 S7 MW
B. S1 S2 S3 S4 S5 S6 S7 MW
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Figure 4.3 Stable expression of the FhlPR-Gga fusion protein in clones of
HEK293 cells
Following stable expression of the FhlPR-Gga cDNA into HEK293 cells, 
membranes from clones 41. 42, 44 and 13, together with parental HEK293 cells 
were prepared and assessed using ~ 10 nM [^HJiloprost. The specific binding of 
[^Hjiloprost was obtained by subtracting non-specific counts (assessed with 10 fiM 
unlabelled iloprost) from total counts, and normalised with the amount of 
membrane protein used in the assay. Expression levels were as follows (fmol/mg 
membrane protein): clone 41 (1060 ±  81; n=2), clone 43 (992 + 33; n=2), clone 44 
(1356 + 143; n=5), clone 13 and HEK293 expression levels were as in Figure 3.1.
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Figure 4.4 Stimulation of cAMP production by iloprost and forskolin in 
clones of HEK293 cells stably expressing FhlPR-Gga
Basal adenylate cyclase activity (stippled bars) and regulation by 1 |j.M iloprost 
(filled bars) or 50 forskolin (hatched bars) was assessed In intact cells of 
HEK293 clones stably expressing FhlPR-Gga (clones 41, 43 and 44). The results 
are expressed as the ratio of cAMP over total adenine nucleotides X 100 and 
represent the mean + SD of 2 independent experiments performed in triplicate.
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Figure 4.5 Displacement of [ HJiloprost binding in membranes of clone 44 
cells
The specific binding of [^H]iloprost (3.4 nM) to membranes of clone 44 cells was 
displaced by increasing concentrations of unlabelied iloprost. Counts obtained in 
the presence of 1 0  jaM unlabelled iloprost were treated as non-specific binding. 
Curve fitting by Kaleidograph™ (v3.02; Abelbeck Software 1993) indicated IC50 of
4.8 + 0.5 nM (n = 3). Hill slope of the graph is 0.86 ± 0.07. Data of clone 13 cells 
was obtained from Figure 3.4. Results are presented as %specific binding of 
[^H]iloprost (100% = specific binding in the absence of unlabelled iloprost). This 
graph is representative of 3 independent experiments performed in triplicate.
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Figure 4.6 Immunodetection of the FLAG™-tagged human IP prostanoid
receptor fused to Gga in clone 44 cells
A. Membranes of clone 44 (lane 1) and clone 13 (lane 2) cells were resolved in 
10% SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted 
with M5 anti-FLAG™ monoclonal antibody. The predominant immunoreactive 
protein in lane 1 migrated with an apparent molecular mass of 89 kDa while a 
series of immunoreactive proteins ranging from 41 to 61 kDa were observed in 
lane 2 .
B. The same membranes in Figure A were immunoblotted with CS antiserum, 
which is specific for the carboyl-terminal decapeptide of Gga. The long and 
short forms of endogenously expressed Gga were detected in both lanes. 
However, an additional 89 kDa immunoreactive protein was detected in lane 1 
but not lane 2 .
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Figure 4.7 Effect of agonist treatment on clone 13 and clone 44 cells
Clone 13 and clone 44 cells were incubated with iloprost (1 j^ iM) for 0, 0.5, 2, 4, 8 , 
and 16 h. Membranes prepared from these cells were resolved by 10% SDS- 
PAGE, transferred to nitrocellulose membrane and immunoblotted using various 
anti-Ga antisera.
A. Immunoblotting with CS antiserum, specific for the carboxyl-terminal 
decapeptide of Gga, demonstrated a time-dependent downregulation of both 
the long and short isoforms of Gga but not FhlPR-Gga. Downregulation of Gga 
occurs at 30 min of iloprost treatment, with only trace amount remaining at 16h.
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Figure 4.7 Effect of agonist treatment on clone 13 and clone 44 cells
B. Immunoblotting with M5 anti-FLAG™ antibody demonstrated that the IP 
prostanoid receptor was slightly down regulated after 2  h iloprost treatment but 
shows signs of recovery after 8  h. Expression levels of the FhlPR-Gga fusion 
protein were not affected by agonist treatment and there was even a slight 
increase at the longer times ( 8  and 16 h) of iloprost incubation.
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Figure 4.7 Effect of agonist treatment on clone 13 and clone 44 cells
C. Immunoblotting with SG antiserum, specific for carboxyl-terminal decapeptide 
of Gji/2a, did not show any downreguiation even after 16 h of incubation with 
iloprost in both sets ofcells.
D. Immunoblotting with CQ antiserum, specific for the carboxyl-terminal 
decapeptide of Gq/na, also did not show any time-dependent pattern of 
downregulation in both sets of cells.
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Figure 4.8 Clone 44 cells exhibit enhanced agonist-stimulated high affinity
GTPase activity compared to clone 13 cells
Membranes of parental HEK293, clone 44, clone 13, and clone 13 transiently
transfected with Gga(L)(HA) were assessed for basal and iloprost (1 pM)-
stimulated high affinity GTPase activity. The stimulations produced by iloprost are 
displayed, and are as follows (mean ±  SEM pmol/min/mg membrane protein); 
HEK293 (0 + 0.2), clone 13 (2.7 + 0.4), clone 44 (6.0 + 0.3), and clone 13
transfected with Gsa(L)(HA) (2.5 ±  0.2). These data represent 3 or more
independent experiments performed in triplicate.
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Figure 4.9 Immunoblot showing overexpression of Gsa(L)(HA) in clone 13
cells
Membranes of clone 44 (lane 1), clone 13 (lane 2) and clone 13 cells transfected
to express Gga(L)(HA) (lane 3) were resolved by 10% SDS-PAGE and
immunoblotted with CS antiserum. Gga(L)(HA) migrated more slowly than
endogenous Gga(L) possibly due to the differences in charge resulting from
*incorporation of the hemagglutinin epitope.
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Figure 4.10 Clone 44 cells exhibit enhanced agonist-stimulated [^^S]GTPyS
binding compared to clone 13 cells
Membranes of parental HEK293, clone 44, clone 13, and clone 13 transiently 
transfected with Gga(L)(HA) were assessed for basal and iloprost (1  pM)- 
stimulated [^^SjGTPyS binding activity. The assay was incubated at 25°C for 60 
minutes. The stimulations produced by iloprost (fmol [^^SJGTPyS bound/mg■W
membrane protein) are displayed in terms of %stimulation by untransfected clone 
13 cells (100% = [^^S]GTPyS bound in clone 13). The results are as follows (mean 
± SEM): HEK293 (3.7 ± 17.7), clone 13 (100 + 16.5), clone 44 (226.5 + 8.7), and 
clone 13 transfected with Gga(L)(HA) (114 + 19). These data represent 3 or more 
independent experiments performed in triplicate.
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Figure 4,11 Effects of cholera and pertussis toxins on agonist-stimulated
high affinity GTPase activity in clone 44 cells
Clone 44 cells and clone 13 cells were treated with cholera toxin (200 ng/ml, 16 h) 
or pertussis toxin (25 ng/ml, 16 h) before harvest. Membranes from these and 
untreated cells were then used to measure basal high affinity GTPase activity and 
its stimulation by iloprost (1 pM). The stimulations produced by iloprost are 
presented and are as follows fçr clone 44 cells (mean + SEM pmol/min/mg 
membrane protein): untreated (6 + 0.3), cholera toxin (0.9 ±  0.4) and pertussis 
toxin (5.9 + 0.3). Data of clone 13 cells are from Figure 3.13. The data represent 
at least 3 experiments performed in triplicate.
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Figure 4.12 Effects of cholera and pertussis toxins on agonist-stimulated
[^®S]GTPyS binding in clone 44 cells
Membranes from Figure 4.11 were used to measure basal and iloprost (1 pM)- 
stimulated binding of [^^S]GTPyS. The stimulations produced by iloprost are 
displayed as in Figure 4.10. The results are as follows for clone 13 cells (% 
stimulation + SEM); untreated (100 + 16.5), cholera toxin (21.6 + 2.2), and 
pertussis toxin (102 + 18). ResuTts of clone 44 cells are as follows: untreated 
(226.5 + 8.7), cholera toxin (139.6 + 16.5), and pertussis toxin (188.7 + 16.7). 
These data represent 3 independent experiments performed in triplicate.
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Figure 4.13 Sustained treatment of clone 13 and clone 44 cells with cholera 
toxin downregulates endogenous levels of G^a
Cells from clone 13 and clone 44 were subjected to cholera toxin treatment (200 
ng/ml) for 0, 2, 4, 8, and -16 h prior to harvest. Membranes prepared from these 
cells were resolved by 10% SDS-PAGE, transferred to nitrocellulose and 
immunoblotted with CS antiserum. Endogenous Gga was down regulated to almost 
undetectable levels after 8 h incubation with cholera toxin in both sets of cells. The 
levels of FhlPR-Gga protein in clone 44 cells were however unaffected.
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Figure 4.14 Time course of adenylate cyclase response to iloprost
stimulation in clone 13 and clone 44 cells
Intact clone 13 and clone 44 cells were assessed for their ability to stimulate 
adenylate cyclase at various incubation times (0, 5, 10, 20, 30 and 45 min) in the 
absence (basal) and presence of iloprost (1 jj.M). Basal cAMP levels of both 
clones were less than 1% of total adenine nucleotides. The iloprost-stimulated 
accumulation of cAMP is shown ^and expressed as the ratio of cAMP over total 
adenine nucleotides X 100. This graph is representative of 2 independent 
experiments performed in triplicate.
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Figure 4.15 Comparison of adenylate cyclase concentration-response for
iloprost in intact clone 13 and clone 44 cells
Intact clone 13 and clone 44 cells were assessed for their ability to stimulate 
adenylate cyclase at various concentrations of iloprost. The results are presented 
as in Figure 4.14 but expressed as % maximum stimulation (activity at 10 pM 
iloprost treated as 100%)." Data of clone 13 is obtained from Figure 3.6. Effective 
concentration at 50% stimulation '(ECso) of clone 44 is estimated at 1.1 + 0.3 X 
10'^° M (mean + SEM). This graph is representative of 3 independent experiments 
performed in triplicate.
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Figure 4.16 Analysis of adenylate cyclase response in clone 13 and clone 44
cells pretreated with cholera toxin
Adenylate cyclase activities in intact clone 13 and clone 44 cells were assessed by 
stimulation with iloprost (1 pM) or forskolin (50 pM). Cholera toxin (200 ng/ml) was 
also incubated with both sets of cells for 16 h and their adenylate cyclase 
response assessed. The results are presented as in Figure 4.4. This graph is a 
typical representation of 3 independent experiments performed in triplicate.
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4.3 Discussion
The FhlPR-Gga fusion protein has simiiar characteristics as the IP 
prostanoid receptor
The construction of a cDNA encoding a fusion protein between the IP 
prostanoid receptor and its cognate G protein, Gga, was successful in the current 
study. The FhlPR cDNA was ligated in-frame with the Gga(L)(HA) cDNA by first 
removing the stop codon and then incorporating a restriction site that is identical to 
that introduced into the 5 -end of Gga(L)(HA) cDNA. The choice of the restriction 
site must be such that it is unique in both the receptor and Gga(L)(HA) coding 
sequences and does not alter many residues in either the receptor C-terminus or 
the Ga N-terminus. AXho\ restriction site (nucleotide bases: GTCGAG) was found 
to satisfy both criteria, causing only a change in the last residue of the receptor 
from cysteine to glutamic acid (Figure 4.1). As glutamic acid is negatively charged 
and polar, it should fit well into the cytoplasmic environment of the receptor 0- 
terminus. The proper expression of the protein in HEK293 cells was demonstrated 
by antisera that interacted with both termini of the fusion protein (Figure 4.6).
HEK293 clone 44, which stably express the FhlPR-Gga at high levels was 
selected out of 27 clones for further characterisation and comparison with clone 
13. Interestingly, although clone 44 expresses the fusion protein while clone 13 
expresses the isolated receptor (FhlPR), both shared similar characteristics. Clone 
44 cells bound [^H]iloprost with similar affinity as clone 13 cells when assessed in 
agonist displacement studies (Figure 4.5), but with a less shallow slope (Hill 
coefficient of clone 44 = 0.86 ± 0.07; clone 13 = 0.64 + 0.05). The lack of an IP 
prostanoid receptor antagonist makes it difficult to assess the proportion of high 
affinity ternary complex in each clone, although the addition of the non- 
hydrolysable GTP analogue, Gpp(NH)p, did reduce the specific binding of 
[^H]iloprost to membranes of both clones (data not shown).
immunobiotting with M5 anti-FLAG™ antibody showed multiple 
immunoreactive polypeptides in clone 13 which presumably reflect differentially N-
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glycosylated forms of the IP prostanoid receptor. By contrast, M5 immunoblot of 
membranes from clone 44 showed a single well defined immunoreactive 
polypeptide (Figure 4.6A). It is unclear whether this reflects an unglycosylated 
FhlPR-Gga protein or unresolved glycosylated forms of the protein due to the high 
molecular mass of the fusion protein (-90 kDa). In further gel-electrophoresis 
studies, this high molecular mass polypeptide was allowed to resolve further down 
the gel. Subsequent M5 immunoblots did detect multiple immunoreactive species 
which differ in their migration through SDS-PAGE (results not shown). Thus the 
FhlPR-Gga protein may potentially be N-glycosylated despite the addition of a 
large cytoplasmic Ga protein.
The functionality of the FhlPR-Gga fusion protein was assessed by 
stimulating with the IP prostanoid agonist iloprost, which resulted in distinct 
elevation of cAMP in HEK293 clones expressing the FhlPR-Gga (Figure 4.4). A 
point to note is that expression of the FhlPR-Gga protein did not result in elevated 
basal adenylate cyclase activity. This indicates that fusing the receptor and G 
protein together did not alter either the GPCR or the Ga conformation towards an 
activated state. Instead, stimulation by agonist is essential for the fusion protein to 
activate adenylate cyclase which it did so in a manner that closely resembled that 
of the freely interacting receptor (Figure 4.15). The spatio-orientation of the 
agonist binding and Ga interacting domains in the FhlPR-Gga protein therefore 
mimics that of the isolated IP prostanoid receptor.
As HEK293 cells endogenously express high levels of Gga, stimulation of 
the fusion protein may simultaneously activate the receptor-linked and the cellular 
pool of Gga. Indeed, sustained agonist treatment of clone 44 cells resulted in a 
time-dependent downreguiation of endogenous Gga (Figure 5A). This proceeded 
on a slightly slower time course as those of clone 13 cells, which may reflect 
differences in receptor expression levels. Apparently, fusing the Gga protein at the 
carboxyl-terminus of FhlPR did not reduce the capacity of the receptor to activate 
endogenous Gga. This could imply that the receptor-fused Gga is not hindering the
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free movement of competing endogenous Gga subunits for coupling with the 
receptor. A similar observation was noted in the studies of GPCR-GFP (Green 
Fluorescent Protein) constructs. For example, Barak et a/. (1997) were able to 
stimulate adenylate cyclase in intact HEK293 cells transiently expressing the 
P2AR-GFP by isoprenaiine in a similar manner to cells expressing |32-adrenergic 
receptor.
The capacity of a receptof^Ga fusion protein to activate endogenous Ga 
subunits was also previously shown by Burt at ai. (1998). By expressing a fusion 
protein between the a2A~adrenergic receptor and a pertussis toxin-resistant mutant 
of Gjia, (C351G)Gjia, they demonstrated that the activation ratio of endogenous 
Gja to receptor-linked G|a is 5:1. However, recent studies by Bahia et al. (1998) 
indicated that the glycine 351 mutant of G^a is activated to a much smaller extent, 
as it binds only 2 0 % of the total [^^S]GTPyS bound by wild type G^a, when 
stimulated by the a2A-adrenergic receptor. This would suggest that the activation 
ratio of endogenous Gja to a a2A-adrenergic receptor-linked wild-type Gj^a is 
closer to 1:1. The activation of endogenous Ga by the fusion protein is also 
subtype specific. Although the a2A~adrenergic receptor was previously shown to 
activate both Gja and Gga subunits (Eason et al. 1992), the a2AAR-Gii(C351G)a 
fusion protein can only activate G,a but not Gga (Sâutel and Milligan 1998). As the 
EC50 for Gja activation is much lower than that for Gga, this may reflect reduced 
affinity of endogenous Ga for the fusion receptor to the extent that Gga can no 
longer interact effectively.
A similar approach of using toxin-resistant Gga cannot be adopted for 
studying receptor-Gga fusion proteins due to the lack of mutants that mimic the 
function of wild-type Gga without being a substrate for ADP-ribosylation by cholera 
toxin. Freissmuth and Gilman (1989) did attempt to generate such mutants by 
replacing the specific arginine residue, which is the site of modification by cholera 
toxin, to alanine, glutamic acid or lysine. However, these mutants were both
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unable to hydrolyse GTP and were not totally resistant to the ADP-ribosylating 
action of the toxin, rendering them useless as toxin-resistant Gga mutants.
Enhanced activation of G a in clone 44 cells is mediated by the FhiPR -G sa  
fusion protein
Despite the many similar characteristics between clone 13 and clone 44 
cells, there exists a distinct difference in the amplitude of G protein signalling in 
these clones. Clone 44 cells show higher agonist-stimulated Ga activity than clone 
13 ceils, based on the results obtained by high affinity GTPase and [^^SjGTPyS 
binding assays (Figure 4.8 & 4.10). Overexpression of Gga(L)(HA) in clone 13 
cells did not result in measurable elevation of Ga activity in both assays. This 
confirmed the observations in Chapter 3, where transient expression of Gga in 
clone 13 cells also did not alter agonist activity. No attempt was then made to 
compare the enhancement effect of Gn/GgSa protein in each assay, due to the 
difficulty of quantifying Gn/GgGa expression levels. However, in this study, 
expression levels can be assessed adequately by radioligand binding studies. 
These results indicated that receptor levels in the two clones are not the same: 
clone 13 express FhlPR at -3  pmol/mg membrane protein, while clone 44 express 
FhlPR-Gga at -1.4 pmol/mg.
Iloprost-stimulated high affinity GTPase activity (pmol Pi / min / mg 
membrane protein) in clone 44 cells is 2.2 times that of clone 13 cells (Figure 4.8). 
Compensating for receptor expression levels, the increase in high affinity GTPase 
activity of each FhlPR-Gga protein with respect to FhlPR is therefore:
fold increase (membrane protein) X expression level of FhlPR (pmol/ma)
expression level of FhlPR-Gga (pmol/mg)
Thus, the GTPase activity of each FhlPR-Gga protein is 2.2 X (3/1.4) = 4.7 
times that of FhlPR. A very similar fold increase (226%) was also obtained in 
[35s]GTPyS binding assay (Figure 4.10). As the agonist-stimulated binding of
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[ S]GTPyS is normally expressed as fmol [ S]GTPyS bound / mg membrane 
protein (see Figure 4.10), the increase is again understated in view of the lower 
receptor expression levels in clone 44 cells. Adjusting for this difference using the 
above formula, each iloprost-activated FhlPR-Gga protein is shown to be 226% X 
(3/1.4) = 484% or -4.8 times better in stimuiating the incorporation of [^^S]GTPyS 
to Gga than the FhlPR protein. These results suggested that the FhlPR-Gga fusion 
protein is more efficient in transducing signal to Gga compared to the isolated 
receptor.
The observation that GPCR-Gga fusion proteins are more efficient signal 
transducing units was previously noted by Berlin et al. (1994) and Seifert et al. 
(1998a). They both used the same construct, a P2AR-Gga fusion protein, which 
when overexpressed, gave higher signalling output compared to the P2-adrenergic 
receptor. Although the results of Berlin et al. (1994) must be treated with caution, 
as 849 lymphoma eye" cells, which also endogenously expressed p2-3drenergic 
receptor were used, Seifert et al. (1998a) showed conclusively that expressing the 
p2AR-Gga in insect Sf9 cells gave robust agonist-stimulated GTPase activity. As 
the endogenous Gga in Sf9 cells was not activated by the p2-adrenergic receptor, 
either due to the low level of expression or species difference, this greatly 
facilitated their study of the subtle differences in coupling between the long and 
short isoforms of Gga by using p2AR-Gga(L) and p2AR-Gga(S) fusion proteins.
Despite certain advantages of using the insect cells for the study of GPCR 
functions, there are also numerous drawbacks. These Include the processing of 
glycosylated proteins, the differences between insect and mammalian signalling 
components and the compromised metabolism of the cell resulting from the 
baculovirus infection (Bouvier et al. 1998). In addition, the recombinant receptor is 
expressed very late in the viral infection cycle and hence only a short window of 
time exists between the moment of receptor expression and cell death. As it is not 
possible to select for stably expressing clones, the expression of receptor will 
fluctuate in each transfection and will therefore affect the results of the assays. In 
this study, the use of stably expressing clones derived from mammalian cell lines
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would therefore reflect more accurately the functions and capacities of the FhlPR- 
Gga fusion protein.
FhlPR-Gsa binds [^^SJGTPyS in the presence of cholera toxin
The abolishment of agonist-stimulated high affinity GTPase activity in clone 
44 cells upon treatment by cholera toxin (Figure 4.11) indicates that the FhlPR- 
Gga only activates Gga protein, vyhich is similar to that observed for the FhlPR. 
This is further confirmed by the lack of effect of pertussis toxin on clone 44 cells, 
which means that “Gja-like” proteins are not involved in the signalling of the fusion 
protein.. Thus, the enhanced stimulation of Ga by agonist-occupied FhlPR-Gga 
certainly did not result from an altered signalling characteristic of the fusion protein 
compared to the FhlPR. It is also very unlikely that other Ga subunits which are 
not sensitive to cholera and pertussis toxin are activated, based on the 
immunoblots of Ga proteins of iloprost-treated clone 44 cells (Figure 4.7). This is a 
rather important point to note as elevation of inositol phosphate levels by the IP 
prostanoid receptor was observed in a previous study (Namba et al. 1994), which 
may implicate activation of G proteins of the Gqa subfamily.
Direct evidence showing that receptor-linked Gga can act as a substrate for 
cholera toxin was not obtained due to the presence of co-migrating polypeptides
32that incorporate [ P]ADP~ribose in a non-specific manner in clone 44 cells 
(results not shown). However, the loss of GTPase activity in cholera toxin-treated 
clone 44 cells indirectly infers that the receptor-linked Gga can be ADP- 
ribosylated, which diminishes its GTP hydrolysis function as for the endogenous 
Gga. This inference was put in jeopardy when it was found that cholera toxin- 
treated clone 44 cells still exhibit capacity to bind [^^SjGTPyS, albeit at a reduced 
level (Figure 4.12). This result is not that alarming when we considered carefully 
the Ga activation and hydrolysis processes:
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Substrate Product Rate (min^)
Ga-GDP Ga + GDP koff(GDP)
Ga + GTP Ga-GTP kon(GTP)
Ga-GTP Ga-GDP + Pi kcat
The rate constant koff(GDP) refers to the dissociation rate of GDP from the 
inactive Ga, kon(GTP) refers to the association rate of GTP to the nucleotide free 
Ga, while kcat refers to the hydrolysis rate of GTP in the activated Ga. As the 
[^^S]GTPyS binding assay monitors the association of [^^S]GTPyS to the inactive 
Ga, it is dependent on the rates of dissociation of GDP (koff) and the subsequent 
association of [^^S]GTPyS, which closely correlate with that of GTP (kon). It is 
independent of alterations in the GTP hydrolysis rate, even if kcat approaches zero 
as in the ADP-ribosylated Gga. Therefore, it is not conceptually incorrect that an 
ADP-ribosylated FhlPR-Gga protein can bind GTPyS.
There is so far no known studies that support the retention of GTP binding 
function in ADP-ribosylated Gga. However, Freissmuth and Gilman (1989) showed 
that mutating the arginine residue involved in ADP.-ribosylation, resulted in a loss 
of GTP hydrolysis but not GTP exchange function. Using the short form of Gga, 
they mutated arginine 187 to 3 different residues (alanine, glutamic acid and 
lysine). The rate constant for hydrolysis of GTP (kcat) by all these mutants was 
reduced approximately 100-fold compared to the wild-type protein, but the rate of 
association of GTPyS was only modestly affected and even slightly elevated. It 
can be inferred from these studies that ADP-ribosylated Gga would manifest the 
same characteristic. The current finding that cholera toxin treated FhlPR -G ga can 
bind GTPyS is therefore tenable and correlates well with the Gga mutant studies. 
Interestingly, this also offers us an opportunity to analyse the ratio of activated 
endogenous Gga to receptor-linked Gga by the FhlPR -G ga fusion protein.
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Assuming that the dissociation rate of GDP (koff) and the association rate of 
G TP yS  (kon) are not altered by the ADP-ribosylation process, this ratio was found 
to range from 1:1 to 1:2. This result is similar to that obtained for a a2AAR- 
G ii(C 3 5 1 G )a  fusion protein when the reduced activation of the glycine mutant was 
taken into account.
Downstream signalling events in the FhlPR -G sa fusion protein
The restriction of Ga mobility in a GPCR-Ga fusion protein may greatly 
hinder the capacity of Ga to directly act on effectors. This was investigated in the 
current study by selectively downregulating endogenous Gga by treatment with 
cholera toxin. As the FhlPR-Gga protein was not degraded after 16 h of toxin 
treatment (Figure 4.13), it would be expected to show signs of constitutive activity 
as a result of the ADP-ribosylation, which diminished its rate of GTP hydrolysis 
( k c a t ) -  Indeed, the basal level of cAMP was significantly increased in intact clone 
44 cells after cholera toxin treatment (Figure 4.16). This conclusively 
demonstrated the ability of a receptor-linked Gga to directly activate adenylate 
cyclase. Such results were also obtained in previous studies of the p2AR-Gga 
fusion protein in 849 lymphoma eye' cells and insect Sf9 cells (Bertin et al. 1994; 
Seifert et al. 1998a). The current result suggest that the effector signalling 
potential of a receptor-Ga protein may not be cell line dependent.
Burt et al. (1998), however, failed to notice the downstream signalling 
events of a a 2 A A R -G ji(C 3 51 G )a  fusion protein expressed in Rat-1 fibroblasts. A  
clone stably expressing this fusion protein was shown to activate both 
endogenous Gja and the receptor-fused G^a based on high affinity GTPase 
studies of pertussis toxin treated cells. However, although inhibition of forskolin- 
stimulated adenylate cyclase activity via Gja subunits was observed in the 
presence of agonists, treatment with pertussis toxin abolished this effect. The 
likely conclusion is that the receptor-fused G^a, which is pertussis toxin resistant, 
cannot directly access the adenylate cyclase enzyme. It is unclear whether this is 
due to the poor effector affinity or the low level of activation of the receptor-fused
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mutant Gna. Another possibility is that the short C-terminai tail of the aaA- 
adrenergic receptor may have constrained the spatial opportunity of the fused G  
protein. A further proof of the lack of downstream signalling activity of the a2AAR- 
G ii(C 3 5 1 G )a  fusion protein is its inability to stimulate p44 mitogen-activated 
protein kinase and p70 S6 kinase, which are mediated via Gpy complex (Burt et 
al. 1998).
Iloprost (1 pM) stimulation'of adenylate cyclase activity in clone 44 cells 
was observed to level off after 20 min incubation which suggests desensitisation 
of the FhlPR-Gga (Figure 4.14). Interestingly, the expression levels of the fusion 
protein were not down regulated despite sustained agonist treatment for up to 16 h 
(Figure 4.7A). This indicates that the rapid desensitisation of the FhlPR-Gga 
construct is independent of the expression levels at the plasma membrane, a 
phenomenon previously noted for most GPCRs (Bohm et al. 1997). Although 
FhlPR in clone 13 cells did not show any sign of desensitisation at up to 45 
minutes of iloprost stimulation (Figure 4.14), this cannot be compared directly with 
clone 44 cells due to the huge difference in receptor expression levels.
Rapid desensitisation of receptor-Ga fusion proteins has not been studied 
in detail elsewhere, but a limited study of agonist-promoted long-term 
desensitisation was performed by Bertin et al. (1994). They noted that 24 h 
isoprenaiine (10 pM) treatment of S49 lymphoma eye' cells stably expressing the 
P2AR-Gga showed elevated basal activity which when re-challenged with agonist, 
can stimulate adenylate cyclase. Similarly treated S49 lymphoma wild type cells 
however, did not exhibit such properties, which led them to conclude that the 
fusion protein is resistant to long-term desensitisation. It is currently unclear 
whether the FhlPR-Gga protein also behave as such, despite its resistance to 
downreguiation by sustained agonist treatment (Figure 4.7A).
The results presented in this study conclusively show the beneficial effect 
of fusing the IP prostanoid receptor with Gga to form a receptor-Ga fusion protein, 
FhlPR-Gga. This protein has similar binding and effector activation profiles of the
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freely interacting receptor, and yet gave strong agonist stimulated response at the 
G protein level. It was observed to rapidly stimulate Gga which resulted in elevated 
high affinity GTPase activity. Receptor-linked Gga can be ADP-ribosylated, based 
on the observation that GTP hydrolysis was abolished in clone 44 cells treated 
with cholera toxin, interestingly, the ADP-ribosylated receptor-linked Gga 
continued to bind GTPyS, a novel finding which may have implications for the 
ADP-ribosylated Gga. ReceptorTused Gga can also interact directly with its 
effector and its expression level is not reduced by long term agonist treatment.
The FhlPR-Gga protein therefore offers a means to analyse agonist 
pharmacology using high affinity GTPase or [^^S]GTPyS binding assays. This 
application is similar to that of clone 13 cells expressing the Gji/Gg6a chimeric 
protein (Chapter 3), but the FhlPR-Gga protein has the advantage of interacting 
with its cognate Ga, which is more physiologically relevant. In addition, the fusion 
protein was observed to be more refractory to agonist-induced downreguiation 
compared to the isolated receptor. A series of agonists with varying potencies and 
efficacies will need to be assessed thoroughly in this system, however, before it 
can be utilised as a high-throughput screen for novel agonists and antagonists.
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CHAPTER 5
Analysis of G Protein Coupling Specificity in 
the Human IP Prostanoid Receptor-Ga 
Fusion Proteins
CHAPTER 5 
Analysis of G  Protein Coupling Specificity In the 
Human IP Prostanoid Receptor - G a  Fusion 
Proteins
5.1 Introduction
A fusion protein between the human IP prostanoid receptor and Gga 
(FhlPR-Gga) was shown in the previous chapter to acquire higher signal 
transduction efficiency over freely interacting components. The reasons for this 
enhancement in the fusion protein are not exactly clear, but may include a 
combination of close proximity and co-localisation of the fused GPCR and Ga 
(Burt et al. 1998), and lower affinity for Gpy complex and guanine nucleotides in 
the receptor-linked Gga (Seifert et al. 1998a). it has also been suggested that 
covalently linking the GPCR and Ga may replaced the role of Ga C-terminus in 
bringing the G protein into close proximity with the intracellular domains of the 
receptor (Medici et al. 1997).
By expressing in Gpa1 deficient yeast cells a fusion protein between the a- 
factor receptor (Ste2) and a chimeric G protein (Gpal-Gga), Medici et al. (1997) 
were able to show functional signal transduction, which was not observed when 
the chimeric G protein was expressed in Ste2 positive cells. The Gpal-Gga protein 
consists of the N-terminai 362 aa of yeast Gpal and C-terminal 128 aa of rat Gga. 
The junction site is within a highiy conserved sequence, and therefore it is likely 
that this chimera would retain the G protein’s normal structure. When assessed in 
Gpa1 deficient S. cerevisiae, the Gpal-Gga protein was able to sequester free 
Gpy complex and hence rescued the haploid cells from lethality, but it failed to 
respond to a-factor. This indicated that the chimeric G protein was not able to 
couple productively with Ste2 receptor. However, covalent linkage between the
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Ste2 receptor and the Gpal-Gga protein seemed to overcome this problem. This 
led Medici et al. to the conclusion that it is not necessary to have a receptor 
recognising C-terminal region in receptor fused Ga. They also argued that the 0- 
terminus of Ga may not have a particular role in transmitting signal from the 
receptor, but is mainly responsible for ensuring close contact between the G 
protein and the receptor (Medici et al. 1997).
There is unfortunately no studies on receptor-Ga fusions that support the 
novel findings of Medici et al. (1997), because all fusion proteins constructed thus 
far involved using receptor and G protein partners that were known to associate 
productively with each other physiologically (Bertin et al. 1994; Seifert et al. 1998a; 
Wise et al. 1997c). However, there could be widespread implications if the 
findings of Medici et al. (1997) were true for most receptor-Ga fusions. The C- 
terminus of Ga is sufficient to allow interactions with some receptors, for example, 
Gqa/Gj2a chimeras containing 4 to 9 carboxyl terminal residues of G|2a can couple 
to Ai adenosine and D2 dopamine receptors to stimulate PLC activity (Conklin et 
al. 1993a). The IP prostanoid receptor was also able to activate a Gn/GgGa 
chimera with the last 6 aa of G^a replaced with those of Gga (Chapter 3). Thus, if 
indeed the C-terminal residues are not directly involved in transducing the signal, 
but only in bringing the G protein in close proximity with the receptor, then fusion 
proteins between the Ai adenosine or D2 dopamine receptor with Gqa or the IP 
prostanoid receptor with G^a should yield productive signal transduction proteins.
The possibility of promiscuous coupling in receptor-Ga fusion proteins may 
open endless opportunities for generating artificial signalling proteins. This implies 
that it may be possible to switch the signalling cascade of GPCRs simply by fusing 
the desired Ga with the receptor. For industry, this might allow development of a 
generic assay format in high-throughput screening of new agents acting on 
GPCRs, with enormous cost savings and convenience. In fact, the quest for a 
common reporter system for agonist screening of GPCRs had previously centred 
on Giea as a potential universal G protein adapter (Milligan et al. 1996). For 
academia, promiscuity of receptor-Ga coupling in fusion proteins would enable the
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study of agonist activity at the G protein level, by using G proteins that give the 
highest output in the desired assay. Furthermore, GPCRs with unknown Ga 
coupling could also be studied in detail, and the discovery of agents acting on 
these receptors speeded up, which in turn would allow faster elucidation of their 
cellular functions. Such possibilities also extend to orphan GPCRs in the discovery 
of their physiological ligands, and subsequent unravelling of any novel 
physiological functions. Finally, fusion proteins could be constructed to attenuate 
the constitutive activity of the receptor in disease conditions. Thus, a receptor-Gia 
fusion protein could perhaps abolish elevated adenylate cyclase activity from a 
Gga activating GPCR, especially if it is due to sustained activation by high level of 
ligands '(e.g. familial hyperthyrodism) or antibodies (e.g. Graves' disease and 
Chagas disease).
Although it may seem unlikely that such a scenario could happen, we must 
not forget that a number of GPCRs have already been shown to be promiscuous 
in G protein coupling. The a2A-adrenergic receptor is able to couple with Gja, Gqa, 
and Gga proteins (Chabre et al. 1994) as measured using a transient co­
expression approach. The human thyrotropin (TSH) receptor can activate G 
proteins of all 4 families (Gga, G;a, Gqa, and G 12a) to incorporate a photoreactive 
GTP analogue ([a-^^P]GTP azidoanilide) upon treatment with TSH and TSH 
receptor-stimulating antibodies (Laugwitz et al. 1996). Even the P2-adrenergic 
receptor was recently shown to couple to a pertussis toxin-sensitive G protein in 
cardiac myocytes (Xiao et al. 1995), besides mediating most of its effects via Gga.
Though some of the studies may not be relevant in physiological settings, 
as overexpression studies tend to cause enforced coupling, these observations 
still suggest that receptor-Ga coupling could be generally promiscuous. Perhaps 
there are factors that prevent such promiscuous coupling phenomena from 
occurring naturally, either by restricting the structural conformations that Ga can 
adopt or preventing close proximity of Ga with the receptor. Fusing and restraining 
the Ga protein with the receptor as in a receptor-Ga fusion protein, may be one 
way to relieve these constraints, and allow the manifestation of promiscuity
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between the receptor and Ga. Indeed, a Gqa mutant lacking the first 6 amino 
acids was recently shown to couple with several different Gj/oa or Gga coupled 
GPCRs including the M2 muscarinic, D2 dopamine, Ai adenosine, and P2- 
adrenergic receptors (Kostenis et al. 1997). The N-termini of Gqa and G ^a  differ 
from those of other Ga subunits in that they display a unique, highly conserved 6 
aa extension. These residues therefore may play a critical role in constraining the 
receptor coupling specificity of GqC^/G-iia proteins.
A reassessment of current receptor-Ga fusion studies will be needed if 
such a model of promiscuous coupling in receptor-Ga fusions is true. If signals 
from the receptor can be transduced via a receptor-fused Ga that does not 
normally occur in physiological settings (i.e. via freely interacting Ga), then this 
may suggest conformational changes in either or both the receptor and the G 
protein. Thus, studies based on fusion proteins may not truly reflect the properties 
of their natural counterparts. These include studies that aim to differentiate subtle 
differences in receptor coupling with various G proteins (Seifert et al. 1998a) and 
the assessment of agonist efficacy (Wise et al. 1997d).
The use of receptor-Ga fusion proteins is in its early stages, but has shown 
much promise judging from the studies done. Using this approach, various groups 
have shown enhancement of Gga activation by agonist to a level that can be 
meaningfully assayed using p^SjGTPyS binding and high-affinity GTPase assays 
(Seifert et al. 1998a; Chapter 4 of this thesis). Fusion proteins can also be used to 
overcome the problem of cellular targeting of receptor and G protein in assessing 
functional interactions, as in the case of acylation-deficient G^a (Wise et al. 
1997b). Furthermore, assessment of agonist efficacy can be done with full 
knowledge and consideration of the relative stoichiometry of receptor and G 
protein (Wise et al. 1997d). However, the work by Medici et al. (1997) has raised 
serious doubts on the fidelity of signal transduction in receptor-Ga fusion studies, 
and also the role of the C-terminus of Ga in receptor coupling.
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In view of the evidence outlined above, this study was designed to address 
conclusively the G protein coupling specificity of such constructs. The studies 
detailed in Chapter 3 had shown that the IP prostanoid receptor can couple to a 
chimeric Gji/Gs6a protein that contains only the last 6 aa of Gga on a G^a subunit 
backbone. Medici et al. (1997) had suggested that the role of the C-terminus of 
Ga is merely to bring the G protein in close proximity with the receptor, but is not 
directly involved in transducing the signal, and this role can be fulfilled by 
covalently linking the receptor ancTG protein. Therefore, a fusion protein between 
the IP prostanoid receptor and full length G^a might be anticipated to allow the 
generation of a functional signalling protein, even though these two proteins do 
not interact effectively when independently co-expressed. However, it was decided 
that a fusion protein between the IP prostanoid receptor and chimeric Gn/GgGa 
should also be constructed, in case promiscuity of coupling did not occur. It would 
then be useful to study the ability of the C-terminus of Gga to restore functional 
coupling in the PhlPR-G^a fusion. The cDNAs of these fusion proteins were thus 
generated and stably transfected into HEK293 cells. The agonist-stimulated 
response of these fusion proteins in the [^^SjGTPyS binding and high affinity 
GTPase assays were measured, with the aid of cholera and/or pertussis toxin 
pretreatment to delineate the Ga involved. The efficiency of coupling between the 
GPCR and Ga in these proteins was also examined by performing agonist 
concentration-response studies.
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5.2 Results
Construction of FtilPR-Gna and FhlPR-Gn/Gs6a fusion cDNAs
The construction of cDNAs encoding the FhlPR-Gna or FhlPR-Gji/GgGa 
was similar to that of FhlPR-Gga in Chapter 4 and is shown in Figure 5.1. 
Receptor-Ga ligated mix was transformed into DH5a E. coll cells and clones were 
picked for inoculation into LB mitri-cultures. DMAs extracted from these cultures 
were analysed for the proper incorporation of Ga cDNAs into the pcDNA3 vector 
containing the FhlPR (no stop codon). Among E. coll clones transformed with 
FhlPR / G jia ligation mix, clones 11 and 15 were found to contain a fragment of 
-2 .2 kiiobases when digested with HindWl and Xba\ restriction enzymes (Figure 
5.2A). Similar digestion of DNAs from E. coH clones transformed with FhlPR/ 
Gii/Gg6a ligation mix indicated clones C1, 02 and 04 contained a similar size 
fragment (Figure 5.2B). Subsequent DNA sequencing of clones II and 01 
confirmed the nucleotide sequence of FhlPR-Gna and FhlPR-Gn/GgGa 
respectively.
Characterisation of HEK293 clones stably expressing FhlPR-Gna and FhlPR- 
Gii/Gs6a fusion protein
Transient expression of FhlPR-Gna and FhlPR-Gn/GgGa proteins in 
FIEK293 cells resulted in low expression levels as was observed for FhlPR and 
FhlPR-Gga proteins (see Chapters 3 and 4). Selection with geneticin (G-418) was 
carried out on transfected cells and high expressing clones were selected. A 
number of these clones are presented in Figure 5.3. HEK293 clones expressing 
FhlPR-G|ia at sufficiently high levels for study were Gi9, G il3, and G il6; clones 
expressing FhlPR-Gn/GgGa at appropriately high levels were Gi/GslO, Gi/Gs14, 
and Gi/Gs19. The expression levels of these clones were lower than clone 13 and 
clone 44 which express FhlPR and FhlPR-Gga respectively. All the highest 
expressing HEK293 clones and their expression levels are tabulated in Table 5.1,
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based on [ Hjiioprost (-10 nM) binding studies of 5 independent experiments 
performed in triplicate:
Table 5.1 Expression levels of HEK293 clones
Protein
expressed
Clone Receptor level (fmol/mg 
membrane protein)
FhlPR 13 2957 + 144
FhlPR-Gga 44 1356 + 143
FhlPR-Gjia Gi16 900 + 107
FhlPR-Gii/Gg6 a Gi/Gs14 915 + 118
To avoid confusion among the many clones, all future references to HEK293 cells 
expressing the various proteins will refer to the highest expressing clones as 
stated in the table.
Confirmation of the expression of FhlPR-Gncc and FhlPR-Gn/GgGa proteins 
in the HEK293 clones was shown by immunobiotting with antisera directed against 
the amino and carboxyl-termini of these proteins. M5 anti-FLAG™ antibody 
detected the presence of immunoreactive peptides in membranes of FIEK293 cells 
expressing FhlPR-Gga, PhlPR-Gna, and FhlPR-Gn/GgGa (Figure 5.4A). 
Immunoreactive peptides in cells expressing FhlPR-Gjia and FhlPR-Gn/GgGa 
migrated at a faster pace than FhlPR-Gga. This correlated well with the lower 
molecular mass of G^a and Gü/Ggôa (both -41 kDa) compared to 
Gga(L)(HA)(-47 kDa). Furthermore, multiple immunoreactive peptides were 
observed in these membranes, which may suggest differential N-glycosylation of 
the fusion proteins.
The carboxyl-termini of FhlPR-Gga and FhlPR-Gn/GgGa were detected by 
CS antiserum, which is specific for the carboxyl-terminus of Gga (Figure 5.4B). 
This indicates that the FhlPR-Gj-i/Ggba protein contains a CS immunoreactive
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carboxyl-terminus, which is characteristic of the Gii/Gg6a chimera but not the G^a 
protein (Figure 3.9). The presence of an internal domain of G ^a  was clearly 
shown in H EK293 cells expressing F h lP R -G na  and F h iP R -G ii/G s6a  (Figure 
5.4C ). The relative migration of these 3 fusion proteins through 10% SD S-PAG E, 
as seen in the M5 immunoblot, was again demonstrated in the CS and I I C 
immunoblots, in that the FhlPR-Gga protein always migrated at a slower rate than 
the others.
The agonist binding affinities of FhlPR-Gna and FhlPR-Gi-j/GgGa were 
compared with FhlPR and FhlPR-Gga using iloprost displacement studies (Figure 
5.5). The iloprost binding profile of FhlPR-Gjia mimics closely that of FhlPR-Gga, 
with almost identical values when applying the formalism of DeBlasi et al. 
(1989): FhlPR-G,ia (1.5 ± 0.7 nM), FhlPR-Gga (1.4 ± 0.6 nM). In contrast, the 
[^Hjiioprost displacement curve of FhlPR-Gji/Gg6 a was moved to the right (Kd =
8.5 + 2.2 nM) and is significantly different from the other fusion proteins (unpaired 
t-test: p<0.05; n=3). The Hill coefficients of the agonist displacement curves of all 
3 fusion proteins are very similar and are significantly higher than the IP 
prostanoid receptor.
Cells expressing FhiPR-Gjia or FhlPR-Gji/Gg6a were able to activate 
adenylate cyclase in a dose-dependent manner upon stimulation by iloprost 
(Figure 5.6). These effects of iloprost, were however less potent when compared 
to the response observed in cells expressing the FhlPR-Gga protein; iloprost 
activity in cells expressing FhlPR-Gjia is at least 5 fold less potent, while that of 
FhlPR-Gji/Gg6a is 2 fold less potent (unpaired t-test: p<0.05 in both proteins). As 
the receptor-linked Ga in both fusion proteins cannot have an activating effect on 
adenylate cyclase, it is presumably the endogenous Gga that is involved in 
signalling to the enzyme. In Chapter 4, the FhlPR-Gga protein was shown to 
down regulate endogenous Gga upon long-term treatment with iloprost (Figure 
4.7A), although a similar experiment was not performed using HEK293 cells
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expressing FhlPR-Gjia or FhlPR-G,i/Gs6 a. While it may be argued that the Gpy 
complex could be involved in activating adenylate cyclase, this would still require 
Gga, as it is a pre-requisite for Gpy activation of adenylate cyclase (Tang et al. 
1991). Thus, endogenous Gga is likely to be activated by all the FhlPR-Ga 
fusions.
Cells expressing FhlPR~G ji/G s6a but not Fh lP R -G na  exhibit enhanced GTP 
exchange and hydrolysis activities
In previous chapters, the activation of Ga by the IP prostanoid receptor or 
the FhlPR-Gga was investigated by [^^SJGTPyS binding and high affinity GTPase 
assays, together with the use of cholera and pertussis toxins to delineate between 
Gga and Gja signalling. Using the same approach, cells expressing FhlPR-Gjia or 
FhlPR-Gji/Gg6a were pretreated with either cholera toxin, pertussis toxin, or a 
combination of both. Membranes made from these toxin-treated cells were 
assessed together with membranes from untreated cells for their capacity to 
activate Ga subunits.
Agonist-stimulated binding of [^^SjGTPyS was clearly enhanced in cells 
expressing the FhlPR-Gji/Gg6a when compared to FhlPR expressing cells, and 
was not abolished by either cholera toxin, pertussis, toxin or a combination of both 
(Figure 5.7). This observation was previously noted in FhlPR expressing cells 
(clone 13) transiently transfected with Gji/Gg6a protein (Figure 3.14). Therefore, 
covalently linking the chimeric G|i/Gg6a protein to the IP prostanoid receptor did 
not alter its characteristics. Fusing the G^a protein to the receptor, as in the 
FhlPR-Gjia fusion protein, reduced the overall level of Ga activation as shown by 
the small level of [^^SjGTPyS bound in the presence of iloprost. This small level of 
[^^SjGTPyS binding was completely abolished when the cells were pretreated with 
cholera toxin or a combination of both cholera and pertussis toxin, but not 
pertussis toxin alone (Figure 5.7).
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A very similar scenario was observed when the same membranes were 
assayed for basal and agonist-stimulated high affinity GTPase activity (Figure
5.8). Iloprost-stimulated high affinity GTPase activity was at least 4 times higher in 
cells expressing FhlPR-Gii/Gs6 a than FhlPR (unpaired t-test: p<0.05; n=3) and 2 
times higher than cells expressing FhlPR-Gga (unpaired t-test: p<0.05; n=3). As 
observed in the [^^SjGTRyS binding assay, pretreatment with neither cholera nor 
pertussis toxin removed the agonist-stimulated activity. Similarly, cells expressing 
FhlPR-Gjia did not produce robust elevation of agonist-stimulated GTPase, and 
pretreatment with cholera but not pertussis toxin completely removed this low level 
of activity. This small level of agonist-stimulated Ga activity is thus very likely to be 
contributed by endogenous Gga subunits. When the GTPase result was analysed 
in combination with the [^^SjGTPyS binding assay, it is apparent that the intrinsic 
property of the receptor-fused Ga was not altered for the FhlPR-Gn/GgGa and 
FhiPR-Gjia proteins.
Comparison of iloprost stimulated activity in PhlPR -G ^a and FhiPR -G n/G s6a  
fusion protein expressing cells
The time-course of agonist-stimulated [^^SjGTPyS binding in cells 
expressing FhlPR-Gga and FhlPR-Gii/Gg6 a was studied in greater detail as both 
gave higher activity than the FhlPR. Over a period of 120 minutes, cells 
expressing FhlPR-Gga and FhlPR-Gii/Gg6 a stimulate [^^SjGTPyS binding in a 
seemingly linear fashion and are not significantly different from each other (Figure
5.9). This confirmed that the observations noted earlier (Figure 5.7), performed at 
an incubation time of 60 min, are representative of their activity and did not arise 
from selective sampling at a particular incubation time. The iloprost dose-response 
of [^^SjGTPyS binding indicates that the FhlPR-Gii/Gg6 a is less responsive to 
agonist stimulation as its EC50 is 30 times higher than FhlPR-Gga (Figure 5.10). In 
addition, the iloprost activation profile of Gn/GgGa (hh = 1 . 6  + 0 .2 ) is more steep 
than FhlPR-Gga (a7h = 0.9 + 0.1).
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The time course of iloprost-stimulated high affinity GTPase in cells 
expressing FhlPR-Gga and FhlPR-Gii/Gg6a was also investigated and showed 
that the FhlPR-Gii/Gg6a expressing cells consistently gave more robust activity 
(Figure 5.11). In both sets of cells, the increase in GTPase activity starts to 
plateau off after 30 min stimulation, contrary to the steady increase in [^^SjGTPyS 
binding for up to 120 min-(Figure 5.9). A possible reason for this difference is the 
rapid dénaturation of protein in the GTPase assay which was incubated at 37°C, 
compared to the lower incubation temperature for the [^^SjGTPyS binding assay 
(at 25°C). Taking this into consideration, an incubation time of 20 min was used 
for all GTPase assays in this study. Iloprost concentration response studies again 
show that FhlPR-Gi-i/GgGa is less responsive to agonist stimulation than FhlPR- 
Gga (Figure 5.12), although the difference in their ECgo values (16 fold) is less 
than that in the [^^S]GTPyS binding assay (Figure 5.10).
As the hydrolysis of GTP to GDP and Pi (inorganic phosphate) is an 
enzymatic reaction (the Ga being the enzyme), it is possible to determine the 
maximum activity (V^ax) and Michaelis Menton Constant (Km) of this process by 
varying the substrate (GTP) concentration. Such enzyme kinetic measurements 
would show up any subtle differences in their maximum hydrolysing capacity and 
substrate affinity. By diluting [^^P]GTP with increasing concentrations of unlabelled 
GTP and assessing basal and iloprost (1 pM)-stimulated high affinity GTPase 
activity, direct plots of the GTPase activity versus GTP concentrations were 
obtained for cells expressing FhlPR, FhlPR-Gga, and FhlPR-Gii/Gg6a (Figure 
5.13 A, B & C). When the graph was extrapolated to infinite substrate 
concentration, maximum activity (Vmax) could be obtained, while the Michaelis 
Menton constant, Km, could be read off the x-axis at half maximal activity. 
However, such linear plots of the activity-substrate concentration profile are prone 
to error due to the grouping of data at the lower end of the scale and the difficulty 
in extrapolation. Hence, other plots like the Lineweaver-Burke plot (also known as 
the double reciprocal plot i.e. velocity'^ versus substrate'^) or the Eadie-Hofstee 
plot (velocity versus velocity/substrate) are more commonly employed. From the
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Eadie-Hofstee plots of cells expressing FhlPR, FhlPR-Gga, and FhlPR-Gi-j/Gg6 a 
(Figures 5.14 A, B & G), Km and Vmax values were obtained and tabulated into 
Table 5.2;
Table 5.2 Km and Vmax values of HEK293 cells expressing FhlPR, FhlPR-Gga 
and FhlPR-Gii/Gg6 a. These results represent the means + SEM of 3 
or more independent experiments performed in triplicate.
Protein Basal Km (pM) Agonist-stimulated 
Km (pM)
Vmax
(pmol/min/mg)
FhlPR 0.49 + 0.03 0.48 + 0.04 7.3+ 0.6
FhlPR-Gga 0.52 + 0.02 0.67 + 0.03 18.0 + 2 . 2
FhlPR-Gji/Gg6 a 0.64 + 0.03 0.63 + 0.03 19.3 + 2.3
The results indicated that the Vmax of FhlPR-Gga and FhlPR-Gii/Gg6a are 
significantly higher than that of FhlPR (unpaired t-test: p<0.05). Interestingly, while 
both the basal and agonist-stimulated Km of cells expressing FhlPR and FhlPR- 
G)i/Gg6a are similar (Figure 5.14A & C), the iloprost-stimulated Km of cells 
expressing the FhlPR-Gga protein is slightly higher than its basal Km (Figure 
5.14B). This could give rise to higher agonist-stimulated GTPase activities when 
the assay is performed at GTP concentrations greater than 0.5 pM, the 
concentration used in routine assays. This altered Km of FhlPR-Gga also 
contributes to give a Vmax value close to that of FhlPR-Gn/GgGa (Table 5.2). As 
basal GTPase activity is mainly derived from "Gja-like” proteins (Gierschik et al. 
1994), the altered Km of FhlPR-Gga likely reflects the activation of non-'Gja-like” 
subunits, which are the endogenous and receptor-linked Gga (Chapter 4).
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Figure 5.1 Schematic representation of Fh lP R -G n a  and Fh lP R -G ji/G s6a
fusion proteins
The last 6 residues of the receptor, and the first and last 6 residues of G a are 
shown. There is an alteration of cysteine to glutamic acid at the last residue of the 
receptor due to the incorporation of a Xho\ site, required for subsequent ligation 
with the open reading frame of G jia  and Gji/Gs6a.
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Figure 5.2 Agarose gel analysis of Fh lP R -G na and FhlP R -G ji/G s6a cDNAs
A. DNAs from E. coli clones (transformed with ligated FhlPR / Gjia mix) were 
digested with Hind\\\ and Xba\ and resolved on a 1% agarose gel. Clones 11 
and 15 contain a digested fragment close to the approximate length of 2.2 kb of 
the FhlPR-Giia cDNA..
B. DNAs from E. coli clones (transformed with ligated FhlPR  / Gn/GgGa mix) were 
similarly digested and resolved. Clones C1, C2 and C4 contain a digested 
fragment close to the approximate length of 2.2 kb of the F h lP R -G ji/G s6 a  
cDNA.
A. 11 15 MW
B. MW C l C2 C4
2 kb 
1 kb
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Figure 5.3 Stable expression of the FhlPR-Gj-ia or FhlPR-Gn/Gsôa fusion
proteins in clones of HEK293 cells
Following stable expression of the FhiPR-Gjia or FhlPR-Gn/Ggba cDNAs into 
HEK293 cells, membranes from clones expressing FhlPR-Gna: GI9, Gi13 and 
Gi16, and clones expressing FhlPR-Gi-|/Gs6 a: Gi/Gs10, Gi/Gs14, and Gi/Gs19, 
together with clone 13 and clone 44 cells were prepared and assessed using ~10
3 3nM [ H]iloprost. The specific binding of [ H]iloprost was obtained by subtracting 
non-specific counts (assessed with 10 |_iM unlabelled iloprost) from total counts, 
and normalised with the amount of membrane protein used in the assay. This 
graph is representative of 2 or more experiments performed in triplicate.
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Figure 5.4 immunodetection of FhlPR-Ga fusion proteins
Membranes of HEK293 clones expressing PhlPR-Gga (lane 1), FhlPR-Gna (lane
2), and FhiPR-Gii/Gs6 a (lane 3) were resolved in 10% SDS-PAGE, transferred to 
nitrocellulose membrane and immunoblotted with various antisera.
A. Immunobiotting with M5 anti-FlAG™ monoclonal antibody indicated multiple 
immunoreactive proteins that migrated with apparent molecular mass of 89 kDa 
in lane 1. M5 immunoreactive proteins in lanes 2 and 3 were observed to co­
rn igrate at a faster pace than lane 1 .
B. Immunobiotting with CS antiserum, which is specific against the carboxyl- 
terminal decapeptide of Ggcc, detected the same immunoreactive proteins seen 
in Figure A, but only in lanes 1 and 3.
C. Immunobiotting with 11C antiserum, which is specific against an internal domain 
(159-168 aa) of G^a, also detected the same immunoreactive proteins seen in 
Figure A, but only in lanes 2 and 3.
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Figure 5.5 Displacement of [^Hjiloprost binding in membranes of HEK293
clones stably expressing FhlPR and FhlPR-Ga fusion proteins
The specific binding of [^H]iloprost (3.4 nM) to membranes of HEK293 clones 
stably expressing PhiPR-Gj^a and FhlPR-Gii/Gs6 a were displaced by increasing 
concentrations of unlabelled iloprost as in Figure 4.5. Results of FhlPR and 
FhlPR-Gga were obtained from Figure 4.5 and Figure 3.4. The IC50 of PhlPR-G^a 
was estimated as 4.9 + 0.6 nM and Hill slope at 0.89 + 0.09, while the IC50 of 
FhlPR-Gii/Gg6 a was estimated as 11.9 + 2.2 nM and Hill slope at 0.79 + 0.11. 
Results are presented as %specific binding of [^Hjiloprost (100% = specific 
binding in the absence of unlabelled iloprost). This graph is representative of 3 
independent experiments performed in triplicate.
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Figure 6.6 Adenylate cyclase concentratîon-response for iloprost
Intact cells of HEK293 clones stably expressing the various proteins were 
assessed for their ability to stimulate adenylate cyclase at various concentrations 
o f iloprost. The results are calculated as the ratio of cAMP over total adenine 
nucleotides (X 100) but expressed as % maximum stimulation (activity at 1 pM 
iloprost treated as 100%)."Results of cells expressing FhlPR and FhlPR-Gga were 
obtained from Figure 4.15. ECso of iloprost activity in cells expressing FhlPR-Gjia
1 nis estimated as 5.5 + 0.8 X 10' M and that of cells expressing FhlPR-Gn/GgGa is 
estimated as 2.1 + 0.3 X 10^° M. This graph is representative of 3 independent 
experiments performed in triplicate.
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Figure 5.7 Effects of cholera and pertussis toxins on agonist-stimulated 
[^^S]GTPyS binding in HEK293 clones expressing FhlPR and 
FhlPR-Ga fusion proteins
HEK293 clones expressing FhlPR and various FhlPR-Ga fusion proteins were 
treated with cholera toxin (200 ng/ml), pertussis toxin (25 ng/ml) or a combination 
of both for 16 h before harvest. Membranes from these and untreated cells were 
assayed for basal and iloprost (1 |LtM)-stimulated binding of f®S]GTPyS. The 
stimulations produced by iloprost (fmol [^^S]GTPyS bound / mg membrane 
protein) are expressed as %stimulation (100% = [^^S]GTPyS bound in cells 
expressing FhlPR).
The results for cells expressing FhlPR and FhlPR-Gga were obtained from Figure 
4.10, with the exception of combined toxins treatment: FhlPR (17.8 + 8.5) and 
FhlPR-Gga (129 ± 5.5). The results for cells expressing FhlPR-Giia are: untreated 
(53.8 + 0.2), cholera toxin (0.9 + 6.2), pertussis toxin (37.8 ±  3), and combined 
toxins (3.6 ± 4.4). Results of cells expressing FhlPR-Gii/Gg6 a are: untreated 
(227.1 + 5.3), cholera toxin (185.2 + 16.1), pertussis toxin (199.6 + 26.2), and 
combined toxins (193.3 + 1.1). These data represent the means of 3 independent 
experiments ±  SEM, performed in triplicate.
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Figure 5.8 Effects of cholera and pertussis toxins on agonist-stimulated 
high affinity GTPase activity in HEK293 clones expressing 
FhlPR and FhlPR-Ga fusion proteins
Membranes from Figure 5.7 were used to measure basal high affinity GTPase 
activity and its stimulation by iloprost (1 pM). The stimulations produced by iloprost 
(mean + SEM pmoi/min/mg membrane protein) are presented.
Results for cells expressing FhlPR and FhlPR-Gga were obtained from Figure 4.8, 
with the exception of combined toxins treatment: FhlPR (0.8 + 0.5) and FhlPR- 
Gga (0.7 + 0.4). The results for cells expressing FhlPR-Gna are: untreated (2.0 ± 
0.6), cholera toxin (-0.2 ± 0.6), pertussis toxin (1.6 + 0.1), and combined toxins (- 
0.2 + 0.3). Results of cells expressing FhlPR-Gn/GgOa are: untreated (11.4 + 0.7), 
cholera toxin (9.4 + 0.4), pertussis toxin (10.2 ± 0.6), and combined toxins (9.3 + 
0.7). These data represent the means of 3 or more independent experiments 
performed in triplicate.
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r35.Figure 5.9 Time course of agonist-stimulated [ S]GTPyS binding in 
HEK293 clones expressing FhlPR-Gga and FhlPR-Gn/GsSa
Membranes of HEK293 ceils stably expressing FhlPR-Gga and FhlPR-Gü/Ggôa 
(pretreated with a combination of 200 ng/ml cholera and 25 ng/ml pertussis toxins 
for 16 h) were assessed for their incorporation of [^^SJGTPyS at various incubation 
times (0, 15, 30, 45, 60, 90 and 120 min) in the absence (basal) and presence of 
iloprost (1 j_iM). Levels of agonist-stimulated [^^SJGTPyS binding are presented as 
cpm / assay (20 pg membrane protein per assay). This graph is representative of 
2 independent experiments performed in triplicate.
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Figure 5.10 Iloprost concentratîon-response of [^®S]GTPyS binding in 
HEK293 clones expressing FhlPR-Gga and FhlPR-Gji/Gg6a 
fusion proteins
Membranes from Figure 5.9 were assessed for their ability to incorporate 
[35g]QTPyS at various concentrations of iloprost. The stimulations produced by 
iloprost are expressed as %maximum stimulation (activity at 1 pM iloprost treated 
as 100%). ECso of iloprost stimulated [^^SjGTPyS binding in cells expressing 
FhlPR-Gga is estimated as 1.7 + 0.2 nM and that of cells expressing FhlPR- 
Gj-i/GgGa is estimated as 50.6 + 5.3 nM. This graph is representative of 3 or more 
independent experiments performed in triplicate.
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Figure 5.11 Time course of high affinity GTPase activity in HEK293 clones 
expressing FhlPR-Gga and FhlPR-GM/Gg6a
Membranes of HEK293 cells stably expressing FhlPR-Gga and FhlPR-Gii/Gg6a 
(pretreated by a combination of cholera and pertussis toxins as in Figure 5.9) were 
assessed for their basal and iloprost (1 pM)-stimulated high affinity GTPase 
activity at various incubation times (0, 10, 20, 30, 45, 60, 90 and 120 min). Levels 
of iloprost-stimulated GTPase actfvity are presented as pmol Pi / mg membrane 
protein. This graph is representative of 2 independent experiments performed in 
triplicate.
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Figure 5.12 Iloprost concentration-response of high affinity GTPase activity 
- in HEK293 clones expressing FhlPR-Gga and FhlPR-Gii/Gg6a 
fusion proteins
Membranes from Figure 5.11 were assessed for their ability to stimulate high 
affinity GTPase activity at various concentrations of iloprost. The stimulations 
produced by iloprost are expressed as % maximum stimulation (1 0 0 % = activity at 
10 pM iloprost). EC50 of iloprost-stimulated GTPase activity in cells expressing 
FhlPR-Gga is estimated as 4.8 + 1 . 2  nM and that of cells expressing FhlPR- 
Gii/Gg6 a is estimated as 76.5 + 6 . 6  nM. This graph is representative of 3 or more 
independent experiments performed in triplicate.
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Figure 5.13 Basai and iloprost-stimulated high affinity GTPase activity at 
various G IF  concentrations
Membranes of HEK293 clones expressing FhlPR (A), FhlPR-Gga (B), and FhlPR- 
G|i/Gs6a (C) were assessed for their basal (open circles) and 1 iloprost 
(closed circles)-stimulated high affinity GTPase at various concentrations of GTP. 
Cells expressing FhlPR-Gn/GgGa were pretreated with a combination of toxins as 
in Figure 5.9 before harvesting. Tine graphs are direct plots of GTPase activity (V) 
versus GTP concentrations (S) and represent a typical experiment among 3 or 
more performed in triplicate.
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Figure 5.14 Eadie-Hofstee plots of basal and Iloprost-stimulated high affinity
GTPase activity at various GTP concentrations
Figures 5,13 A, B & C were transformed into Eadie Hofstee plots: (A) FhlPR , (B) 
F h lP R -G sa  , and (C) F h lP R -G ii/G s6a. The maximum velocity (V^ax) is obtained by 
the difference in y-intercept between the basal (open circles) and iloprost (closed 
circles) stimulated activity, while the Michaelis Menton constant (K^) is obtained 
by the negative value of the slopd" of the graph. Each graph represents a typical 
experiment among 3 or more performed in triplicate.
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5.3 Discussion
Cells stably expressing FhlPR~Gna or FhlPR-Gn/Gs6a fusion proteins exhibit 
simiiar characteristics as FhlPR-Gsa
FhlPR-Giia and F h lP R -G ;i/G s6a  proteins exhibit certain similar 
characteristics as PhlPR-G^a. Immunological detection of their N-termini FLAG™- 
epitope and their Ga C-termini or internal domains was successful using the M5 
anti-FLAG™ antibody and the appropriate anti-Ga antisera (Figures 5.4 A, B & C). 
N-glycosylated forms (doublets) of these fusion proteins were apparent in the M5 
and CS blots, but not so with the 110 antiserum. The N-glycosylated forms of the 
isolated receptor (FhlPR) was previously shown in Figure 3.5B in stably 
expressing HEK293 cells. As the glycosylation of asparagine residues is essential 
for proper targeting and expression of transmembrane receptors, it is therefore 
gratifying to note that these FhlPR-Ga fusion proteins can also be glycosylated in 
a similar manner as FhlPR. However, multiple forms of the glycosylated fusion 
proteins are not as apparent in these blots as observed for the FhlPR.
Cells expressing the various Fh lP R -G a fusion proteins bind [^H]iloprost with 
high affinity with the F h lP R -G ji/G s6a  being the least among them (Figure 5.5). As 
agonists demonstrate high affinity for receptor states due to the promotion of G 
protein coupling (Colquhoun 1985), poor coupling efficiency between the GPCR 
and G a, as in the Fh lP R -G n/G s6a  fusion protein (Figures 5.10 & 5.12), may 
contribute to its lower agonist affinity. Agonist binding affinity of FhlPR-G;ia 
protein may not be affected as the receptor-fused G^a did not have any affinity for
the receptor (Figures 5.7 & 5.8) and hence presumably only endogenous Gga 
interacts with the receptor.
The lack of [ Hjantagonists acting at the IP prostanoid receptor restricted 
the assessment of receptor expression levels to radioligand binding studies using 
[^H]iloprost or fH]PGE1. [^H]iloprost is the preferred radioligand due to its higher 
affinity and selectivity at the IP prostanoid receptor (Coleman et al. 1994). Routine
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estimates of receptor levels using [^Hjiloprost (Table 5.1) at concentrations of 3 
times or more Kd are sufficiently accurate for the various proteins except the 
F h lP R -G ji/G s6a. This is because the concentration of [^H]iloprost used (~10 nM) 
is only slightly more than the estimated Kd of cells expressing F h lP R -G ji/G s6 a  (8.5 
nM) and hence may cause an underestimation of expression level. Assuming that 
only 60%  of the total level of Fh lP R -G ji/G s6a  specifically binds [^H]i!oprost at 
lOnM, the estimated receptor expression level would be closer to -1 .5  pmol/mg 
membrane protein.
All the FhlPR-Ga fusion proteins stimulated adenylate cyclase in the 
presence of iloprost in a concentration-dependent manner (Figure 5.6). A 
significantly higher concentration of iloprost (unpaired t-test: p<0.05; n=3) was 
required to stimulate 50% activity in cells expressing FhlPR-Gna (EC50 = 5.5 + 0.8 
X 10'^° M) compared to FhlPR-Gga (EC50 = 1.1 ± 0.3 X 10"^° M), despite their 
similar affinities to bind [^H]iloprost. This poorer activity of FhlPR-Gna could be 
attributed to the inability of receptor-linked Gna to be activated by the fused 
receptor (Figures 5.7 & 5.8) which may hinder the access of endogenous Gga to 
the activated receptor. Furthermore, agonist promoted accumulation of cAMP in 
cells expressing the FhlPR-Gga protein can be mediated via the combined effect 
of receptor-linked and endogenous Gga. Strangely, although the affinity for 
[^H]iloprost In cells expressing FhlPR-Gn/Gg6 a is about 6  times weaker than 
FhlPR-Gga, iloprost potency in FhlPR-Gn/Gg6 a expressing cells is only 2 times 
lower (Figure 5.6). Furthermore, the adenylate cyclase inhibitory effect of receptor- 
linked Gii/Gg6 a should reduce the activity of adenylate cyclase and hence further 
lower the potency of iloprost. it is therefore unclear why the adenylate cyclase 
activity of FhlPR-Gii/Gg6 a did not correlate well with its affinity for agonist. A 
possible reason for it may be the differential accessibility of endogenous Gga to 
these FhlPR-Ga fusion proteins upon stimulation by iloprost.
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Specificity of coupling in the FhlPR-Ga fusion proteins
Results obtained from the [^^S]GTPyS binding and high affinity GTPase 
assays, which monitor Ga activity, demonstrate that the receptor-linked G,ia of the 
FhlPR-Giia protein cannot be activated (Figures 5.7 & 5.8). While co-expression 
of G iia and FhlPR also .did not result in activation of G;ia (Chapter 3), it was 
thought that the covalent fusion of these 2 components might enable productive 
interactions to occur, as suggested by Medici et at. (1997). This is particularly the 
case as a chimeric G protein, Gn/GgGa, which is predominantly Gna except the 
last 6 aa (from Gga), was shown to interact productively with the IP prostanoid 
receptor (Chapter 3). As the C-terminus of Ga was suggested to fulfil the role of 
bringing the G protein in close proximity with the receptor, this C-terminal 
sequence is therefore not crucial in a GPCR-Ga fusion construct (Medici et al. 
1997). However, the results obtained in this study with the FhlPR-Gna protein 
proved otherwise.
Substituting the last 6 aa of Gga into the FhlPR-Gna, as in the FhlPR- 
Gn/Gg6a protein, promoted functional interactions between the 2 fused partners. 
The authenticity of receptor-linked Gn/Gg6a activation is shown by its resistance 
to both cholera and pertussis toxins in the [^^S]GTPyS binding and high affinity 
GTPase assays (Figures 5.7 & 5.8), a phenomenon previously observed when the 
Gn/Gg6a protein was co-expressed with FhlPR (Chapter 3). Thus, it appears that 
the last 6 aa of Gga is still critical for transduction of signal from the GPCR to the 
Ga subunit in a fusion construct. These results further proved that the covalent 
link is not sufficient to enforce interaction between the FhlPR and a Ga subunit 
that it does not interact with physiologically, unless a recognition sequence is also 
present at the C-terminus of the Ga subunit.
Fusing the FhlPR with Ga did not affect the characteristics of the receptor- 
linked Ga. The activity of FhlPR-Gga was shown in the previous chapter to be 
modulated by the ADP-ribosylating action of cholera toxin. The activity of FhlPR-
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Gii/Gg6a however, is resistant to both cholera and pertussis toxins, an observation 
also noted of the freely interacting G|i/Gg6a protein (Chapter 3). As the various 
FhlPR-Ga fusion proteins also bind [^Hjiloprost with high affinity and activate 
adenylate cyclase, this implies that covalently linking the receptor and Ga subunit 
did not alter the characteristics of either the receptor or the Ga.
Receptor-Ga interaction is more efficient in the FhiPR-Gsa than FhlPR-
Gji/Gs6a
Agonist promoted receptor-Ga interactions were studied in greater detail in 
cells expressing FhlPR-Gga and FhlPR-Gi-i/GgGa. Iloprost concentration response 
studies of membranes from these cells in either GTPase or [^^S]GTPyS binding 
assays indicated that the FhlPR-Gji/Gs6a protein is 16 to 30 times less responsive 
to iloprost stimulation than the FhlPR-Gga protein (Figures 5.10 & 5.12). A partial 
explanation for the poor sensitivity of FhlPR-Gji/Gg6a to iloprost stimulation could 
be its lower affinity for the agonist (Figure 5.5). However, the 6 fold difference in 
binding affinity between the FhlPR-Gji/GgBa and FhlPR-Gga proteins cannot fully 
account for the large difference in activation of Ga. As the cells expressing FhlPR- 
Gi-j/GgOa were pretreated with a combination of both cholera and pertussis toxins 
to remove coupling with endogenous Gga and G,a-like subunits, the activation 
profile observed only reflects the activation of receptor-linked Gii/Gs6a. This is 
however not the case for cells expressing FhlPR-Gga, which is untreated and 
hence would activate a combination of both endogenous and receptor-linked Gga 
(Chapter 4). This may suggests that the activation of receptor-linked Ga is less 
sensitive in general.
However, the most probable reason for the observed difference in iloprost 
potencies is that activation of Ga by the GPCR may be mediated via other 
domain(s) of Ga apart from the C-terminus. Various studies have implicated the 
involvement of the extreme N-terminus of Ga and a region mapped to residues 
311 to 328 of Gta (see Section 1.3.2). In particular, the N-terminus of G^a was
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shown to be cross-linked to the the IC3 region of the a2A-9clrenergic receptor 
(Taylor et al. 1994) and to mastoparan (Higashijima et al. 1991), while a synthetic 
N-terminal peptide of Gta inhibited interaction of Gta with rhodopsin (Hamm et al. 
1988). It is therefore very likely that these domains of the Gji/Gs6a protein, which 
differ from Gga, may contribute to the poor interactions with the receptor at sub- 
optimal agonist concentrations. Therefore, while these domains of G^a may 
substitute for the corresponding domains of Gga, the transduction of signal from 
the FhlPR may not be as efficient. It will be interesting to map the exact locations 
of these domains of Gga by substituting into the FhlPR-G|i/Gg6a fusion construct 
and reassessment of their receptor-Ga interactions.
Fusion proteins are more productive signai transducers than the isoiated 
receptor
The enhancement of signal transduction by the FhlPR-Gga fusion protein 
was clearly shown in Chapter 4. One of the reasons for such enhancement is the 
elevated activity of the receptor-linked Ga. Through the use of cholera toxin, which 
downregulates endogenous Gga but not FhlPR-Gga, the ratio of activated 
endogenous Gga to receptor-linked Gga was found to range from 1:1 to 1:2 
(Section 4.3). The predominance and enhanced activity of receptor-linked Ga in 
the FhlPR-Gii/Gg6a protein was also apparent. By comparing the agonist 
promoted activities of untreated and toxins-treated cells (Figures 5.7 and 5.8), the 
ratio of activated endogenous Ga versus receptor-linked Ga in the FhlPR- 
Gii/Gg6a expressing cells was observed to range from 1:4 to 1:5. The high 
dominance of receptor-linked Ga activity in the FhlPR-Gii/Gg6a protein is likely a 
feature of the Gji/Gg6a protein.
The enhancement of signal transduction by the Gn/GgGa protein was not 
studied in detail in co-expression systems in Chapter 3 due to the difficulty of 
assessing expression levels of the Gji/Gg6a. However, through the use of FhlPR- 
Ga fusion proteins in the current study, the expression levels of Gn/GgGa can be
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accurately determined by receptor binding studies. This enabled a comparison to 
be made with cells expressing the FhlPR and FhlPR-Gga proteins, despite 
differences in their levels of expression. As presented in Table 5.1, the receptor 
expression levels of all 4 clones expressing the FhlPR and the fusion proteins are 
not uniform. By compensating for the amount of receptor expressed, the true 
“benefit” or "enhancement” of signal transduction of each fusion protein can be 
determined with respect to the isolated IP prostanoid receptor.
Iloprost (1 pM) stimulation resulted in enhanced binding of [^^S]GTPyS to 
the fusion proteins FhlPR-Gga and FhlPR-Gp/GsGa (Figure 5.7). The 
concentration of [^^S]GTPyS used in the assay ranged from 0.3 to 0.5 nM and was 
not diluted with unlabelled GTPyS to give a high concentration due to the low 
window of counts (2000 to 3000 cpm) in the assay. As such, the incorporation of 
|-35s]GTpyS is not saturating and does not reflect the maximum amount bound at 
equilibrium. The counts obtained in the present assay at a fixed incubation time 
(60 min), would therefore give an indication of the rate of [^^S]GTPyS incorporated 
by the various proteins. Comparison of this rate among the various proteins after 
normalising for their expression levels is tabulated below:
35,Table 5.3 Rates of [ SjGTPyS incorporation
Protein [^®S]GTPyS Bound 
(% of FhlPR / mg 
membrane protein)
f®S]GTPyS 
Bound (%) at 
equal expression 
level
Rate of 
Ga 
activation
Fh lP R 100 100 1
FhlPR -G ga 226.5 494 4.9
FhlPR-G p/G gO a 227.1 440* 4.4
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The expression level of FhlPR"Gji/Gs6a was re-estimated at 1.5 pmol/mg by 
ssu 
nM).
a ming that only 60% of it binds [^Hjiloprost at -10  nM in view of its high Kd (8.5
The rate of [^^S]GTPyS incorporation clearly indicates that the fusion 
proteins activate Ga subunits at a much faster rate than the isolated FhlPR. The 
similar rates of Ga activation for the FhlPR-Gga and FhlPR-Gii/Gg6a proteins 
suggest of a common characteristic of the FhlPR-Ga fusion protein to stimulate 
GTP exchange in such constructs.
The comparison of high affinity GTPase activity by the fusion proteins is 
best achieved by comparing their respective Vmax- This is because the GTPase 
activity is strongly influenced by the concentration of GTP used in the assay, 
especially for G proteins with different Km values (Table 5.2). Differences in Km 
values indicate differential affinity for GTP and hence imply that unless the GTP 
concentration used is at least 3 times of Km, results obtained from such assays 
cannot be used to compare the relative activity of different Ga subunits. In routine 
GTPase assays, a final GTP concentration of 0.5 pM was used due to the need to 
consider both the velocity and the specific activity of [ P]GTP in the reaction. As 
this concentration is very close to the Km values of FhlPR and the fusion proteins, 
the results were not utilised for comparison of FhlPR-Gga and FhlPR-Gii/Gg6a 
with FhlPR. Instead, the Vmax values obtained by the Eadie-Hofstee plots (Figures 
5.14A, B & C) were used.
A relatively simple measure of the GTP binding and hydrolysing capacities 
of Ga subunits is to measure their ability to bind and hydrolyse GTP per unit time 
per molecule, known as the GTP turnover number (Wise et al. 1997c). Hence, by 
using the Vmax (pmol/min/mg) values of each construct and dividing this by their 
expression levels (pmol/mg), the turnover number (min'^) is obtained and 
presented in Table 5.4:
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Table 6.4 Rates of GTP turnover
Protein Vmax
(pmol/min/mg)
Expression
levels
(pmol/mg)
Turnover
number
(min’ )^
Ratio of 
turnover 
number
F h lP R 7.3 3.0 2.5 ±0 .2 1
Fh lP R -G ga ' 18.0 1.4 13.3 + 1.6 5.3
F h lP R -G ii/G g 6a 19.3 1.5* 12.9 + 1.5 5.1
* The expression levels of FhlPR-G;i/Gg6a differ from Table 5.1 for the reasons 
mentioned in Table 5.3
A comparison of their GTP turnover number again strongly suggests that 
fusion proteins are more efficient than the isolated receptor in binding and 
hydrolysing GTP. This result, together with that obtained in the [^^S]GTPyS 
binding assay, conclusively show that the fusion proteins are more productive 
signal transducers.
In summary, this study is the first to show that coupling specificity is 
retained in the FhlPR-Ga fusion proteins. Furthermore, this study also illustrates 
the importance of the C-terminus of Gga in restoring the coupling between FhlPR 
and Ga, a role which cannot be replaced by covalently linking them as suggested 
by Medici et al. (1997). In addition, it is apparent that the characteristics of the 
receptor and Ga in these FhlPR-Ga fusion proteins are similar to that of the freely 
interacting components. Finally, functional FhlPR-Ga fusion proteins exhibit much 
higher activity than the isolated FhlPR when assessed by both [^^SJGTPyS 
binding and high affinity GTPase assays.
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CHAPTER 6
DISCUSSION
CHAPTER 6 DISCUSSION
GPCRs transduce extracellular signals into the cell by activating 
heterotrimeric G proteins. Both the Ga and G(3y complex have been shown to act 
on a variety of effectors ranging from enzymes (adenylate cyclase, phospholipase 
C & cGMP phosphodiesterase) to ion channels (K^, Ca^^ & Na"** channels). As 
signals are amplified down the signalling cascade, most functional assays 
measure the activity of the downstream effectors either directly or via reporter 
genes and reporter proteins. However, although these functional assays are 
sensitive, analysis of the resulting output can be complex and subject to the type 
of tissue or cell line used, mainly due to variations in their downstream signalling 
components. The stoichiometry of the GPCRs, G proteins and effectors also 
differs greatly between cell lines, and this can give rise to different functional 
responses (Kenakin 1995a). This particularly affects GPCRs that are promiscuous 
in their coupling, as the stoichiometry of GPCRs to the various Ga can determine 
the signalling cascades to be activated. This phenomenon can also be observed 
in recombinant systems by expressing GPCRs and Ga subunits to different levels 
(Kenakin 1997).
The determination of agonist efficacy at the earliest point of the signalling 
pathway (I.e. at the level of G protein activation) is besieged with various problems 
for GPCRs that do not couple to “Gja-like” subunits (Wieland et al. 1994; Gierschik 
et al. 1994). However, through the use of a chimeric Gn/GgBa protein, high levels 
of activity were observed upon stimulation by the IP prostanoid receptor (Chapter 
3). The retention of intrinsically high rates of GTP exchange and hydrolysis of the 
G jia subunit enabled the detection of IP prostanoid receptor agonist activity based 
on conventional assays that measure G protein output. By activating only the 
chimeric Gn/GgGa but not full length G^a, the IP prostanoid receptor also 
demonstrated its selective interaction with G^a via the extreme carboxyl terminus.
This study therefore allowed the opportunity to study agonist function at the 
level of the G protein for a Gga-coupled GPCR. Traditionally, assays that detect
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activation of Gga frequently involved measuring the activity of adenylate cyclase, a 
downstream effector of activated Gga. While this assay is generally sensitive and 
reliable, there are various drawbacks to its use for assessing agonist efficacy. 
There are currently 9 isoforms of mammalian adenylate cyclase known. Although 
all 9 isoforms can be activated by Gga, not all the isoforms have been carefully 
assessed for their sensitivity to Gga. In addition, the type of isoforms and their 
levels of expression will naturally yary between cell lines, and their activity can be 
modulated by various proteins including Gja and G%a subunits, and the G(3y 
complex. All these factors make it difficult to directly compare the efficacy of 
agonists across different cell lines based on the measurement of adenylate 
cyclase activity (Birnbaumer 1992).
Furthermore, there appears to be distinct differences in the capacity to 
activate adenylate cyclase among the splice variants of Gga. The short isoform of 
Gga (Gga(S)) was previously shown to be more effective in activating adenylate 
cyclase than the long isoform (Gga(L)) in both co-expression and GPCR-Ga fusion 
studies (Walseth et al. 1989; Seifert et al. 1998). While agonist trafficking of 
GPCRs had been studied in some detail (Kenakin 1995b), the ability of agonists to 
promote preferential coupling of the splice variants of Gga is currently unclear. As 
such, it is rather crucial that agonist activity be determined at the level of Ga, as 
this would circumvent the inherent problems associated with measuring secondary 
effector activity.
The finding that the IP prostanoid receptor activates Gga via a recognition 
sequence located at the G-terminus extends the list of GPCRs that have been 
shown to exhibit this property (Conklin et al. 1993a; Voyno-Yasenetskaya et al. 
1994). There is as yet no clear pattern as to why certain GPCRs show such a 
characteristic, while others do not. This short fragment involved in the coupling 
between GPCR and Ga suggests that selective uncoupling can be achieved with 
either short peptides or even small molecule entities. Such selective uncoupling 
may confer a therapeutic advantage over an antagonist that acts on the GPCR 
and hence blocks all signalling processes. Indeed, various studies have
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concentrated on discovering selective antagonists of GPCR and Ga coupling 
(Hohenegger 1998; Freissmuth et al. 1996). However, as most of the currently 
available antagonists are analogues of suramin, which is a non-selective inhibitor 
of GDP/GTP exchange for Ga, they do not particularly discriminate between the 
various Ga subunits. Furthermore, as very high micromolar concentrations are 
required, it is unlikely that these compounds block the interactions between the 
GPCR and Ga via the Ga G-terminus. This is especially in v iew . that 
subnanomolar of Gga and submicromolar of Gja are sufficient to exert their effect 
on adenylate cyclase (Taussig et al. 1993). The use of chimeric G proteins, such 
as the Gii/Gg6a chimera, to screen for selective antagonists acting at the C- 
terminus of Ga may instead yield more useful and discriminating compounds.
It is very interesting that functional chimeric G proteins can be generated to 
combine the desired properties of another Ga and yet retain coupling to the GPCR 
under study (Conklin et al. 1993a; Komatsuzaki et al. 1997; Chapter 3 of this 
thesis). As the pharmaceutical industry is always in search of generic assay 
formats for the different Ga activating GPCRs, the use of chimeric G proteins may 
greatly facilitate this development. In the current study, high levels of activity in 
both the [^^SjGTPyS binding and high affinity GTPase assays were obtained for a 
Gga-coupled GPCR acting via the chimeric Gji/Gg6a protein. This concept can 
therefore be extended to GPCRs that couple to 6 a subunits other than Gga. As 
the [^^SjGTPyS binding assay can be adapted as a high-throughput screen 
through the use of SPA™ (Scintillation Proximity Assay) and Flashplate™ assay 
formats, it may thus be possible to use a series of G^/Gxa (x = any Ga) chimeras 
as adapter proteins for the screening of novel agonists acting at any GPCR.
The search for a common Ga reporter protein had previously centred on 
G-iea and the use of the Ca^^ / aequorin system as a generic screen for GPCRs 
(Milligan et al. 1996; Stables et al. 1997). Recent studies had however indicated 
that G i60t may not be capable of coupling to all GPCRs (Lee et al. 1998). While 
such a promiscuous Ga subunit may not be found in nature as it would be difficult 
to regulate its effect in the cell, detailed mutagenesis of the C-terminal residues of
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Ga may eventually yield a truly promiscuous mutant Ga. This is supported by the 
recent finding that an N-terminat truncation of G q a , which lacks the first 6  aa, 
enabled it to couple with various Ga-activating GPCRs (Kostenis et al. 1997). In 
addition, the promotion of GTP exchange in the Ga subunits may be non-specific 
in nature, as shown by the capacity of mastoparan and its related amphiphilic 
peptides and hydrophobic amines to catalyse the exchange in a number of Ga 
subunits (Higashijima etal. 1990).
The impact of varying stoichiometry of GPCR to Ga in signalling was 
reduced to the minimum through the use of GPCR-Ga fusion proteins. The 
covalent fusion of the IP prostanoid receptor with G$a, to form the FhlPR-Gga, 
also resulted in a highly productive signal transducing protein when compared to 
the freely interacting receptor (Chapter 4). As a result, this fusion protein also 
offers a means to analyse agonist pharmacology using high affinity GTPase or 
[^^S]GTPyS binding assays and with the advantage of interacting with its cognate 
Ga. As the increase in agonist-stimulated high affinity GTPase activity correlated 
well with that observed in the [^^S]GTPyS binding assay, it is very likely that a 
faster level of activation of Gga is the main reason contributing to the elevated 
activity. Cholera toxin treatment of HEK293 cells expressing the FhlPR-Gga was 
shown to downregulate the level of endogenous Gga but not the FhlPR-Gga 
protein. Therefore, the agonist-promoted incorporation of [^^SjGTPyS into the 
membranes of such toxin-treated cells indicates that the enhanced activity is a 
result of activating the receptor-linked Gga.
Overexpression of Gga in the FhlPR expressing cells did not result in 
elevated activity (Chapters 3 & 4). This suggests that either the close proximity or 
the co-targeting of GPCR and Ga could have accounted for the ease with which 
receptor-linked Ga can be activated. There is substantial evidence suggesting that 
GPCR and Ga subunits may not be located in the same microdomain at the 
plasma membrane (Neubig 1994). In particular, Ga subunits were found to be 
associated with caveolae, which are vesicular invaginations of the plasma
193
membrane characterised by the presence of caveolin proteins (Okamoto et at. 
1998). Besides the endothelin receptor, few GPCRs are currently known to 
associate with caveolae. However, recent studies showed that the M2 muscarinic 
(Feron et at. 1997) and B2 bradykinin receptors (Weerd et at. 1997) translocate to 
caveolin-rich fractions upon stimulation by agonists but not antagonists. This 
suggests that such agonist-induced translocation is an essential step in the 
initiation of signalling cascades, as many downstream transducers of GPCRs are 
localised to the caveolae fractions^Okamoto et al. 1998).
Caveolin proteins were also found to have an inhibitory effect on the 
activation of Ga subunits. An N-terminal cytoplasmic domain of caveolin-1 
(residues 61-101) binds Ga and suppresses the basal GTPase activity of purified 
Ga by inhibiting GDP/GTP exchange (Li eta l. 1995). In contrast, the analogous 
region of caveolin-2 possesses GTPase-activating protein activity with regard to 
heterotrimeric G proteins (Scherer et al. 1996). The functions of these proteins 
therefore act to maintain the Ga subunits in the inactive GDP-liganded state. 
While agonist-induced translocation of FhlPR or FhlPR-Gga into caveolin-rich 
fractions was not observed in the present study, sucrose density fractionations of 
Triton X-100 treated FhlPR and FhlPR-Gga expressing cells clearly indicate that 
both proteins did not associate with caveolin-rich fractions (results not shown). 
This could have accounted for the enhanced activity of receptor-linked Gga in the 
FhlPR-Gga protein as it is not under the influence of the caveolin proteins. More 
studies however will need to be performed to substantiate these preliminary 
findings.
The covalent fusion of the C-terminus of a GPCR with the N-terminus of G a 
could affect the conformation and functions of these termini. The C-terminus of 
the IP prostanoid receptor contains sites for PKC phosphorylation (Figure 1.6), 
which are essential for regulating desensitisation of the receptor (Smyth et al. 
1996). Recent evidence showed that serine 328 is the primary site for PKC 
phosphorylation of hIPR (Smyth et at. 1998). A reassessment of these results may 
be necessary for desensitisation studies of the FhlPR -G ga fusion construct. The
194
N-terminus of Ga, was previously shown in crystallographic studies to be in direct 
contact with the Gpy complex, although the switch II region is also involved in the 
binding (Lambright etal. 1996). Furthermore, N-terminal truncations of various Ga 
subunits (Neer et al. 1988; Graf et al. 1992) including Gga (Journot et al. 1991) 
abrogates their ability to bind Gpy. As the Gpy complex prevents dissociation of 
GDP from Ga (Higashijima et al. 1987), it would be anticipated that loss of Gpy 
binding might result in a faster^ exchange of GDP for GTP (Sprang 1997). 
However, the Gpy complex also stabilises the GPCR/Ga interface and enhances 
binding of Ga to its appropriate receptor (Kleuss et al. 1992 & 1993), which makes 
the effect of N-terminal Ga truncates more difficult to assess in vivo. This may not 
pose a problem for GPCR-Ga fusions as their interactions may not require any 
further facilitation by the Gpy complex. The question arising therefore is whether 
the enhanced GDP/GTP exchange observed in the FhlPR-Gga is a result of loss 
of Gpy binding.
The association of the Gpy complex with GPCR-Ga fusion proteins has 
been a question of debate. The expression of a Ste2-Gpa1 fusion in Gpa1 
deficient yeast cells clearly shows that it can bind Gpy, as the haploid cells were 
rescued from lethality (Medici et al. 1997). However, Burt et al. (1998) failed to 
activate both the p44 mitogen-activated protein kinase and p70 S6  kinase in 
pertussis toxin treated a2AAR-Gjia(C351G) fusion protein expressing cells, results 
which would be consistent with a loss of association with Gpy. On the other hand, 
co-expression of Gpy increased the GTPase activity of the a2AAR- 
G;a(G2A/C351G) fusion (Wise et al. 1997b) but not the P2AR-Gga fusion (Seifert 
et al. 1998b). These contradictory findings suggest that the affinity of Gpy with 
each fusion protein may differ. Detailed analysis will therefore need to be 
performed to ascertain whether a loss or lower affinity of Gpy complex could have 
accounted for the enhanced activity of the FhlPR-Gga protein.
The fidelity of signalling in GPCR-Ga fusion proteins was confirmed by a 
series of FhlPR-Ga fusions, which also showed that the characteristics of both the
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receptor and Ga were not altered by the covalent linkage (Chapter 5). This refuted 
the claim by Medici et al. (1997) that the covalent fusion of GPCR with Ga could 
replace the function of the C-terminus and hence re-established the importance of 
this domain in transducing signal from the receptor, even in a fusion construct. 
There is no doubt that this finding will mean it is not possible to generate 
promiscuous signal transducing proteins and hence reduces the utility of GPCR- 
Ga fusions for such purposes, as discussed in Section 5.1. However, there are 
other studies where such fusion proteins may be useful.
Firstly, the study of GPCR coupling with various Ga can be determined with 
“equal opportunity" by using the fusion protein approach. As the expression level 
of Ga is equal to the receptor in the GPCR-Ga fusion, their relative stoichiometry 
would be 1:1 when endogenous Ga coupling can be eliminated. Furthermore, by 
taking into account the expression level of each GPCR-Ga fusion construct, the 
activation of various receptor-linked Gas can be directly compared and analysed 
as demonstrated in Section 5.3. Moreover, the fusion construct does not suffer 
from any interference arising from differential localisation or compartmentalisation 
of the GPCR and Ga at the plasma membrane (Neubig 1994). Finally, as the 
coupling of Ga with the appropriate receptor can also be affected by the Gp 
(Kleuss et al. 1992) and Gy subunits (Kleuss et al. 1993), the use of GPCR-Ga 
fusions will not require the presence of appropriate, Gpy complexes in the cell line 
under study. Such “controlled” studies of Ga coupling are analogous to 
reconstitution studies where the appropriate amount of receptor and Ga are 
allowed to interact in an artificially created environment. The GPCR-Ga fusion 
approach is however more akin to the cellular system, simpler to perform and 
offers better control of expression levels.
The GPCR-Ga fusion approach may also enable the detailed study of 
interactions between GPCR and Ga to be done at a level that is not possible 
before. Previous structural mapping Studies of domains critical for effective 
coupling were mainly performed through the expression of mutant or chimeric 
receptor and Ga. While such expression studies provided a good assessment of 
the construct under study, they failed to differentiate between the affinity and
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exchange capacity of the mutants. Productive coupling between the GPCR and 
Ga can only occur when both partners are brought into close proximity, through 
the acylation of Ga and the C-terminus of GPCR, and enhancement by specific 
G(3Y complex. The generation of certain mutants or chimeric proteins may 
therefore destroy such functions in either partner and hence abrogate coupling. A 
good example is the truncation of the N-terminus of Gga, which removed its 
palmitoylation and association with Gpy complex, and therefore caused a failure to 
activate adenylate cyclase (Journot et al. 1991). Others include modifying the 
residue for acylation (Wise et al. 1997a) or exchanging the N-terminus of Ga 
(Osawa etal. 1990b).
The ability of the GPCR-Ga fusion protein to discriminate between affinity 
and exchange capacity could be applied to the study of Ga coupling in receptor 
splice variants. A prototypical example is the distinct coupling characteristics of the 
4 splice variants of the bovine EP3 prostanoid receptor, which differ only in their 
intracellular C-termini (Namba et al. 1993; see Section 1.3.1). It is very likely that 
the C-termini are involved in bringing the various Ga in close association with the 
receptor, while the intracellular loops are responsible for catalysing the exchange 
of GDP/GTP in the various Ga subunits. By constructing fusion proteins between 
a C-terminal truncated form of the EP3 receptor linked to the various Ga proteins 
by a linker sequence and monitoring their activatioh, evidence can be collected to 
support or destroy this hypothesis. Hence, GPCR-Ga fusion proteins may be 
applied in the mapping of GPCR domains involved in Ga association and Ga 
activation.
Finally, there is no reason why such a fusion approach cannot be extended 
to the study of other signalling proteins. There is evidence that Ga subunits can be 
activated by receptors not belonging to the GPCR superfamily. For example, short 
peptides of the insulin-like growth factor II receptor were shown to couple with 
Gj2a, while the epidermal growth factor receptor was observed to couple with a 
Gja-like subunit (Spiegel 1992). Fusions between such proteins may unravel the 
capacity of non-GPCRs to activate Ga which could not be observed either due to
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a low level of activity or occur under circumstances where their detection may be 
difficult.
A recent study also suggests direct interaction between GPCRs and small 
G proteins (Mitchell et a i 1998). In that study, GPCRs that contain the amino acid 
sequence AsnProXXTyr in their TM7 domain and activate phospholipase D, do so 
in a ARF and RhoA-dependent manner. Furthermore, these small G proteins were 
co-immunoprecipitated with the^ receptor on exposure to agonists. Interestingly, 
there are also GPCRs that activate phospholipase D independent of these small 
G proteins, but contain the sequence AspProXXTyr in their TM7 domain. Mutating 
the aspartic acid to asparagine in the corresponding TM7 sequence of the 
gonadotropin-releasing hormone receptor confers sensitivity to an inhibitor of 
ARF. These results strongly suggest that receptors carrying the AsnProXXTyr 
motif may form functional complexes with ARF and RhoA. It will therefore be very 
interesting to link GPCRs with these small G proteins and investigate the 
possibility of direct interactions between them by using the appropriate assays and 
inhibitors.
In conclusion, this study achieved the objective of setting up systems for 
improving G protein output to a level detectable by conventional assays, for a Gga- 
coupled GPCR, the human IP prostanoid receptor. While the chimeric Gji/GgGa 
protein showed substantial elevated activity upon-‘Stimulation by an agonist acting 
on the IP prostanoid receptor, it is difficult to control its expression level. The 
generation of FhlPR-Gga and FhlPR-Gii/Gg6 a fusion proteins produced highly 
productive signal transducing proteins, which have the advantage of defined 
GPCR/Ga stoichiometry and co-targeting of the interacting proteins. It is 
envisaged that such systems will be used in the screening of novel compounds 
acting on the human IP prostanoid receptor and various other GPCRs.
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